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Protocolised Management In Sepsis (ProMISe): a multicentre
randomised controlled trial of the clinical effectiveness and
cost-effectiveness of early, goal-directed, protocolised
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Paul R Mouncey,1 Tiffany M Osborn,2 G Sarah Power,1
David A Harrison,1 M Zia Sadique,3 Richard D Grieve,3 Rahi Jahan,1
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Background: Early goal-directed therapy (EGDT) is recommended in international guidance for the
resuscitation of patients presenting with early septic shock. However, adoption has been limited and
uncertainty remains over its clinical effectiveness and cost-effectiveness.
Objectives: The primary objective was to estimate the effect of EGDT compared with usual resuscitation
on mortality at 90 days following randomisation and on incremental cost-effectiveness at 1 year. The
secondary objectives were to compare EGDT with usual resuscitation for requirement for, and duration of,
critical care unit organ support; length of stay in the emergency department (ED), critical care unit and
acute hospital; health-related quality of life, resource use and costs at 90 days and at 1 year; all-cause
mortality at 28 days, at acute hospital discharge and at 1 year; and estimated lifetime incremental
cost-effectiveness.
Design: A pragmatic, open, multicentre, parallel-group randomised controlled trial with an integrated
economic evaluation.
Setting: Fifty-six NHS hospitals in England.
Participants: A total of 1260 patients who presented at EDs with septic shock.
Interventions: EGDT (n= 630) or usual resuscitation (n= 630). Patients were randomly allocated 1 : 1.
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Main outcome measures: All-cause mortality at 90 days after randomisation and incremental net benefit
(at £20,000 per quality-adjusted life-year) at 1 year.
Results: Following withdrawals, data on 1243 (EGDT, n= 623; usual resuscitation, n= 620) patients
were included in the analysis. By 90 days, 184 (29.5%) in the EGDT and 181 (29.2%) patients in the
usual-resuscitation group had died [p= 0.90; absolute risk reduction −0.3%, 95% confidence interval (CI)
−5.4 to 4.7; relative risk 1.01, 95% CI 0.85 to 1.20]. Treatment intensity was greater for the EGDT group,
indicated by the increased use of intravenous fluids, vasoactive drugs and red blood cell transfusions.
Increased treatment intensity was reflected by significantly higher Sequential Organ Failure Assessment
scores and more advanced cardiovascular support days in critical care for the EGDT group. At 1 year,
the incremental net benefit for EGDT versus usual resuscitation was negative at −£725 (95% CI −£3000
to £1550). The probability that EGDT was more cost-effective than usual resuscitation was below 30%.
There were no significant differences in any other secondary outcomes, including health-related quality of life,
or adverse events.
Limitations: Recruitment was lower at weekends and out of hours. The intervention could not be blinded.
Conclusions: There was no significant difference in all-cause mortality at 90 days for EGDT compared with
usual resuscitation among adults identified with early septic shock presenting to EDs in England. On
average, costs were higher in the EGDT group than in the usual-resuscitation group while quality-adjusted
life-years were similar in both groups; the probability that it is cost-effective is < 30%.
Future work: The ProMISe (Protocolised Management In Sepsis) trial completes the planned trio of
evaluations of EGDT across the USA, Australasia and England; all have indicated that EGDT is not superior
to usual resuscitation. Recognising that each of the three individual, large trials has limited power for
evaluating potentially important subgroups, the harmonised approach adopted provides the opportunity
to conduct an individual patient data meta-analysis, enhancing both knowledge and generalisability.
Trial registration: Current Controlled Trials ISRCTN36307479.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 19, No. 97.
See the NIHR Journals Library website for further project information.
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Plain English summary
What was the problem/question?
Sepsis is a severe infection in the blood which can damage important organs in the body, such as the
heart and lungs. Patients who develop sepsis are at a high risk of dying. A research study in a US hospital
emergency department found that patients with sepsis treated using a 6-hour structured treatment plan
(compared with usual treatment) were more likely to survive and to spend less time in hospital.
The ProMISe (Protocolised Management In Sepsis) study wanted to find out if the 6-hour structured
treatment plan would work in the UK, compared with usual treatment.
What did we do?
A total of 1260 patients from 56 hospitals across the country took part in the study. Patients were evenly
split into two groups to receive either the 6-hour structured treatment plan or usual treatment. They were
followed up for 1 year to see the long-term effects of receiving treatment.
What did we find?
There was no significant difference in the number of patients who died after 3 months or after 1 year of
receiving either treatment. The costs of treatment (in hospital and after leaving hospital) were higher for
patients who received the 6-hour structured treatment plan.
What does this mean?
The 6-hour structured treatment plan did not improve survival for patients with sepsis and was
more expensive.
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Scientific summary
Background
The incidence of severe sepsis and septic shock in adults is estimated to range from 56 to 91 per 100,000
population per year. Affected patients have high mortality, morbidity and resource utilisation.
Since 2002, the Surviving Sepsis Campaign has promoted best practice, which includes early recognition,
source control, appropriate and timely antibiotic administration, and resuscitation with intravenous fluids
and vasoactive drugs. Resuscitation guidance is largely based on a 2001 single-centre, proof-of-concept
trial, which indicated that protocolised delivery of 6 hours of early goal-directed therapy (EGDT) to patients
presenting at the emergency department (ED) with early septic shock reduced hospital mortality and
hospital length of stay. EGDT aims to optimise tissue oxygen transport using continuous monitoring of
pre-specified physiological targets – central venous pressure, mean arterial pressure and central venous
oxygen saturation (ScvO2) – to guide the delivery of intravenous fluids, vasoactive drugs and packed
red blood cell transfusions.
However, despite Surviving Sepsis Campaign recommendations, adoption of EGDT has been limited, with
concerns about the external validity of results from a single-centre trial, the complexity of protocol delivery,
the potential risks of the components and the resources required for implementation.
To address these concerns, multicentre trials of EGDT in the USA (Protocolized Care for Early Septic Shock:
ProCESS), Australasia (Australasian Resuscitation In Sepsis Evaluation: ARISE) and England (Protocolised
Management In Sepsis: ProMISe) were conducted, employing harmonised methods to permit an individual
patient data meta-analysis.
The ProMISe trial tested the hypothesis that the 6-hour EGDT resuscitation protocol is superior, in terms of
clinical effectiveness and cost-effectiveness, to usual resuscitation in patients presenting with early septic
shock to NHS EDs in England.
Objectives
The primary objectives of the trial were:
l to estimate the effect of EGDT compared with usual resuscitation on all-cause mortality at 90 days
l to compare incremental cost-effectiveness at 1 year of EGDT with usual resuscitation.
The secondary objectives were to compare EGDT with usual resuscitation for:
l requirement for, and duration of, critical care unit organ support
l length of stay in the ED, critical care unit and acute hospital
l health-related quality of life at 90 days and at 1 year
l resource use and costs at 90 days and at 1 year
l all-cause mortality at 28 days, at acute hospital discharge and at 1 year
l estimated lifetime incremental cost-effectiveness.
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Methods
Trial design and governance
ProMISe was a pragmatic, open, multicentre, parallel-group randomised controlled trial. The North West
London Research Ethics Committee approved the trial. The UK National Institute for Health Research
funded the trial and convened a Trial Steering Committee and an independent Data Monitoring and Ethics
Committee. The Clinical Trials Unit at the Intensive Care National Audit & Research Centre (ICNARC)
managed the trial. The trial was prospectively registered for an International Standard Randomised
Controlled Trial Number (ISRCTN36307479).
Participants: sites and patients
The trial was conducted in English NHS hospitals not routinely using EGDT including continuous ScvO2
monitoring. Patients aged 18 years or over were eligible if, within 6 hours of ED presentation, they had a
known or presumed infection, two or more systemic inflammatory response syndrome criteria, and either
refractory hypotension (systolic blood pressure < 90mmHg or mean arterial pressure < 65mmHg, despite
intravenous fluid resuscitation of at least 1 l within 60 minutes) or hyperlactataemia (blood lactate
concentration ≥ 4mmol/l) and did not meet any exclusion criteria.
Randomisation had to be completed within 2 hours of meeting inclusion criteria following informed
consent from the patient or agreement from a personal/professional consultee or an independent clinician.
Patients were allocated in a 1 : 1 ratio, via 24-hour telephone randomisation, to EGDT or usual
resuscitation. Allocation was by randomised permuted blocks, with variable block lengths, stratified by site.
Antimicrobials had to be commenced prior to randomisation.
Treatment groups
Following randomisation, the usual-resuscitation group continued to receive monitoring, investigations
and treatment determined by the treating clinician(s) while the EGDT group commenced the resuscitation
protocol. For the latter, during the first hour, a central venous catheter capable of continuous ScvO2
monitoring was inserted. The resuscitation protocol was followed for 6 hours (intervention period) with
personnel involved and treatment location decided by sites, although at least one trained member of staff
was available throughout. All other treatment, during the intervention period and after, was at the discretion
of the treating clinician(s). Blinding to treatment allocation was not possible. Edwards Lifesciences Ltd
(Newbury, Berkshire) lent monitors and provided training and technical support, but had no other role
in the trial.
Data sources
A secure, dedicated electronic case report form was set up to enable trial data to be entered by staff at
participating sites. Inclusion criteria, baseline, intervention, physiology and location of care data to the
point of hospital discharge were collected by the sites. Following linkage with the Health and Social Care
Information Centre Data Linkage and Extract Service to confirm mortality status, a Health Services
Questionnaire and a European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire were sent to
patients at 90 days and 1 year. These provided information about the patient’s use of health services and
quality of life following discharge from the acute hospital. Linkage to the ICNARC Case Mix Programme
database provided information on subsequent admission to adult general critical care following discharge
from the acute hospital.
Analysis principles
All analyses were by intention to treat, following a pre-specified statistical analysis plan. A p-value of 0.05
was considered statistically significant. All tests were two-sided with no adjustment for multiple comparisons.
As missing data for the clinical effectiveness primary outcome were anticipated to be minimal, a sensitivity
approach was taken when the primary outcome was missing. Missing data for the cost-effectiveness analysis,
as well as missing baseline data for adjusted analysis of clinical outcomes, were handled by multiple
imputation using chained equations.
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Outcome measures
The primary clinical effectiveness outcome was all-cause mortality at 90 days. The primary cost-effectiveness
outcome was incremental net monetary benefits (INBs) at £20,000 per quality-adjusted life-year (QALY) at
1 year. Secondary outcomes were Sequential Organ Failure Assessment (SOFA) score at 6 and 72 hours;
receipt of and days alive and free (up to 28 days) from advanced cardiovascular, advanced respiratory or renal
support; ED, critical care and acute hospital length of stay; duration of survival; all-cause mortality at 28 days,
at acute hospital discharge and at 1 year, and health-related quality of life (measured by the EQ-5D-5L
questionnaire), resource use, and costs at 90 days and 1 year, and lifetime incremental cost-effectiveness.
Adverse events were monitored to 30 days. The cost-effectiveness analysis estimated INBs by valuing
incremental QALYs at the threshold value for a QALY gain (£20,000) that is recommended by the National
Institute for Health and Care Excellence and then subtracting the incremental costs.
Secondary analyses of the primary outcomes included adjusted analysis [adjusted for Mortality in
Emergency Department Sepsis (MEDS) score components], learning curve analysis (clinical effectiveness
only) and adherence-adjusted analysis. Pre-specified subgroup analyses were conducted, testing
interactions between the effect of EGDT and the following: degree of protocolised care for usual
resuscitation; age; MEDS score; SOFA score; and time from ED presentation to randomisation. Sensitivity
analyses were performed for missing data in the primary clinical outcome and to test the main
assumptions of the cost-effectiveness analysis.
Results
Sites and patients
In total, 6192 patients were screened at 56 sites, with 1260 enrolled between 16 February 2011 and
24 July 2014. Four patients requested complete withdrawal and five were ineligible, resulting in 1251 patients
for initial analysis (625 EGDT and 626 usual resuscitation). Eight patients withdrew before 90 days, resulting
in 1243 patients for analysis of outcomes (623 EGDT and 620 usual resuscitation). Groups were well matched
at baseline.
Adherence to protocol
Most patients randomised to EGDT had timely insertion of a central venous catheter capable of continuous
ScvO2 monitoring; two, inserted in error in the usual-resuscitation group, were not used for monitoring
ScvO2. Standard central venous catheters (not mandated) were inserted in 50.9% of the usual-resuscitation
group and ScvO2 measurement from aspirated blood samples occurred in six patients. Arterial catheters
(not mandated) were inserted in most patients. EGDT was stopped prematurely in 21 patients. Overall,
adherence to EGDT was good.
Delivery of care by treatment group
During the 6-hour intervention period, EGDT patients received more intravenous fluid. Hourly fluid volume
decreased over the 6 hours but usual-resuscitation patients received a larger initial volume. In both groups,
crystalloid was used more frequently. More EGDT patients received vasopressors and dobutamine.
Although more EGDT patients received packed red blood cells, larger volumes were transfused in the
usual-resuscitation group. During the 6-hour intervention period, administration of platelets and
fresh-frozen plasma was similar, although volumes of both were higher in the EGDT group. At 6 hours,
central venous pressure, mean arterial pressure, systolic blood pressure and haemoglobin, where measured
(greater frequency in the EGDT group), were similar.
Between 6 and 72 hours, use of intravenous fluids was similar but usual-resuscitation patients received
higher volumes. Intravenous colloid use was higher in EGDT patients but volumes were similar in the two
groups, intravenous crystalloid use was similar but volumes were higher in usual-resuscitation patients and
use of packed red blood cells was higher in EGDT patients but the volumes delivered were higher in
usual-resuscitation patients. Although use of platelets and fresh-frozen plasma was similar, the volume of
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platelets transfused was higher in EGDT patients and the volume of fresh-frozen plasma was higher in
usual-resuscitation patients. Vasopressor and dobutamine use remained higher in EGDT patients. At
72 hours, physiological, biochemistry and SOFA values were similar.
Primary outcome: clinical effectiveness
At 90 days following randomisation, 184 (29.5%) patients randomised to EGDT had died, compared with
181 (29.2%) patients randomised to usual resuscitation, corresponding to an absolute risk reduction of
−0.3 [95% confidence interval (CI) −5.4 to 4.7; p= 0.90] and a relative risk of 1.01 (0.85 to 1.20). This
difference remained non-significant after adjustment for baseline characteristics (adjusted odds ratio 0.95,
95% CI 0.74 to 1.24; p= 0.73; unadjusted odds ratio 1.02, 95% CI 0.80 to 1.30).
Secondary outcomes: clinical effectiveness
For EGDT patients, the mean SOFA score at 6 hours, the proportion receiving advanced cardiovascular
support and the median critical care length of stay were significantly greater. No other secondary
outcomes were significantly different. Thirty (4.8%) EGDT patients and 26 (4.2%) usual-resuscitation
patients experienced one or more serious adverse events (p= 0.58).
Subgroup and secondary analyses
There was no difference in effect of EGDT according to pre-specified subgroups (p-values for test of
interaction 0.39 to 0.72). Sensitivity analyses for missing primary outcomes (EGDT, n= 2; usual resuscitation,
n= 6) reported relative risks from 0.99 to 1.03. There was no evidence of a learning-curve effect (p= 0.56).
Adherence-adjusted analysis reported a relative risk of 1.02 (95% CI 0.78 to 1.32; p= 0.90).
Cost-effectiveness analysis
At 1 year following randomisation, a slightly higher proportion of EGDT patients than usual-resuscitation
patients were alive. The net effect of EGDT patients having higher survival but a lower average patients
European Quality of Life-5 Dimensions utility score resulted in similar 1-year QALYs between the treatment
groups. The mean total cost was higher in EGDT patients, with an incremental cost of £764 (95% CI −
£1402 to £2930), and hence the INB for EGDT versus usual resuscitation was negative at −£725 (95% CI
−£3000 to £1550). The estimated INBs were similar for adherence-adjusted analysis and across all
pre-specified subgroups. The estimated INBs were also similar for the alternative scenarios considered in the
sensitivity analyses. The probability that EGDT is cost-effective, at the recommended threshold of £20,000 per
QALY, is below 30%. Cost-effectiveness results were similar at 90 days (INB −£1000, 95% CI −£2720 to
£720) and when extrapolated to the lifetime (INB −£1446, 95% CI −£8102 to £5210).
Conclusions
Among adults identified with early signs of septic shock presenting to the ED of one of 56 NHS hospitals
in England and receiving 6 hours of protocolised resuscitation, there was no significant difference in
mortality at 90 days, compared with usual resuscitation. Although mortality was lower than anticipated,
these results rule out a relative risk reduction with EGDT of > 15%. On average, EGDT increased costs and,
given similar QALYs across groups, INB at 1 year was negative. The probability that EGDT is cost-effective
(at a willingness to pay of £20,000 per QALY) is below 30%.
There was no significant interaction between treatment effect and mortality at 90 days across pre-specified
subgroups. More patients receiving EGDT were admitted to critical care, resulting in significantly more days
spent in critical care in this group. Treatment intensity was greater for EGDT patients, driven by adherence to
the protocol, and indicated by increased use of central venous catheters, intravenous fluids, vasoactive drugs
and packed red blood cells. Increased treatment intensity was reflected in significantly higher SOFA scores
and more advanced cardiovascular support days in critical care for the EGDT group. There were no significant
differences in any other secondary outcomes including health-related quality of life, which was substantially
poorer in this severely ill patient group at both 90 days and 1 year than for the age-/sex-matched
general population.
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Implications for health care
The results suggest that usual resuscitation has evolved over the 15 years since the Rivers et al. trial (Rivers E,
Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of
severe sepsis and septic shock. N Engl J Med 2001;345:1368–77); NHS hospitals now achieve levels of
in-hospital survival similar to those achieved with EGDT in the Rivers et al. trial for patients with septic shock
identified early and receiving intravenous antibiotics and adequate fluid resuscitation. The addition of
continuous ScvO2 monitoring and strict protocolisation of care was, on average, more costly and did not
improve outcomes.
Recommendations for research
Recommendation 1: an individual patient data meta-analysis of the three
completed trials should be conducted
These results complete the planned trio of evaluations of EGDT across the USA, Australasia and England.
Each has their own strengths and weaknesses, but all have indicated that EGDT is not superior to usual
resuscitation. Recognising that each of the three individual large trials has limited power for evaluating
potentially important subgroups, the harmonised approach adopted provides the opportunity to conduct
an individual patient data meta-analysis, enhancing both knowledge and generalisability.
Recommendation 2: further research to consider alternative definitions of
adherence to the resuscitation protocol should be conducted
Both the clinical effectiveness and cost-effectiveness analyses reported estimates that were adherence-adjusted
as part of pre-specified secondary analyses. However, further research to consider alternative definitions of
adherence to the EGDT resuscitation protocol are warranted. In particular, future research could apply
differential weights for adherence to the different elements of the EGDT resuscitation protocol, or to particular
time points within the 6-hour intervention period. Hence subsequent research could report whether EGDT
was clinically effective or cost-effective when these alternative definitions of adherence were met.
Trial registration
This trial is registered as ISRCTN36307479.
Funding
This project was funded by the Health Technology Assessment programme of the National Institute for
Health Research.
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Chapter 1 Introduction
Background and rationale
The incidence of infections severe enough to cause systemic sepsis and septic shock in adults is estimated
to range from 56 to 91 per 100,000 population per year.1 Affected patients have high mortality, morbidity
and resource utilisation.2–5 Efforts to improve care for these patients have been hampered by multiple
factors including limited evidence regarding the timing and delivery of therapies. It has been suggested
that there are ‘golden hours’ in the initial management of emerging septic shock during which prompt,
rigorous, protocolised care may reduce unwanted consequences and improve clinical outcomes.
In 2001, Rivers et al.6 reported the results of a single-centre, randomised controlled trial, which took
place in the USA. This trial investigated the delivery of 6 hours of early goal-directed therapy (EGDT),
with pre-determined haemodynamic goals, to patients presenting at an emergency department (ED) with
emerging septic shock. EGDT, compared with usual resuscitation, significantly reduced hospital mortality
(from 46.5% to 30.5%) and shortened hospital length of stay for survivors. The rationale for EGDT is that
many patients with emerging septic shock have global tissue hypoxia that is not adequately identified
using traditional resuscitation end points (such as blood pressure) and that rapid correction of occult tissue
hypoxia leads to improved survival. Accordingly, resuscitation incorporating EGDT incorporates the invasive
measurement of central venous oxygen saturation (ScvO2) to detect occult global tissue hypoxia. EGDT
aims to optimise tissue oxygen transport by continuous monitoring of pre-specified physiological
targets – central venous pressure, mean arterial pressure and ScvO2 – to guide delivery of intravenous fluids,
vasoactive drugs and packed red blood cell transfusions.
The plausible biological rationale for EGDT, combined with the results of the Rivers et al.6 trial and some
observational studies,7–12 led to its recommendation for the initial management of patients with septic
shock by the Surviving Sepsis Campaign guidelines for the resuscitation and management of severe
sepsis13–15 and incorporation into the associated ‘bundles’ of care.16 However, adoption of, and compliance
with, these resuscitation and management bundles has been limited.2,17
The lack of adoption of EGDT has primarily been due to concerns about the external validity of results
from a single-centre trial, generalisability into other health-care settings, the complexity of delivery of
EGDT, potential risks of the components of EGDT and the resources required for implementation.18,19
Reports of successful implementation of EGDT have identified important enablers, including leadership
(local champion); communication, education and training; buy-in to the protocol; provision for protocol
transition from ED to the intensive care unit (ICU); and locally determined delivery.20,21
Resuscitation practice in the UK, though not standardised across hospitals, usually involves intravenous
fluid and vasoactive drug administration, with the intensity of resuscitation typically being determined by
clinical assessment. Therapeutic strategies to improve ScvO2 are not routinely employed during
resuscitation in UK hospitals.
Despite its promising results, the Rivers et al.6 trial can be considered only as ‘proof of concept’, and it is
necessary to establish whether or not these results are generalisable to the UK NHS. The sample size was small
(n= 263 patients) and single-centre studies often reflect local, and sometimes unique, processes of care. It may
not be possible to replicate the results of single-centre studies in larger, multicentre studies, and important
examples of this have recently been reported in the critical care literature.22
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To address these concerns, three research teams collaborated to conduct multicentre trials of EGDT in the
USA (Protocolized Care for Early Septic Shock: ProCESS),23 Australasia (Australasian Resuscitation In Sepsis
Evaluation: ARISE)24 and England (Protocolised Management In Sepsis: ProMISe). The three trials employed
harmonised methods25 and, following full reporting, data will be pooled into one individual patient data
meta-analysis.26 Both ProCESS23 and ARISE24 have published their results (in March 2014 and October
2014, respectively) and reported no benefit of EGDT. However, both trials reported mortality in the
usual-resuscitation group that was lower than anticipated (ProCESS, 60-day in-hospital mortality,
18.9% observed, 30–46% anticipated; ARISE, 90-day mortality, 18.8% observed, 38% anticipated).
Consequently, neither trial could exclude, with 95% confidence, the potential for a 20% relative reduction
in 90-day mortality for EGDT compared with usual resuscitation [ProCESS, relative risk 0.94, 95%
confidence interval (CI) 0.77 to 1.15; ARISE, relative risk 0.98, 95% CI 0.80 to 1.21].
Aim
The overall aim of the ProMISe trial was to test the hypothesis that EGDT is superior, in terms of both its
clinical effectiveness and its cost-effectiveness, to usual resuscitation in patients presenting with early septic
shock to NHS EDs in England.
Objectives
Primary
The primary objectives of the ProMISe trial were:
l to estimate the effect of EGDT compared with usual resuscitation on all-cause mortality at 90 days
l to compare incremental cost-effectiveness at 1 year of EGDT with usual resuscitation.
Secondary
The secondary objectives of the ProMISe trial were to compare EGDT with usual resuscitation for:
l requirement for, and duration of, critical care unit organ support
l length of stay in the ED, critical care unit and acute hospital
l health-related quality of life at 90 days and at 1 year
l resource use and costs at 90 days and at 1 year
l all-cause mortality at 28 days, at acute hospital discharge and at 1 year
l estimated lifetime incremental cost-effectiveness.
INTRODUCTION
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Chapter 2 Methods
Trial design
ProMISe was a pragmatic, open, multicentre, parallel-group randomised controlled trial with an integrated
economic evaluation.
Research governance
ProMISe was sponsored by the Intensive Care National Audit & Research Centre (ICNARC) and co-ordinated
by the ICNARC Clinical Trials Unit (CTU). An ethics application was made to the North West London Research
Ethics Committee 1 on 4 May 2010 and a favourable opinion was received on 2 August 2010 (reference
number 10/H0722/42).
Global NHS permissions were obtained from London North West Comprehensive Local Research Network
(CLRN) on 8 September 2010 and local NHS permissions were obtained from each participating NHS
hospital trust. A clinical trial site agreement, based on the model agreement for non-commercial research
in the NHS, was signed by each participating NHS hospital trust and the sponsor (ICNARC).
The National Institute for Health Research (NIHR) Clinical Research Network (CRN) Portfolio details
high-quality clinical research studies that are eligible for support from the NIHR CRN in England. The trial
was adopted onto the NIHR CRN Portfolio on 11 July 2011.
To ensure transparency, the trial was registered for an International Standard Randomised Controlled Trial
Number (ISRCTN). Registration was confirmed on 19 November 2009 (ISRCTN36307479).
Following guidelines from the NIHR, a Trial Steering Committee (TSC), with a majority of independent
members, was convened to oversee the trial on behalf of the funder (NIHR) and the sponsor (ICNARC).
The TSC met at least annually during the trial and comprised an independent chair (an experienced triallist);
independent lay members (representing patient perspectives); independent clinicians (specialising in critical
care medicine and emergency care medicine); the chief investigator (KR); and a co-investigator (JB)
representing the Trial Management Group (TMG).
Additionally, an independent Data Monitoring and Ethics Committee (DMEC) was convened to monitor
trial data and ensure the safety of trial participants. The DMEC met at least annually during the trial and
comprised two expert clinicians specialising in critical care medicine and emergency care medicine, and
was chaired by an experienced statistician.
Management of the trial
The trial manager (PM) was responsible for the day-to-day management of the trial with support from the
research assistant (RJ), data manager (JT) and trial statistician (SP). The TMG was responsible for overseeing
the day-to-day management of the trial and comprised the chief investigator (KR), SH, TO and the
co-investigators (DB, JB, TC, DH, MS and DY). The TMG met regularly throughout the trial to ensure
adherence to the trial protocol and to monitor the conduct and progress of the trial.
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Network support
To maintain the profile of the trial, regular updates on trial progress were provided at quarterly meetings
of the NIHR CRN Critical Care Specialty Group and at local CLRN meetings. In addition, updates were
provided at national meetings, such as the Annual Meeting of the Case Mix Programme and the UK
Critical Care Research Forum.
Design and development of the protocol
As part of the international collaboration to evaluate the effectiveness of EGDT for managing patients
with septic shock, the ProMISe TMG worked closely with the ProCESS and ARISE TMGs in developing
the trial protocol to ensure common standards, design elements and the data variables collected across the
three trials. This will enable a prospective individual patient data meta-analysis to be conducted on
completion and publication of all three trials.25
Individuals representing emergency medicine, acute medicine and critical care medicine from NHS hospitals
across the UK were invited to attend a meeting to discuss the trial protocol and the proposed intervention,
EGDT. The meeting took place on 16 March 2010 and was attended by 91 clinicians from 54 NHS
hospitals. The chairperson of the ARISE TMG also attended the meeting to share experiences in the set-up
and ongoing delivery of the ARISE trial in Australasia.
Following the meeting, minor changes were made to Rivers’ EGDT protocol6 as follows:
l arterial catheter – insertion of an arterial catheter was changed from being mandated to recommended
l physiological goals – rather than a range for physiological goals, clinicians agreed that they preferred a
minimum physiological goal, with no upper limit, for both central venous pressure and blood pressure
l blood pressure – a minimum physiological goal was agreed for systolic blood pressure as well as for
mean arterial pressure to allow for variation in practice across NHS hospital trusts.
The trial protocol was approved by the TSC and DMEC.
Amendments to the trial protocol
Following receipt of a favourable opinion of the trial protocol from the research ethics committee on
2 August 2010, five substantial amendments were submitted and received favourable opinion.
In summary, these were as follows.
Amendment 1 (March 2011): the consultee consent form was amended to the consultee agreement form
to clarify that, in accordance with the Mental Capacity Act 2005,27 personal/professional consultees were
being asked for their agreement, rather than their consent, for the patient to participate in the trial.
A telephone agreement form was added to document cases where personal/professional consultee
agreement was obtained via telephone and an emergency consent form was added to document cases
where emergency consent was obtained from an independent clinician.
Amendment 2 (September 2011): in consultation with the research ethics committee, guidance was added
for situations where a patient did not regain the mental capacity to provide informed consent (retrospectively)
to continue participating in the trial; where possible, agreement was to be sought from a personal consultee.
The exclusion criterion – immunosuppressive agents for uncured cancer or immunosuppression for organ
transplantation or from systemic disease – was removed following review by the trial clinicians, who felt that
this was an important group of patients who potentially might benefit from an intervention for septic shock.
In addition, minor semantic changes were made to the trial protocol and the patient follow-up letter.
METHODS
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Amendment 3 (January 2012): the letter to the patient’s general practitioner informing them of the
patient’s participation in the trial was amended for use in cases where the patient was known to have
died. The patient follow-up letters were amended to be specific to the follow-up time point, namely
90 days and 1 year post randomisation. Following feedback from patients, relatives and clinicians, a short
version of the patient information sheet was produced which provided salient information about the trial.
Amendment 4 (November 2012): the exclusion criterion ‘known to be participating in an interventional
study’ was removed following review by the TMG; it was agreed that patients could be co-enrolled into
two interventional studies if, after careful consideration, there were no concerns about patient safety, risk
of biological interaction or the scientific integrity of the trial. Local principal investigators (PIs) were advised
to contact the trial on a case-by-case basis to discuss the co-enrolment of patients. In addition, minor
semantic changes were made to the trial protocol and the consent/consultee agreement forms.
Amendment 5 (November 2013): a newsletter for patients participating in the trial was produced and sent
with the follow-up questionnaires at 90 days and at 1 year post randomisation. Permission was also sought
from the research ethics committee to e-mail follow-up questionnaires to patients, if requested.
NHS support costs
Trials in emergency and critical care are challenging and expensive to conduct. Unlike in other areas of
health care, such as oncology, recruitment cannot take place solely within usual office hours. Resources are
needed to enable screening and recruitment 24 hours per day, 7 days per week. Patients with severe
sepsis and emerging septic shock are more likely to present at the ED in the afternoon through to late at
night. Another challenge of emergency and critical care research is the informed consent process, which
often has to be completed within a very short time frame, as treatments are often time limited. For
ProMISe, consent and randomisation occurred within 2 hours of the patient meeting eligibility. Critically ill
patients usually lack the mental capacity to be able to provide informed consent prior to randomisation, in
which case it is necessary to involve a personal or professional consultee in accordance with the Mental
Capacity Act 2005.27 Senior, experienced staff are needed to be able to assess the patient’s mental
capacity and to be able to effectively communicate information about the trial to the patient and/or their
relatives in a stressful situation.
To this end, resources equivalent to 0.9 whole-time equivalent band 8 research nurse NHS support costs
were successfully agreed with the London North West CLRN on 3 December 2010. Resources were based
on an estimated 22 eligible admissions per site per year, of whom 14 would be recruited and 7 would be
randomised to receive EGDT. Using these recommendations, participating sites, assisted by the TMG,
negotiated resources required locally for the trial with their respective research and development
departments and CLRNs.
Trial equipment
The central venous catheters with ScvO2 monitoring capability (PreSepTM central venous oximetry catheter),
for use in patients allocated to the EGDT (intervention) group, were purchased from Edwards Lifesciences
Ltd (Newbury, Berkshire) and distributed to participating sites by the ICNARC CTU. Edwards Lifesciences
loaned the VigileoTM monitor required for continuous monitoring of ScvO2 to each participating site for the
duration of the trial. Both the PreSepTM central venous oximetry catheter and the VigileoTM monitor are
manufactured by Edwards Lifesciences and are commercially available and licensed for use in the UK.
Each participating site received training in the use of the PreSepTM central venous oximetry catheter and the
VigileoTM monitor, provided free of charge by Edwards Lifesciences. In addition, Edwards Lifesciences
provided 24-hour, 7-days-per-week telephone support for any technical queries. Edwards Lifesciences had
no further role in the trial.
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Patient and public involvement
Engagement with patients was vital to the successful conduct of the trial. Two former critical care patients
were independent members of the TSC and provided input into the conduct of the trial, including reviewing
literature to be given to patients and their families (e.g. patient information sheets and patient newsletters).
Participants: sites
The trial aimed to recruit a representative sample of 48 NHS hospitals in the UK. The criteria for
inclusion were:
l EGDT, including continuous monitoring of ScvO2, was not already part of usual resuscitation for
patients presenting with severe sepsis/septic shock
l agreement from senior clinical staff in emergency care, acute care and critical care to recruit eligible
patients and to adhere to the trial protocol – sites were asked to identify a ‘champion’ from each
specialty to promote the trial locally
l identification of a local PI and a dedicated research nurse to take responsibility for the local conduct of
the trial
l provision of timely data on recruited patients entered onto a secure, dedicated, electronic case
report form.
Invitations for expressions of interest were sent to lead clinicians in acute medicine, emergency medicine
and critical care medicine at NHS hospitals throughout the UK. Invitations were also circulated via the
College of Emergency Medicine, the Society of Acute Medicine and the Intensive Care Society. The trial
was promoted through presentations at national meetings of all three organisations.
Site initiation
Prior to opening sites to recruitment, regional site initiation meetings were held across England. The
purpose of these meetings was to present the background and rationale for the ProMISe trial and to
discuss delivery of the protocol, including screening and recruiting patients; delivery of the intervention,
EGDT; data collection and validation; and safety monitoring. The operational challenges of conducting the
trial at sites were discussed in detail, including strategies for ensuring effective communication between
the ED, the acute care units/ward and the critical care unit. The PI from each participating site was required
to attend the meeting. A representative from Edwards Lifesciences also attended the meeting to provide
training in the use of the PreSepTM central venous oximetry catheter and the VigileoTM monitor to be used
as part of delivery of the intervention, EGDT.
Investigator site file
An investigator site file was provided to all participating sites. This contained all essential documents for
the conduct of the trial and included the approved trial protocol; all relevant approvals (e.g. local NHS
permissions); a signed copy of the clinical trial site agreement; the delegation of trial duties log; copies of
the approved patient information sheets, patient consent form and personal/professional consultee
agreement forms; and all standard operating procedures, for example for screening participants, for
obtaining informed consent or consultee agreement, for randomising patients, for delivery of the
intervention and for collecting and entering data onto the secure, dedicated, electronic case report form.
The site PI was responsible for maintaining the investigator site file.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
Site management
Communication
The trial manager (PM), with support from the data manager (JT) and research assistant (RJ), maintained
close contact with the PI and trial team at participating sites by e-mail and telephone throughout the trial.
Teleconferences were held, initially every month and then every 2 months, with trial teams at participating
sites. The purpose of these was to provide updates on trial progress and to provide a forum for site teams
to ask questions, discuss local barriers and challenges to the conduct of the trial and to share successes
and best practice. Notes, including ‘hints and tips’, from the teleconferences were distributed to all
participating sites. The ICNARC CTU team facilitated communication between sites via an e-mail forum for
research nurses.
Teleconferences were also held with individual site teams, as required, to address site-specific issues in the
conduct of the trial and/or to support training new staff.
Site monitoring visits
At least one routine monitoring visit was conducted at all participating sites during the trial. During the site
visit, the investigator site file was checked for completeness, that is that all essential documents were
present; the patient consent forms, personal/professional consultee agreement forms and emergency
consent forms were checked to ensure that the relevant completed form was present for every patient
recruited into the trial; and a random sample of patient case report forms were checked against the source
data for accuracy and completeness. After the visit, the PI and the site team were provided with a report
summarising the trial documents that had been reviewed and actions required by the site team. The site PI
was responsible for addressing the actions and reporting back to the ICNARC CTU.
Maintenance and motivation
During the trial, an e-mail was sent each week to site teams with an update on patient recruitment and
a newsletter was sent every quarter. These provided an opportunity to clarify any issues related to the
conduct of the trial and to share ideas for maximising recruitment, as well as maintaining motivation and
involvement through regular updates on progress.
To maintain the profile of the trial at participating sites, posters were displayed in staff areas and at
relevant locations within the ED, for example beside the blood gas machine; pocket cards summarising the
eligibility criteria were distributed; and certificates were given to clinical staff in recognition of their
contribution to the trial. Other promotional materials distributed to staff included pens and lanyards.
Support
A 24-hour, 7-days-per-week telephone support service was available to site teams for advice on screening
and recruitment of patients and on delivery of the intervention. In addition, Edwards Lifesciences provided a
24-hour, 7-days-per-week telephone support service for queries relating to the ScvO2 monitoring equipment.
Collaborators’ meeting
A collaborators’ meeting was held on 30 May 2013 to provide an update on trial progress and to provide
a forum for site teams and investigators to discuss operational challenges to the trial and identify possible
solutions, and to share successes and best practice.
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Participants: patients
The trial procedures for recruitment and follow-up of patients are summarised in Figure 1.
Eligibility
Eligibility was confirmed within 6 hours of the patient presenting at the ED. Patients were eligible for
inclusion in the trial if they met all of the following criteria:
l known or presumed infection
l refractory hypotension – defined as a systolic blood pressure of < 90mmHg or a mean arterial pressure
of < 65mmHg, despite an intravenous fluid challenge of a minimum of 1 l (fixed bolus) within
60 minutes (including intravenous fluids administered pre hospital), or hyperlactataemia – defined as a
venous or arterial blood lactate concentration of ≥ 4mmol/l
Randomisation
Via 24-hour central telephone randomisation
Screening
Eligibility met with 6 hours of ED presentation
Follow-up – 90 days
•
•
Primary clinical outcome – mortality
Health-related quality of life, resource use and costs
Informed consent
•
•
If a patient lacked mental capacity, agreement sought from 
personal/professional consultee or emergency consent from 
independent clinician
Retrospective consent obtained from patient once mental 
capacity regained
Early goal-directed therapy
(Intervention; n = 630)
Usual resuscitation
(Control; n = 630)
Follow-up – 1 year
•
•
Mortality
Health-related quality of life, resource use and costs
FIGURE 1 Summary of trial procedures for the recruitment and follow-up of patients. HSCIC, Health and Social
Care Information Centre.
METHODS
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l two or more of the following systemic inflammatory response syndrome (SIRS) criteria:28
¢ core temperature of ≤ 36 °C or of ≥ 38 °C
¢ heart rate of ≥ 90 beats/minute
¢ respiratory rate of ≥ 20 breaths/minute [or hyperventilation indicated by either a partial pressure of
carbon dioxide (PaCO2) of < 4.3 kPa or mechanical ventilation for an acute process]
¢ white blood cell count of ≤ 4 × 109/l or of ≥ 12 × 109/l [or the presence of > 10% immature
neutrophils (bands)].
Patients were excluded from the trial if they met any of the following criteria:
l were aged < 18 years
l had a known pregnancy
l had a primary diagnosis of:
¢ acute cerebral vascular event
¢ acute coronary syndrome
¢ acute pulmonary oedema
¢ status asthmaticus
¢ major cardiac arrhythmia (as part of primary diagnosis)
¢ seizure
¢ drug overdose
¢ injury from burns or trauma
l had haemodynamic instability due to active gastrointestinal haemorrhage
l had a requirement for immediate surgery
l had a known history of acquired immunodeficiency syndrome
l had a do-not-attempt-resuscitation order
l had advanced directives restricting implementation of the EGDT resuscitation protocol
l had a contraindication to central venous catheterisation
l had a contraindication to blood transfusion
l the attending clinician deemed aggressive resuscitation unsuitable
l had been transferred from another in-hospital setting
l were not able to commence the EGDT resuscitation protocol within 1 hour of randomisation or
complete 6 hours of EGDT from commencement.
The first dose of intravenous antimicrobial therapy had to be initiated prior to the patient being randomised.
During the trial, on the advice of the research ethics committee, patients who were known to have a
pre-existing condition, such as dementia, which would have precluded them from providing informed
consent at any point during the trial were also excluded.
Screening and recruitment
Following attendance at a site initiation meeting, screening and recruitment was commenced at participating
sites once the clinical trial site agreement had been signed and all necessary approvals were in place.
To promote awareness of the trial and facilitate recruitment, posters providing information about ProMISe
were displayed in the ED and in family/visitor waiting rooms.
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Potentially eligible patients were identified and approached by authorised members of staff about taking
part in the trial. Information about the trial was provided to the patient; this included the purpose of the
trial, the consequences of taking part or not, data security and funding of the trial. This information was also
provided in a patient information sheet (see Appendix 1), along with the name and contact details of the
local PI, which was given to the patient to read before making the decision whether or not to take part
in the trial. A short version of the patient information sheet, summarising the salient information about the
trial, was also provided (see Appendix 2).
If the patient lacked mental capacity (because of their acute illness) to understand the information about
the trial, then, in accordance with the UK Mental Capacity Act 2005,27 a personal consultee, who could be
a relative or close friend, was identified with whom the patient’s participation in the trial could be
discussed. If there was no personal consultee available, the patient was provided with a professional
consultee – an independent mental capacity advocate appointed by the NHS hospital trust – with whom
the patient’s participation in the trial could be discussed. If there was neither a personal nor a professional
consultee immediately available in person or via the telephone, an independent clinician (senior doctor or
nurse) was consulted in person or via telephone for emergency consent. The personal/professional
consultee or independent clinician was provided with the same information as patients (see Appendix 1)
along with an explanation that they were being asked for their agreement for the patient taking part in
the trial. Patients, personal/professional consultees and independent clinicians were provided with an
opportunity to ask questions before being invited to sign the consent form, personal/professional consultee
agreement form or emergency consent form, as appropriate.
Informed consent
Staff members who had received training on the background, rationale and purpose of ProMISe and on
the principles of the International Conference on Harmonisation Good Clinical Practice guidelines were
authorised to take informed consent from patients, informed agreement from a personal or professional
consultee or emergency consent from an independent clinician.
Once the staff member taking informed consent, consultee agreement or emergency consent was satisfied
that the patient, personal/professional consultee or independent clinician had read and understood the
patient information sheet and all their questions about the trial had been answered, the patient, personal/
professional consultee or independent clinician was invited to sign the consent form, personal/professional
consultee agreement form or emergency consent form, as appropriate.
For patients who had lacked mental capacity prior to randomisation, informed consent to continue
participating in the trial was sought as soon as possible after the patient had regained mental capacity. If a
patient did not regain mental capacity, then, if possible, agreement from a personal consultee was
obtained for the patient to continue participating in the trial.
Randomisation and allocation procedure
Following informed consent from the patient, agreement from a personal/professional consultee or
emergency consent from an independent clinician, eligible patients were randomised within 2 hours of
meeting eligibility via a central 24-hour, 7-days-per-week, telephone randomisation service hosted by
Sealed Envelope Ltd. Patients were randomly allocated 1 : 1 to either the EGDT group or the
usual-resuscitation group, by computer-generated randomised permuted blocks (with variable block
lengths of 4, 6 and 8) stratified by recruiting site. A manual randomisation list was prepared a priori by the
trial statistician in case the central telephone randomisation service was not available for any reason. Staff
at participating sites were advised to call the 24-hours-per-day, 7-days-per-week telephone support service
if they experienced any problems with the central telephone randomisation service. Manual randomisation
was carried out, as required, by the on-call member of the TMG.
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Screening log
To enable full and transparent reporting for the trial, brief details of all patients who met eligibility criteria
or who met all inclusion criteria plus one or more of the exclusion criteria were recorded in the screening
log. The reasons for eligible patients not being recruited were recorded, which included the patient
declining the invitation to take part, the patient being excluded by the treating clinician, logistical reasons,
etc. No patient identifiers were recorded in the screening log.
Treatment groups
Early, goal-directed therapy (intervention)
For patients randomised to the EGDT group, during the first hour (defined as the next whole hour, e.g. if
randomised at 09.24, then by 11.00), a PreSepTM central venous oximetry catheter was inserted into either
a subclavian or an internal jugular vein using standard techniques for central venous access and calibrated
against a sample aspirated from the catheter and analysed by co-oximetry. Central venous catheters
were managed according to the guidelines of the Central Venous Catheter Care Bundle.29 If not already
initiated, supplemental oxygen was administered, with intubation and mechanical ventilation as needed,
to maintain an arterial oxygen saturation (SpO2) of ≥ 93%. An arterial catheter was recommended,
but not mandated.
The EGDT resuscitation protocol (Figure 2) was followed for 6 hours (intervention period) with personnel
involved and treatment location decided by each site. At least one trained member of staff was available
throughout the 6-hour intervention period. All other treatment, during the intervention period and after,
was at the discretion of the treating clinician(s).
Each element of the resuscitation protocol was administered in series or simultaneously, depending on the
clinical assessment of the patient’s requirements. For example, the clinical team could choose to administer
intravenous fluids in conjunction with vasopressors if a patient was in extremis.
Central venous pressure
Intravenous fluid boluses in half-litre or equivalent increments were given every 30 minutes until a
minimum central venous pressure of 8 mmHg was achieved, unless the treating clinician discerned a risk to
patient safety. The type of intravenous fluid and the rate of administration were at the discretion of the
treating clinician(s).
Blood pressure
If the mean arterial pressure was < 65mmHg or the systolic blood pressure was < 90mmHg and the
central venous pressure was at least 8mmHg, vasopressors were administered and titrated to a achieve a
minimum mean arterial pressure of 65mmHg or a systolic blood pressure of 90mmHg. The choice of
vasopressor was at the discretion of the treating clinician(s) based on best evidence, the patient’s clinical
needs and local policy. If the mean arterial pressure was > 90mmHg, clinicians could consider
administering a vasodilator agent to reduce afterload, if clinically indicated.
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Supplemental oxygen for
SpO2 ≥ 93%
Insertion of CVC with ScvO2 monitoring
capability
Insertion of arterial line
CVP ≥ 8 mmHg?
ScvO2 ≥ 70%?
Goals achieved?
Reassess goals
every 30 minutes for 6 hours
500-ml fluid bolus
every 30 minutes until
CVP ≥ 8 mmHg1
Consider
mechanical
ventilation,
sedation and
paralysis
Vasopressor agents
≥ 70%
Hb < 10 g/dl
→ PRBC3
No
Hb ≥ 10 g/dl →
Dobutamine4
ScvO2
< 70%
ScvO2
< 70%
≥ 70%≥ 70%Yes
Yes
No
1.
2.
3.
4.
Crystalloid or colloid equivalent per standard practice
If MAP > 90 mmHg, consider vasodilator
Hb post-i.v. fluid administration
2.5 µg/kg/minute, over 30 minutes initially, then
increased by 2.5 µg/kg/minute every 30 minutes.
Maximum dose 20 µg/kg/minute: reduce/discontinue if
concerned about drug-induced tachycardia
Yes
Yes
Based on patient requirements, each element in the
resuscitation protocol should be:
(a) performed either in series or simultaneously
(b) initiated where there are no potential
      contraindication(s)
(c) delivered at the discretion of the treating clinician(s)
MAP > 65 mmHg?2
SBP > 90 mmHg?
No
No
FIGURE 2 Early goal-directed therapy resuscitation protocol. CVC, central venous catheter; CVP, central venous
pressure; Hb, haemoglobin; i.v., intravenous; MAP, mean arterial pressure; PRBC, packed red blood cells;
SBP, systolic blood pressure.
Central venous oxygen saturation
Once the central venous pressure was at least 8mmHg and the mean arterial pressure was at least
65mmHg or the systolic blood pressure at least 90mmHg, treatment was initiated, if necessary, to achieve
a minimum ScvO2 of 70%. If the ScvO2 was < 70% and the post-fluid resuscitation haemoglobin was
< 10 g/dl, packed red blood cells were transfused. If the ScvO2 was < 70% and the haemoglobin was at
least 10 g/dl, an infusion of dobutamine was commenced, at an initial rate of 2.5 µg/kg/minute for 30 minutes,
and then increased by 2.5 µg/kg/minute every 30 minutes, to a maximum dose of 20 µg/kg/minute, until a
ScvO2 of ≥ 70% was achieved. The dose of dobutamine was reduced or the infusion discontinued if there
was concern about drug-induced tachycardia or arrhythmia. If the ScvO2 remained < 70%, the clinician could
consider mechanical ventilation (with sedation and paralysis) to decrease oxygen consumption.
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Monitoring
Once all physiological goals for central venous pressure, blood pressure and ScvO2 were met, the patient
was monitored continuously for the remainder of the intervention period (a total of 6 hours). If the central
venous pressure, blood pressure or ScvO2 fell below its physiological goal during the 6-hour intervention
period, the EGDT resuscitation protocol recommenced. At the end of 6 hours, continuous ScvO2
monitoring was no longer mandated and the patient returned to standard care.
Usual resuscitation (control)
For patients randomised to usual resuscitation, all investigations, monitoring and treatment were
determined by the treating clinician(s). Although ScvO2 could be measured intermittently, continuous
monitoring of ScvO2 was not permitted in control group patients.
Outcome measures
The primary clinical effectiveness outcome was all-cause mortality at 90 days following randomisation and
the primary cost-effectiveness outcome was incremental net monetary benefit (INB) gained at 1 year, at a
willingness to pay of £20,000 per quality-adjusted life-year (QALY). Secondary outcomes were as follows:
l Sequential Organ Failure Assessment (SOFA) score30 at 6 and 72 hours
l receipt of and days alive and free (up to 28 days) from advanced cardiovascular, advanced respiratory
or renal support31
l ED, critical care and acute hospital length of stay
l duration of survival
l all-cause mortality at 28 days, at acute hospital discharge and at 1 year
l health-related quality of life, resource use and costs at 90 days and at 1 year
l lifetime incremental cost-effectiveness.
Safety monitoring
Patients were monitored for adverse events that occurred between randomisation and 30 days following
randomisation. Specified adverse events were defined as follows:
l pneumothorax – defined as any new pneumothorax requiring insertion of a chest drain
(intercostal catheter)
l haemo-pneumothorax – defined as any new haemo-pneumothorax requiring insertion of a chest drain
l bleeding – defined as any new, overt blood loss requiring transfusion of one or more units of blood
l thrombosis – defined as any new clinical and radiographic evidence of a deep-vein thrombus
l pulmonary emboli – defined as any new evidence from computed tomography pulmonary angiogram
with appropriate clinical history
l vascular catheter infection – defined as any new vascular catheter-related infection in which a vascular
catheter, such as a central venous catheter, was identified as the primary source of infection and
associated with signs and symptoms of infection requiring antimicrobials
l pulmonary oedema – defined as any new radiographic evidence consistent with pulmonary oedema
l blood transfusion reaction – defined as any allergic reaction to blood transfusion, haemolysis related to
incompatible blood type or alteration of the immune system related to blood transfusion
l myocardial ischaemia – defined as any new acute electrocardiogram changes with appropriate clinical
findings and changes in cardiac troponins or non-ST segment elevation myocardial infarction with
appropriate increases in cardiac troponins but without electrocardiogram changes
l peripheral ischaemia – defined as any new sustained depression or loss of arterial pulse (as determined
by palpation or Doppler ultrasonography) resulting in symptoms consistent with ischaemia or
obvious gangrene.
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Unspecified adverse events were defined as an unfavourable symptom or disease temporally associated
with the use of the trial treatment, whether or not it was related to the trial treatment, that was not
deemed to be a direct result of the patient’s medical condition and/or standard critical care treatment.
All adverse events were recorded in the electronic case report form and reported, as part of routine
reporting throughout the trial, to the DMEC and the research ethics committee. Adverse events that were
assessed to be serious (i.e. prolonging hospitalisation or resulting in persistent or significant disability/
incapacity), life-threatening or fatal – collectively termed serious adverse events – were reported to the
ICNARC CTU and reviewed by a clinical member of the TMG. Serious adverse events that were unspecified
and considered to be possibly, probably or definitely related to the trial treatment were reported to the
research ethics committee within 15 calendar days of the event being reported.
Data collection
A secure, dedicated electronic case report form, hosted by ICNARC, was set up to enable trial data to be
entered by staff at participating sites. The electronic case report form was accessible only to authorised
users, and access was approved centrally by the trial manager or the data manager (after cross-checking
the site delegation of trial duties log). Each individual was provided with a unique username and
password, and had access to data only for the patients recruited at their site.
The data set for ProMISe included the minimum data required to confirm patient eligibility, to describe the
patient population, to monitor and describe delivery of the intervention, to assess primary and secondary
outcomes and to enable linkage to the ICNARC Case Mix Programme, the national clinical audit of adult
critical care32 (see Appendix 3).
Randomisation
Data were collected to enable the patient to be randomised, and included confirmation that the patient
met all of the inclusion criteria and none of the exclusion criteria and that the first dose of intravenous
antimicrobial(s) had been initiated (see Appendix 3).
Baseline
The following data were collected at baseline to enable follow-up and to describe the patient population:
l full name and address of the patient and their general practitioner
l date of birth
l sex
l raw physiology data to enable calculation of the of the following severity of illness scores:
¢ SOFA score30 (see Appendix 4)
¢ Acute Physiology And Chronic Health Evaluation version II (APACHE II) score and predicted risk of
hospital death33 (see Appendix 4)
¢ Mortality in Emergency Department Sepsis (MEDS) score34 (see Appendix 4)
l severe comorbidities defined according to APACHE II33 which were present and documented in the past
medical history within the 6 months prior to presentation at the ED (see Appendix 4).
METHODS
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Intervention period
Data were collected hourly throughout the 6-hour intervention period to monitor adherence to the
treatment allocation (EGDT resuscitation or usual resuscitation) and to describe and cost delivery of the
EGDT resuscitation protocol compared with usual resuscitation. During the 6-hour intervention period,
data were collected prospectively for the EGDT group and retrospectively for the usual-resuscitation group
in order to avoid data collection influencing treatment delivery. The data collected comprised:
l interventions delivered during the previous hour, for example supplemental oxygen, mechanical
ventilation, intravenous fluids, blood products and vasoactive drugs
l physiology, for example central venous pressure, blood pressure, ScvO2 and haemoglobin.
At 6 hours
At 6 hours post randomisation, the following data were collected:
l interventions delivered during the previous hour, for example supplemental oxygen, mechanical
ventilation, intravenous fluids, blood products and vasoactive drugs
l physiology, for example central venous pressure, blood pressure, ScvO2 and haemoglobin
l raw physiology data to enable calculation of the SOFA score30 (see Appendix 4).
Ancillary care
Data were collected to describe and cost interventions delivered after the end of the 6-hour intervention
period up to discharge from the acute hospital.
At 24 hours
At 24 hours post randomisation, the following data were collected:
l interventions delivered between 6 and 24 hours, for example supplemental oxygen, mechanical
ventilation, intravenous fluids, blood products and vasoactive drugs
l raw physiology data to enable calculation of the SOFA score30 (see Appendix 4).
At 72 hours
At 72 hours post randomisation, the following data were collected:
l interventions delivered between 24 and 72 hours, for example supplemental oxygen, mechanical
ventilation, intravenous fluids, blood products and vasoactive drugs
l raw physiology data (48–72 hours) to enable calculation of the SOFA score30 (see Appendix 4)
l site of infection and causative organism.
At acute hospital discharge
At the time of discharge from the acute hospital, the following data were collected:
l the locations of care during the patient’s stay in the acute hospital, for example ED, critical care unit
or ward
l date of discharge from, or death in, the acute hospital
l discharge location, for example home, nursing home or other hospital
l organ support, as defined by the UK Department of Health Critical Care Minimum Data Set31
(see Appendix 5) during the critical care unit stay, if applicable
l co-interventions for the source of sepsis, for example surgery, steroids or activated protein C.
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Longer-term follow-up
Following randomisation, a letter was sent to the patient’s general practitioner informing them of the
patient’s participation in the trial and issuing a request for assistance with follow-up, if required. All
patients who survived to leave hospital were followed up at 90 days for the primary clinical effectiveness
outcome (all-cause mortality) and secondary outcomes (health-related quality of life and resource use), and
at 1 year for secondary outcomes (all-cause mortality, duration of survival, health-related quality of life
and resource use) and to calculate the primary cost-effectiveness outcome (INB).
Data linkage with death registration
Follow-up of patients was carefully monitored to prevent any potential distress to those who care for the
patient receiving a letter addressed to a deceased relative, partner or friend. The follow-up process
started at 75 days for the 90-day follow-up and at 350 days for the 1-year follow-up to allow for the
administrative processes. Each week a list of all patients who had been discharged alive from hospital
and who were either 75 days or 350 days post randomisation was sent to the Health and Social Care
Information Centre Data Linkage and Extract Service to confirm their mortality status. Patients indicated as
having died were logged and the follow-up process ended.
Follow-up procedure
Patients identified by the Health and Social Care Information Centre Data Linkage and Extract Service as
not having died started the follow-up process, as summarised in Figure 3. A questionnaire pack was sent
from the ICNARC CTU, by post, to the patient. Following evidence-based practice for maximising
responses to postal surveys,35 the questionnaire pack included a cover letter (see Appendix 6); the patient
information sheet (see Appendix 1) or patient newsletter (which replaced the patient information sheet
in November 2013); two questionnaires – the Health Questionnaire (see Appendix 7) and the Health
Services Questionnaire (see Appendix 7); a stamped, addressed return envelope; and a pen. The Health
Questionnaire (see Appendix 7) included the required questions from the European Quality of Life-5
Letter sent to
general practitioner
If no response after 2 weeks,
patient telephoned, if possible
General practitioner/
recruiting site
contacted for
confirmation
Questionnaire pack
returned, for example
‘not known at this
address’ – patient’s
contact details
checked
HSCIC Data Linkage and
Extract Service identified
patient was not dead
First questionnaire pack
sent to patient
If no response after 2 weeks,
second questionnaire pack
sent to patient
YesNot
confirmed
FIGURE 3 Patient follow-up process at 90 days and at 1 year. HSCIC, Health and Social Care Information Centre.
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Dimensions-5-Level (EQ-5D-5L) questionnaire to evaluate health-related quality of life and the Health
Services Questionnaire (see Appendix 7) included questions about the patient’s use of health services
following discharge from the acute hospital and was used to cost subsequent use of health services.
The cover of the questionnaires included a ‘do not wish to participate’ tick box.
If no response was received after 2 weeks, a reminder letter was sent with another questionnaire pack.
If no response was received after a further 2 weeks, the patient was telephoned, if his or her contact
details were available. Telephone calls were made at various times from Monday to Friday between 08.30
and 20.30 to maximise the chances of contacting the patient. Patients who were successfully contacted by
telephone were asked if they had received the questionnaire pack and were invited to complete the
questionnaires over the telephone, if this was convenient. In addition, patients were reminded about
completing the questionnaire when they attended hospital follow-up appointments.
Follow-up ended on receipt of a completed (or blank) questionnaire; on receipt of a questionnaire with a
ticked ‘do not wish to participate’ box; on notification to the ICNARC CTU by telephone or e-mail that the
patient wished to withdraw from the trial; or if there was no response to the telephone follow-up. For
questionnaire packs returned indicating that the recipient was not known at the address, the contact
details for the patient were checked with the recruiting hospital and/or general practitioner.
For patients who were identified as being either a hospital inpatient or resident in a care home or
rehabilitation centre, the relevant institution was contacted to establish the status of the patient and the
most appropriate way to proceed with follow-up. If the patient had the mental capacity to consent but
required assistance in reading and/or completing the questionnaire, health-care professionals usually
assisted the patient. For patients who lacked the mental capacity to consent, institutions advised on the
most appropriate person to contact to complete the questionnaires.
If patients were identified as having no fixed abode but were registered with a general practitioner or had
regular contact with a homeless shelter, the questionnaire pack was sent to be given (when appropriate)
to them at their next appointment or visit.
Data linkage with the Case Mix Programme
The linkage of patient identifiable trial data to the ICNARC Case Mix Programme database provided information
on subsequent admission to adult, general, critical care following discharge from the acute hospital.32
Data for the CMP are collected by trained data collectors to precise rules and definitions. The data then undergo
extensive local and central validation for completeness, illogicalities and inconsistencies prior to pooling.
Data management
Data management was an ongoing process. Data entered by sites onto the electronic case report form
were monitored and checked throughout the recruitment period to ensure that they were as complete and
accurate as possible.
Two levels of data validation were incorporated into the electronic case report form. The first was to prevent
obviously erroneous data from being entered, for example entering a date of birth that occurred after the
date of randomisation. The second level involved checks for data completeness and any unusual data
entered, for example a physiological variable, such as blood pressure, that was outside the pre-defined
range. Site staff could generate data validation reports, listing all outstanding data queries, at any time via
the electronic case report form. The site PI was responsible for ensuring that all data queries were resolved.
Ongoing data entry and validation at sites were closely monitored by the data manager (JT) and any
concerns were raised with the site PI.
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The contact details for patients and their general practitioners (name and postal address) were checked
weekly for completeness to avoid unnecessary delays in sending out questionnaire packs at 90 days and at
1 year.
Adherence to the trial protocol was closely monitored, including adherence to all elements of the EGDT
resuscitation protocol. Any queries relating to adherence were generated in a separate report which was
sent to the site PI.
Data received from completed European Quality of Life-5 Dimensions (EQ-5D) and Health Services
Questionnaires were entered centrally into a secure database at the ICNARC CTU following a standard
operating procedure. All identifiable information, such as names (e.g. of patients, family members or
hospital staff members), was removed. All queries relating to data entry were reviewed by two members of
the TMG (SH/PM) and any disagreement was reviewed and discussed with a third member (KR).
To ensure that data were entered accurately, all questionnaire data entered into the database were
cross-checked by a second member of the CTU team. Any errors found were logged and corrected on
the database.
Sample size
Estimates for baseline mortality in the usual-resuscitation group were based on the ICNARC Case Mix
Programme database.32 Between 1 January 2005 and 31 December 2006, there were 24,155 patients
admitted to 156 participating adult general ICUs direct from the ED. Of these, 6671 (28%) met at least two
SIRS criteria during the first 24 hours following ICU admission and had evidence of infection. Acute hospital
mortality for these patients was 35%. To allow for additional deaths after discharge from hospital and before
90 days, sample size calculations were based on an anticipated mortality at 90 days of 40% in the
usual-resuscitation group. To achieve 80% power to detect a 20% relative reduction in mortality at 90 days
(corresponding to an 8% absolute reduction) from 40% to 32% associated with EGDT compared with usual
resuscitation (p< 0.05, two-sided) required a sample size of 589 patients per treatment group (Stata/SE version
10.1, StataCorp LP, College Station, TX, USA). Allowing for 6% of patients refusing consent to follow-up
(in the PAC-Man trial, 2% of patients refused consent after randomisation36) or being lost to follow-up before
90 days, our aim was to recruit 630 patients per group (1260 patients in total). This sample size provided
> 99% power to detect an absolute risk reduction of the magnitude observed in the Rivers et al. trial (i.e. 16%).6
Interim analysis
Unblinded comparative data on recruitment, withdrawal, adherence with the trial protocol and serious
adverse events were regularly reviewed by the DMEC. Without specific analysis of the primary outcome,
the DMEC reviewed data from the first 50 trial participants and continued to review data at least 6-monthly
to assess potential safety issues and to review adherence with the trial protocol. A single planned formal
interim analysis was performed once 90-day outcome data from the first 500 patients enrolled were available.
A Haybittle–Peto stopping rule (p< 0.001) was used to guide recommendations for early termination
owing to harm.
Analysis principles
All analyses were based on the intention-to-treat principle. Patients were analysed according to the
treatment group they were randomised to, irrespective of whether or not the allocated treatment was
received (i.e. regardless of whether or not they adhered to the EGDT algorithm). All tests were two-sided
with significance levels set at p< 0.05 and with no adjustment for multiplicity. All a priori subgroup analyses
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were carried out irrespective of whether or not there was strong evidence of a treatment effect associated
with the primary outcome. As missing data for the clinical effectiveness primary outcome were anticipated to
be minimal, a sensitivity approach was taken when the primary outcome was missing (see Secondary
analyses of the primary outcome). Missing data for the cost-effectiveness analysis, as well as missing baseline
data for adjusted analysis of clinical outcomes, were handled by multiple imputation.
Multiple imputation
Missing data in baseline covariates, resource use and health-related quality of life variables at 90 days and
1 year were handled with multivariate imputation by chained equations.37 Under this approach each
variable was imputed conditional on fully observed baseline variables such as age, sex, past medical
history, site of sepsis, SOFA score, MEDS score, admitted from nursing home, length of stay in critical
care and general medical wards up to 90 days and 1 year, and all other imputed variables. Patients who
were eligible for 90-day follow-up (i.e. alive at 90 days) but did not return or fully complete the EQ-5D
questionnaire administered at 90 days, had their EQ-5D utility scores imputed from those survivors who did
fully complete the questionnaire. Similarly, for those eligible patients who did not return the Health Services
Questionnaire, information on the use of outpatient services up to 90 days following randomisation, was
imputed from those patients who did complete this questionnaire. In the same way, patients who were
eligible for 1-year follow-up but did not return or fully complete the EQ-5D questionnaire or the Health
Services Questionnaire administered at 1 year also had their information imputed from those survivors who
did fully complete the questionnaire. When addressing the missing data, multiple imputation assumes that
the data are missing at random conditional on the observed data.
The same multiple imputation approach was used to address the administrative censoring, which applied
to the total costs, vital status and quality of life at 1 year for patients randomised after 12 November 2013.
In this case it was assumed that the data were censored completely at random, which was plausible as the
censoring was administrative, that is it is unlikely that there would be systematic differences between those
whose end points (cost, vital status and quality of life) were observed and those who were censored.
One-year cost and quality-of-life end points were conditional on survival status; as such, the imputation
was conducted in 2 stages. In the first stage, imputation models were specified for mortality at 1 year
according to baseline covariates and auxiliary variables, including duration of the initial inpatient stay, and
costs at 90 days. In the second stage, for each of the imputed data sets from stage 1, imputation models
were specified for costs and quality of life at 1 year for those patients who were missing these but were
known to be alive at 1 year, or were predicted to be alive by the first-stage imputation model. These
imputation models included those variables in the first-stage imputation model but also information on
costs and quality of life at 1 year for those individuals for whom this end point was observed. Each of the
resultant estimates was combined with Rubin’s rules, which recognise uncertainty both within and
between imputations. All multiple imputation models were implemented in the statistical package R
(The R Foundation for Statistical Computing, Vienna, Austria).
Statistical analysis: clinical effectiveness
Statistical analyses were conducted according to a pre-specified, published statistical analysis plan.38
The final analyses were conducted using Stata/SE version 13.0.
Baseline characteristics
Baseline demographic and clinical data were summarised by treatment group but not subjected to
statistical testing. Discrete variables were summarised as numbers and percentages, which were calculated
according to the number of patients for whom data were available; where values were missing, the
denominator was reported. Continuous variables were summarised by standard measures of central
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tendency and dispersion: mean and standard deviation (SD) and/or median and interquartile range (IQR),
as specified below.
l Inclusion criteria
¢ refractory hypotension, n (%)
¢ systolic blood pressure or mean arterial pressure value at which criterion for refractory
hypotension was met, mean (SD)
¢ hyperlactataemia, n (%)
¢ blood lactate value at which criterion for hyperlactataemia was met, mean (SD).
l Age, mean (SD) and median (IQR).
l Sex, n (%).
l Severe comorbidities (as defined by APACHE II33), n (%).
¢ severe liver disease
¢ severe renal disease
¢ severe respiratory disease
¢ severe cardiovascular disease
¢ immunocompromised.
l Pre-randomisation treatment, n (%) received and median (IQR) volume of
¢ intravenous fluids (total before admission to hospital and total from ED presentation to randomisation)
¢ blood products (total from ED presentation to randomisation).
l Acute severity of illness.
¢ APACHE II score,33 mean (SD) and median (IQR)
¢ MEDS score,34 mean (SD) and median (IQR)
¢ individual MEDS score components, n (%)
¢ SOFA score,30 mean (SD) and median (IQR)
¢ individual SOFA score components, n (%).
l Time from ED presentation to inclusion criteria met, mean (SD) and median (IQR).
l Time from ED presentation to randomisation, mean (SD) and median (IQR).
l Patient likely to be admitted directly to ICU from ED if not enrolled in ProMISe, n (%).
l Infection, n (%).
¢ site
¢ organism
¢ antimicrobial change between ED presentation and 72 hours.
Adherence
Non-adherence with the allocated treatment was reported as:
l insertion of a central venous catheter with ScvO2 monitoring capability to a patient allocated to
usual resuscitation
l failure to insert a central venous catheter with ScvO2 monitoring capability to a patient allocated to EGDT
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l failure to act on a goal in the EGDT algorithm for a patient allocated to EGDT, defined as
¢ no fluid resuscitation when central venous pressure < 8mmHg
¢ no administration of vasopressors when mean arterial pressure < 65mmHg or systolic blood
pressure < 90mmHg and the central venous pressure goal was met
¢ no administration of packed red blood cells when ScvO2 < 70% and haemoglobin < 10 g/dl and
the central venous pressure and blood pressure goals were met
¢ no administration of dobutamine when ScvO2 < 70% and haemoglobin ≥ 10 g/dl and the central
venous pressure and blood pressure goals were met
l early (< 6 hours) termination of EGDT in a patient allocated to EGDT (other than due to death or
discharge from hospital).
For comparison, adherence in ProMISe was also assessed according to the criteria used in the published
reports of ProCESS23 and ARISE.24
Delivery of care
Delivery of care was summarised by treatment group but not subjected to statistical testing. As with
baseline characteristics, discrete variables were summarised as numbers and percentages. Percentages
were calculated according to the number of patients for whom data were available; where values were
missing, the denominator was reported. Continuous variables were summarised by mean (SD) and/or
median (IQR).
Intervention data were summarised as the total over the 6-hour intervention period (hour 0 to hour 6); the
total from the end of the 6-hour intervention period to the end of the first 72 hours (hour 6 to hour 72);
and from randomisation to the end of the first 72 hours (hour 0 to hour 72). Where measurements were
recorded, baseline values were also reported. Catheter insertion and location of care details were included
in the hour 0 to hour 6 table. The following were reported:
l catheter insertion, n (%), and time from randomisation to insertion, mean (SD) and median (IQR)
¢ central venous catheter with ScvO2 monitoring capability
¢ any central venous catheter
¢ arterial catheter
l interventions, n (%) received
¢ supplemental oxygen
¢ mechanical ventilation
l fluids, n (%) received and mean (SD) and median (IQR) volume of
¢ any intravenous fluid
¢ intravenous colloid
¢ intravenous crystalloid
¢ packed red blood cell transfusion
¢ platelets
¢ fresh-frozen plasma
DOI: 10.3310/hta19970 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 97
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Mouncey et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
21
l drugs, n (%) received
¢ vasopressors
¢ dobutamine
¢ sedatives
¢ neuromuscular blocking agent
l co-interventions for the source of sepsis, n (%) received
¢ surgery
¢ activated protein C
¢ steroids
l location of care
¢ critical care admission, n (%), and mean (SD) and median (IQR) time from randomisation
to admission
¢ location of protocol delivery, n (%)
¢ review by consultant, n (%)
¢ specialty of most senior doctor to review the patient, n (%).
The mean volume of intravenous fluids and the number and percentage receiving vasopressors, packed red
blood cell transfusions, dobutamine, sedatives, mechanical ventilation and neuromuscular blocking agents
were additionally reported hourly for the duration of the 6-hour intervention period.
Physiology data were summarised as the total over the 6-hour intervention period (hour 0 to hour 6); the
total from the end of the 6-hour intervention period to the end of the first 24 hours (hour 6 to hour 24);
and from the end of the first 48 hours to the end of the first 72 hours (hour 48 to hour 72). Where
measurements were recorded, baseline values were also reported. The following values were reported:
l lowest mean arterial pressure, mean (SD)
l lowest systolic blood pressure, mean (SD)
l haemoglobin value at the end of the time period, mean (SD)
l blood lactate value at the end of the time period, mean (SD)
l lowest partial pressure of oxygen (PaO2)/fraction of inspired oxygen (F iO2), mean (SD)
l highest creatinine, mean (SD)
l highest bilirubin, mean (SD)
l lowest platelets, mean (SD)
l lowest Glasgow Coma Scale (GCS) score, mean (SD)
l individual SOFA score components, n (%).
Mean (SD) of central venous pressure, mean arterial pressure, systolic blood pressure and ScvO2 were
additionally reported hourly for the duration of the 6-hour intervention period.
Primary outcome: clinical effectiveness
The number and percentage of deaths at 90 days following randomisation due to any cause were reported
for each treatment group. The primary effect estimate was the relative risk of all-cause mortality at
90 days, reported with a 95% CI. The absolute risk reduction and 95% CI were also reported. Deaths at
90 days after randomisation were compared between the treatment groups, unadjusted, using Fisher’s
exact test. A secondary analysis of the primary outcome, adjusted for baseline variables, was conducted
using multilevel logistic regression. Baseline variables adjusted for in the multilevel logistic regression model
were the components of the MEDS score (age, metastatic cancer, nursing home residence, altered mental
status, septic shock, respiratory difficulty, low platelet count, high bandforms and low neutrophil count)
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and a site-level random effect. Baseline variables were selected for inclusion in the adjusted analysis
according to anticipated relationship with outcome. The results of the multilevel logistic regression model
were reported as an adjusted odds ratio with 95% CI. The unadjusted odds ratio was presented
for comparison.
Secondary outcomes: clinical effectiveness
The mean SOFA score at 6 hours and 72 hours after randomisation was reported for each treatment
group. Differences in the mean SOFA score at 6 hours and 72 hours after randomisation were compared,
adjusted for baseline SOFA score, using analysis of covariance.
The number and percentage of patients receiving advanced cardiovascular, advanced respiratory and renal
support were reported for each treatment group. Differences in receipt of advanced cardiovascular,
advanced respiratory and renal support were compared, unadjusted, using Fisher’s exact test. The mean
(SD) of the number of days alive and free from advanced cardiovascular, advanced respiratory and renal
support, up to 28 days, in each treatment group were reported. Patients who died within the first 28 days
were assigned 0 days alive and free of each organ support. Differences between the treatment groups
were tested using the t-test, using the non-parametric bootstrap to account for anticipated non-normality
in the distributions.39 A total of 1000 bootstrap replications were taken, stratified by treatment group, with
bias-corrected and accelerated CIs reported.
The median (IQR) of the length of stay in the ED, in critical care and in acute hospital was reported for
each treatment group. Differences in length of stay between the treatment groups were tested using the
Wilcoxon rank-sum test, stratified by survival at end of ED stay, critical care discharge and acute hospital
discharge, respectively.
Kaplan–Meier curves by treatment group were plotted up to 90 days and 1 year after randomisation and
compared using the log-rank test. An adjusted comparison was performed using a Cox proportional
hazards model adjusted for the same baseline variables as the primary outcome, including shared frailty
within sites (gamma-distributed latent random effects). The appropriateness of the proportional hazards
assumption was assessed graphically by plotting –log[−log(survival)] against log(time) within treatment
groups. The number and percentage of deaths at acute hospital discharge and by 28 days, 90 days and
1 year after randomisation were reported for the treatment groups. Differences in all-cause mortality at
each time point were compared, unadjusted, using Fisher’s exact test and adjusted using multilevel logistic
regression, adjusted for the same baseline variables as the primary outcome.
Safety monitoring
The number and percentage of patients experiencing each serious adverse event (occurring between
randomisation and 30 days) were reported for each treatment group. The total number of patients
experiencing one or more serious adverse events was compared between treatment groups using Fisher’s
exact test and summarised as a relative risk with 95% CI.
Subgroup analyses of the primary outcome
Subgroup analyses were conducted using the likelihood ratio test to assess interactions between treatment
group and pre-specified subgroups in multilevel logistic regression models for all-cause mortality at 90 days,
adjusted for the same baseline variables as the analysis of the primary outcome. The subgroups compared
were degree of protocolised care for the usual-resuscitation group; age; MEDS score; SOFA score; and time
from ED presentation to randomisation. Degree of protocolised care for the usual-resuscitation group was
assessed based on established guidelines14,16,40 as the proportion of patients allocated to the usual-resuscitation
group that had lactate measured at baseline and, if ≥ 4mmol/l at baseline, remeasured within 6 hours.
Sites were categorised as having a higher degree of protocolised care if the proportion of patients in the
usual-resuscitation group who met this condition was > 50%. Sites with fewer than three patients allocated
to the usual-resuscitation group were excluded from this subgroup analysis. The remaining subgroups were
analysed in quartiles.
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Secondary analyses of the primary outcome
Sensitivity analyses for missing data in the primary outcome
The primary analysis was repeated once, assuming that all patients allocated to EGDT with missing data in
the primary outcome survived and all patients allocated to usual resuscitation with missing data in the
primary outcome did not survive. The analysis was then repeated again with the opposite assumptions.
This gave the absolute range of how much the results could change if the primary outcome was complete.
Learning curve analysis
The delivery of a complex intervention may improve with time as those delivering the intervention
gain experience and familiarity. Typically, such improvements will be more rapid at first and then tail off
over time to reach a steady state; this relationship is termed a ‘learning curve’. Modelling the learning
curve enables estimation of the treatment effect for an experienced team (the asymptotic value to which
the curve trends over time). A site-level learning curve for patients allocated to EGDT was modelled by
repeating the multilevel logistic regression on the primary outcome and including a power curve (aX−b) for
the sequential observation number (X) for each EGDT patient within each site.41 The power curve model
was estimated by direct maximisation of the log-likelihood function using a modified Newton–Raphson
algorithm.42 A single estimate for each of the parameters a and b was fitted across all sites.
Adherence-adjusted analysis
While the intention-to-treat analysis gives the best estimate of the clinical effectiveness of EGDT as delivered,
it is also of interest to estimate what the efficacy of this intervention may be if all elements of the protocol
were delivered as intended. In a randomised controlled trial, the allocated treatment can be used as an
‘instrumental variable’, that is, a variable associated with receipt of the intervention and only associated with
the outcome through its association with the intervention.43 This relationship enables us to estimate what
the treatment effect would be for patients who were fully adherent to the protocol. The primary analysis
was repeated, adjusting for adherence using a structural mean model with an instrumental variable of
allocated treatment, assuming a linear relationship between the degree of adherence (proportion of the
6 hours that the patient was adherent to the EGDT protocol) and treatment effect.37,44
Cost-effectiveness analysis
A full cost-effectiveness analysis was undertaken to assess which treatment strategy, EGDT or usual
resuscitation, was more cost-effective. This analysis assessed whether or not any intervention costs
associated with EGDT were offset by any subsequent reduction in morbidity costs, for example from
reduced use of critical care, and whether there were improvements in either mortality or health-related
quality of life. The cost-effectiveness analysis was reported for three time periods: randomisation to
90 days, randomisation to 1 year and lifetime. For each time period the cost-effectiveness analysis took a
health and personal health services perspective,45 using information on health-related quality of life
collected at 90-day and 1-year follow-up, combined with information on vital status, to report QALYs.
Each QALY was valued using the National Institute for Health and Care Excellence (NICE)-recommended
threshold of willingness to pay for a QALY gain (£20,000), in conjunction with the costs of each treatment
strategy to report the INBs of EGDT versus usual resuscitation.
The primary objective of the cost-effectiveness analysis was to compare incremental cost-effectiveness at
1 year between the treatment groups. There were also a number of secondary objectives:
l to compare health-related quality of life at 90 days and 1 year between the treatment groups
l to compare resource use and costs at 90 days and 1 year between the treatment groups
l to estimate the lifetime incremental cost-effectiveness between the treatment groups.
The main assumptions of the cost-effectiveness analysis were subjected to extensive sensitivity analyses.
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Resource use
The resource use categories considered were chosen a priori, where differences between the treatment
groups were judged as being possible and likely to drive incremental costs, and were reported for each
treatment group. Data for interventions, staff time and acute hospital stay for the index hospital admission
were collected as part of the ProMISe data set. Readmissions to acute hospital including a critical care stay
were identified from the Case Mix Programme database.32 Readmission to acute hospital not involving
critical care as well as hospital outpatient and community services use were collected as part of the Health
Services Questionnaires completed at 90 days and 1 year.
Interventions
The type of catheter inserted (central venous catheter capable of ScvO2 monitoring, standard central
venous catheter and/or arterial catheter) as well as the use of other catheter insertion-related consumables
including pressure transducers to measure intravascular pressures, and the consumables (saline infusion,
cleaning packs, sterile gloves) associated with each type of catheter insertion were considered (Table 1).
The use of packed red blood cells, platelets, fresh-frozen plasma and dobutamine was also considered. The
costs associated with other clinical interventions such as intravenous crystalloid, intravenous colloid,
albumin, other blood products and other vasoactive drugs were not anticipated to differ across treatment
groups. As such, these were not considered as separate items; however, their costs were included within
the unit cost per critical care bed-day according to the Healthcare Resource Group definition. The duration
for which EGDT was delivered (up to 6 hours) in the ED and in total was reported.
Staff time
The EGDT protocol required additional staff time for central venous catheter insertion (doctors’ time);
monitor set-up (nurses’ time); monitoring patients in ED (nurses’ time); and staff training (nurses’ and
doctors’ time). The level of additional staff time for EGDT was estimated according to expert opinion (see
Table 1), with alternative levels considered in the sensitivity analyses. It was assumed that in the ED at least
one trained nurse was available for the duration of delivery of EGDT. The base-case analysis assumed that,
when delivered in the ED, each patient in the EGDT group required an additional 10 minutes of nurses’
monitoring time per hour of EGDT. To provide EGDT in the ED as part of routine practice required
additional formal or informal training beyond the existing hospital education program. It was assumed that
at each site each clinical member of ED staff required 20 minutes’ additional training to deliver EGDT. The
total training time for introducing the EGDT protocol into the ED was then calculated for each site in the
trial. The average mix of ED staff was assumed to be seven (attending) consultants, 23 junior doctors and
75 nurses46 over the life cycle of EGDT, which was assumed to be 5 years. Where EGDT was delivered in
ICU, it was assumed that no additional staff training time or monitoring time for patients was required.
TABLE 1 Equipment, consumables and staff time for catheter insertion and monitor set-up
Catheter Equipment
Doctor time
(catheter insertion)
Nurse time
(monitor set-up) Consumables
PreSepTM central
venous oximetry
catheter
Monitor 30 minutes 20 minutesa+
30 minutesb
Transducer,a saline, consumables
pack for insertion
Standard CVC – 30 minutes 20 minutesa Transducer,a saline, consumables
pack for insertion
Arterial catheter – 20 minutes 20 minutesa Transducer,a saline, skin cleaning
device and dressing
CVC, central venous catheter.
a It is assumed that one transducer pack and the same amount of nurse time is required whether single or multiple
catheters are inserted.
b Additional nurse time for setting up the monitor.
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Acute hospital length of stay
Length of stay in ED, critical care and general medical wards within the index acute hospital admission
(i.e. the hospital in which a patient was randomised to the trial) were reported. For critical care stays,
Healthcare Resource Groups were assigned according to the maximum number of organs supported
during the stay.31 An acute hospital readmission was defined as a further hospital admission, for any
reason, following discharge from the index admission. Length of stay in critical care and general medical
wards within acute hospital readmissions were taken from the Case Mix Programme database and the
Health Services Questionnaires.
Hospital outpatient visits and community service use
The number of hospital outpatient visits and community service use for any reason were reported. Items of
community service use included visits to the general practitioner (family doctor), nurse, health visitor,
occupational therapist, physiotherapist and psychologist. The levels of resource use were taken from
responses to the Health Services Questionnaire.
Unit costs
The unit costs required for valuing the resource use data listed in Table 2 were taken from three sources:
manufacturers’ list and procurement prices, national unit cost databases and published sources. The unit
costs of the additional monitor and central venous catheter required for delivering EGDT were obtained
from the manufacturer and the procurement department of a participating hospital. The fixed unit costs of
the monitor were assigned to an individual patient, according to the assumed 5-year life cycle of the
monitor, and assuming that the volume of eligible patients was the annual average recorded in the trial
screening logs. In calculating the unit cost per patient, it was also assumed that to provide EGDT in routine
practice each site would require two monitors, which would have an average lifespan of 5 years. The
monitor costs per patient were calculated by dividing the total costs of the monitors by the expected
number of eligible patients over 5 years. Unit costs for blood products and other drugs were taken from
NHS Blood and Transplant47 and the British National Formulary.48
TABLE 2 Unit costs in GBP
Items Unit costs (£) Source
Equipment and consumables
Monitora 70 Manufacturer’s price
PreSepTM central venous oximetry catheter 130 Manufacturer’s price
Standard CVC 24 Local NHS finance department
Arterial catheter 13 Local NHS finance department
Other equipment/consumables
Transducer 13 NHS supply chain
Insertion pack for CVCb 22 Local NHS finance department
Cleaning device for arterial catheterb 5 Local NHS finance department
Blood products
PRBC (280ml) 122 NHSBT47
Platelets (200ml) 208 NHSBT47
Frozen fresh plasma (250ml) 28 NHSBT47
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TABLE 2 Unit costs in GBP (continued )
Items Unit costs (£) Source
Drugs
Dobutamine (250mg)c 9 BNF48
Staff time
Doctor: consultant (per hour) 139 Curtis49
Doctor: registrar level (per hour) 59 Curtis49
Nurse: grade 6 (per hour) 49 Curtis49
Staff training costs (per patient)d 11 ProMISe data and assumption
Hospital costs (bed-day)
ED (per hour) 27 Dixon et al. 200950
Critical care bed-day: 0 organs supported 619 Department of Health51
Critical care bed-day: 1 organ supported 852 Department of Health51
Critical care bed-day: 2 organs supported 1236 Department of Health51
Critical care bed-day: 3 organs supported 1422 Department of Health51
Critical care bed-day: 4 organs supported 1573 Department of Health51
Critical care bed-day: 5 organs supported 1697 Department of Health51
Critical care bed-day: 6+ organs supported 1867 Department of Health51
General ward bed-day 265 Department of Health51
Outpatient and community health services
Hospital outpatient (per visit) 135 Curtis49
GP practice visit (per visit) 45 Curtis49
GP home visit (per visit) 114 Curtis49
GP practice nursee 10 Curtis49
Hospital staff nursee 12 Curtis49
Health visitore 13 Curtis49
Occupational therapiste 9 Curtis49
Psychologiste 15 Curtis49
Speech and language therapiste 9 Curtis49
Physiotherapiste 9 Curtis49
Dietitiane 9 Curtis49
BNF, British National Formulary; CVC, central venous catheter; GP, general practitioner; NHSBT, NHS Blood and Transport;
PRBC, packed red blood cells.
a Two monitors per site over average life span of 5 years were costed. The monitor costs per patient were calculated by
dividing the total costs of the monitors (£4000 each) by the expected number of eligible patients (23 patients per year)
over 5 years.
b Cost of saline included.
c Cost of syringe, giving set and saline included.
d The training costs per patient per hour of protocol were calculated from total training costs per site divided by total
eligible patients (23 patients per site per year) over 5 years.
e 15 minutes of consultation time.
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The unit costs associated with the additional staff training required to deliver EGDT were taken from
national sources. The total additional training cost per site was calculated by valuing the time of the
average mix of ED staff who required training to deliver EGDT. The average additional staff training cost
per patient was calculated by dividing the total training costs per site, by the volume of eligible patients
per site over 5 years, the assumed life cycle of EGDT. The costs per critical care bed-day, by Healthcare
Resource Group, and per general medical bed-day were taken from the ‘Payment by Results’ database.51
Unit costs for hospital outpatient visits and community service use were obtained from a recommended
published source for Health and Social Care costs.49 All unit costs were reported in 2012–13 prices.
Health-related quality of life
The responses to the EQ-5D questionnaire were used to report each patient’s described health, which was
then valued according to health state preferences from the general population to calculate EQ-5D utility
scores, anchored on a scale from 0 (death) to 1 (perfect health).52 The number and percentage of patients
in each level of each dimension were reported by treatment group.
Sensitivity analysis
The main assumptions of the cost-effectiveness analysis were subjected to extensive sensitivity analyses.
The main assumptions made in the base-case scenario, and how each was relaxed in sensitivity analyses,
are detailed below and summarised in Table 3.
Equipment costs for the intervention
In the base case, unit costs for the monitor and central venous catheter for ScvO2 monitoring were taken
from the manufacturer’s discounted costs, which were judged to be those which would be paid by NHS
providers if EGDT was introduced into routine clinical practice. These unit costs imply discounts of over 50%
from list prices. In the sensitivity analysis, full list prices were applied for the requisite monitor and catheters.
Staff monitoring time during delivery of the early goal-directed therapy
resuscitation protocol
The intervention requires intensive monitoring of patients for the duration of EGDT (up to 6 hours). In the
base case, it was assumed that this monitoring would require an additional 10 minutes of nurses’ time per
hour of the resuscitation protocol. In the sensitivity analysis, the additional nurses’ time was varied from
5 to 15 minutes per hour over the duration of EGDT.
Staff training time for delivery of the early goal-directed therapy
resuscitation protocol
The base-case analysis assumed that when EGDT was provided in the ED, each member of staff would require
20 minutes of training. In the sensitivity analysis, training time was varied between 15 and 30 minutes.
TABLE 3 Alternative assumptions for sensitivity analysis
Assumption Base case Sensitivity analysis
Equipment costs for the
intervention
Unit costs as per business deal option Manufacturer’s list price
Staff monitoring time 10 minutes per hour of protocol 5–15 minutes per hour of protocol
Staff training time 20 minutes’ training time for all ED staff 15–30 minutes’ training time for all ED staff
Location of protocol delivery Protocol delivered in both ED and ICU Protocol delivered exclusively either in ED or
in ICU
Readmissions from Health
Services Questionnaires
Included in the analysis Excluded from the analysis
Baseline covariates Unadjusted analysis Adjusted for components of MEDS score
Distributional assumptions Costs and QALYs normally distributed Costs and QALYs gamma distributed
METHODS
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Location of delivery of the early goal-directed therapy resuscitation protocol
The base-case analysis incorporated the relative time that each patient in the EGDT group received the
protocol in the ED versus an ICU. In practice, EGDT may be exclusively delivered in either setting. The
sensitivity analysis allowed the costs of monitoring and training to reflect either extreme, namely EGDT
delivered entirely in the ED or EGDT delivered entirely in ICU. All other aspects of staff time required to
deliver the EGDT protocol were assumed to be the same across location (ED or ICU). As with the preceding
scenarios, only the costs were allowed to change in the sensitivity analysis; it was assumed that the relative
effectiveness of EGDT versus usual care was the same as in the original base-case analysis.
Readmissions from Health Services Questionnaire
The base-case analysis included hospital readmissions including a critical care stay recorded in the Case Mix
Programme database but also hospital readmissions recorded from responses to the Health Services
Questionnaire. To consider the possible impact of double-counting the same readmissions across both sources,
in the sensitivity analysis only the readmissions from the Case Mix Programme database were included.
Baseline covariates
The base-case analysis reported incremental costs and QALYs without any covariate adjustment, assuming
randomisation had ensured no imbalances in key prognostic factors such as components of the MEDS
score.34 In the sensitivity analysis, any chance imbalances in components of the MEDS score were adjusted
for using seemingly unrelated regression.
Distributional assumptions for costs and quality-adjusted life-years
The base-case analysis assumed that costs and QALYs were normally distributed when reporting the 95%
CIs around incremental costs and QALYs. In sensitivity analyses the robustness of the cost-effectiveness
results to alternative distributional assumptions about both outcomes were assessed. Following
methodological guidance, the sensitivity analysis considered a gamma distribution for costs as they had a
right-skewed distribution. For QALYs, the sensitivity analysis also considered a gamma distribution because
a large proportion of decedents had zero QALYs, and the remainder of the distribution was again
right-skewed. In this sensitivity analysis, costs and QALYs were modelled as univariate regression models
assuming a gamma distribution for each end point (i.e. ignoring possible correlation between the end points).
Cost-effectiveness at 90 days following randomisation
Mean EQ-5D utility scores, QALYs, total costs and INBs up to 90 days were reported for each treatment
group. Unadjusted mean differences between the treatment groups in quality of life, QALYs, incremental
costs and INBs at 90 days were reported with 95% CIs. These were reported both overall and by each of
the pre-specified subgroups, and tested using the t-test.
For survivors at 90 days, QALYs were calculated by valuing each patient’s survival time by their
health-related quality of life according to the ‘area under the curve’ approach,53 assuming an EQ-5D utility
score of zero at randomisation, and a linear interpolation between randomisation and 90 days. Zero
QALYs were assumed for decedents between randomisation and 90 days. Total costs up to 90 days were
calculated by combining the resource use with unit costs. The differences in average costs and QALYs
between the treatment groups were used to calculate the INBs of EGDT versus usual resuscitation. The
incremental QALY was valued according to the NICE recommended threshold of willingness to pay for a
QALY gain (£20,000); the incremental cost was then subtracted from this.
The uncertainty around the differences in average costs and QALYs between the treatment groups was
illustrated on the cost-effectiveness plane. The incremental costs and QALYs were estimated with a
seemingly unrelated regression model. To express the uncertainty in the estimation of the incremental
costs and QALYs, the estimates of the means, variances and the covariance from the regression model
were used to generate 500 estimates of incremental costs and QALYs from the joint distribution of these
end points, assuming asymptotic normality. These incremental costs and QALYs were then plotted on the
cost-effectiveness plane. A cost-effectiveness acceptability curve was also plotted by calculating the
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probability that, compared with usual resuscitation, EGDT is cost-effective given the data, at alternative
levels of willingness to pay for a QALY gain.
As sensitivity analyses, the mean INB at 90 days with corresponding 95% CIs was also reported for each of
the alternative assumptions (see Table 3).
Cost-effectiveness at 1 year following randomisation (primary outcome)
Mean EQ-5D utility scores, QALYs, total costs and INBs up to 1 year were reported for each treatment
group. Unadjusted mean differences between the treatment groups in quality of life, QALYs, incremental
costs and INBs at 1 year were reported with 95% CIs. These were reported both overall and by each of the
pre-specified subgroups, and tested using the t-test. The incremental costs and QALYs at 1 year were
plotted on the cost-effectiveness plane and the cost-effectiveness acceptability curve was plotted.
As sensitivity analyses, the mean INB at 1 year with corresponding 95% CI was also reported for each of
the alternative assumptions (see Table 3).
All analyses followed the same approach as that at 90 days, although for survivors at 1 year QALYs were
calculated assuming an EQ-5D utility score of zero at randomisation, and using the quality-of-life scores at
90 days and 1 year, applying linear interpolation between each pair of time points. Quality-of-life scores
at 90 days were applied for decedents between 90 days and 1 year.
Lifetime incremental cost-effectiveness
The cost and outcome data reported at 1 year were used to estimate the effect of EGDT versus usual
resuscitation on longer-term costs and outcomes. The chosen time horizon of 20 years was judged a
reasonable time frame over which to fully assess the relative impact of EGDT versus usual resuscitation,
and exceeded those taken in previous studies.54 The maximum available survival data from the trial was
used to plot Kaplan–Meier survival curves out to the date of censoring (12 November 2014). Alternative
parametric functions were considered for extrapolating mortality by fitting commonly recommended
alternatives to the survival data, excluding that for the first 30 days, as the event rate during this early
period was atypical and did not provide an appropriate basis for subsequent extrapolation. Although the
relative fit of the alternative curves to the observed data was reported, the one applied gave the most
plausible extrapolation according to the previous literature.55,56 After 15 years following randomisation,
it was assumed that all-cause death rates were those of the age-/sex-matched general population.
The parametric extrapolation for years 2–15 was combined with applying all-cause death rates for years
16–20 to report life expectancy for each patient observed to survive at 1 year.
The lifetime analysis allowed for the mean differences in estimated survival at 1 year, but these differences
were judged small and unlikely to be maintained, and were not statistically significant, and therefore, after
1 year, the same mortality rates were applied to both treatment groups. For calculating lifetime QALYs,
it was judged plausible to assume that the mean differences in quality of life reported at 1 year, although
not statistically significant, were maintained. For each treatment group, the level of the quality-of-life
decrement observed at 1 year versus the age-/sex-matched general population57 was maintained for years
2–15, which was the same duration as the period of assumed excess mortality, after which quality-of-life
values for the age-/sex-matched general population were applied. To project lifetime costs attributable to
the initial episode of severe sepsis, it was assumed that the average inpatient (general medical not critical
care), outpatient and community service costs reported up to 1 year following randomisation applied annually
for years 2–15 (period of excess mortality). For years 16–20, it was assumed that there were no further costs
attributable to the initial episode. Long-term INB over 20 years was calculated by valuing each QALY at
£20,000 per QALY. All future costs and life-years were discounted at the recommended rate of 3.5%.45
Mean lifetime QALYs, total costs and INBs were reported for each treatment group. Unadjusted mean
differences between the treatment groups in lifetime QALYs, incremental costs and INBs were reported
with 95% CIs. These were reported both overall and by each of the pre-specified subgroups, and tested
using the t-test. The lifetime cost-effectiveness acceptability curves were also plotted.
METHODS
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The sensitivity analyses for lifetime INB considered the scenario from Table 3 that was judged most
relevant, that of providing EGDT exclusively in the ED versus in ICU. The following additional scenarios
pertinent to the lifetime analysis were also reported:
l allowing for excess mortality versus the general population to be maintained for a shorter (10 years)
and a longer (20 years) period of time than the base case (15 years)
l allowing for a larger (30%) and smaller (10%) decrement in quality of life over years 2–15 versus the
general population than the base case (20%)
l allowing for the excess costs attributable to the initial episode to be maintained for a shorter (10 years)
and a longer (20 years) period of time than the base case (15 years).
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Chapter 3 Results: sites and patients
Participants: sites
Expressions of interests were received from 83 NHS hospitals in the UK. A total of 57 hospitals in England
obtained local NHS permissions and opened to recruitment between 15 February 2011 and 25 March
2013. Forty-four sites were opened within the first 9 months of the trial’s opening on 15 February 2011
(Figure 4).
The rate at which sites were opened for the ProMISe trial was higher than for ProCESS and ARISE. Within
12 months of the trial opening, 47 sites had been opened for ProMISe, compared with 20 each for
ProCESS and ARISE (Figure 5).
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FIGURE 4 Sites open to recruitment during the trial recruitment period.
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FIGURE 5 Recruitment of sites for ProMISe compared with ProCESS and ARISE.
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The median time from local NHS permission to the trial opening at sites (i.e. start of screening) was 83
(IQR 51–151) days (Figure 6). Reasons for delays in opening were issues related to the confirmation of NHS
support costs from the CLRN and delays in the local set-up of the trial, for example training staff.
Overall, sites participated in the ProMISe trial for a median of 30 (IQR 19–35) months. Of the 57 sites that
opened, seven were closed early because of poor recruitment (one site recruited no patients), two were
closed because of insufficient resources locally for screening and recruitment and two were closed for
other local logistical reasons. As part of the staggered close-down of the trial, nine sites were closed in
October 2013 and a further eight were closed in April 2014, with 29 sites remaining open until the end of
recruitment in July 2014 (Figure 7).
There were eight sites that had at least one period when screening and recruitment was suspended either
because of insufficient resources (n= 6) or to enable new staff to be trained in delivery of the trial protocol
(n= 2) (see Figure 7).
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FIGURE 6 Time (in days) from local NHS permission to start of screening.
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Characteristics of participating sites
A slightly higher proportion of the hospitals that participated in ProMISe were university teaching hospitals
[defined as the main hospital(s) linked with each medical school] than all acute hospitals in England with
an ED (Table 4).
The characteristics of the 57 participating sites are presented in Table 5. There was considerable variation
in the number of hospital beds, ranging from 234 to 1313, and in the annual number of ED presentations,
ranging from 40,000 to 185,000. The number of patients recruited ranged from 1 to 83 patients per site
in the 56 sites that recruited one or more patients.
TABLE 4 Representativeness of participating sites
Type of hospital Hospitals in ProMISe, n (%) All hospitals in England with an ED, n (%)
Teaching 16 (28.1) 36 (19.9)
Non-teaching 41 (71.9) 145 (80.1)
TABLE 5 Characteristics of participating sites
Site
Type of
hospital Recruitment period
Hospital
beds
Annual ED
presentations
Total patients
randomised
Addenbrooke’s
Hospital
Teaching November 2011–October 2012
and April 2013–July 2014
950 100,000 30
Arrowe Park Hospital Non-teaching June 2011–July 2014 750 93,000 31
Barnsley Hospital Non-teaching September 2011–January 2014
and April 2014–July 2014
450 80,000 28
Bedford Hospital Non-teaching November 2011–October 2013 380 70,000 11
Birmingham Heartlands
Hospital
Non-teaching May 2011–October 2013 730 112,171 14
Blackpool Victoria
Hospital
Non-teaching November 2012–July 2014 769 92,000 9
Bristol Royal Infirmary Teaching September 2011–December 2012 450 65,000 6
Broomfield Hospital Non-teaching May 2011–April 2014 521 81,513 15
Chelsea and
Westminster Hospital
Non-teaching May 2011–July 2014 430 114,695 16
Derriford Hospital Teaching April 2011–November 2013 900–1000 87,000 12
Dorset County Hospital Non-teaching October 2011–April 2014 292 40,000 17
Frenchay Hospital Non-teaching April 2012–July 2014 526 88,000 25
Good Hope Hospital Non-teaching September 2011–April 2012 480 78,713 0
Hinchingbrooke
Hospital
Non-teaching May 2011–April 2014 247 44,962 19
Hull Royal Infirmary Teaching May 2011–July 2014 709 122,000 30
John Radcliffe Hospital Teaching July 2011–January 2013 and
June 2013–October 2013
832 137,766 8
Kettering General
Hospital
Non-teaching February 2011–October 2013 580 88,000 15
continued
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TABLE 5 Characteristics of participating sites (continued )
Site
Type of
hospital Recruitment period
Hospital
beds
Annual ED
presentations
Total patients
randomised
King’s College Hospital Teaching July 2012–July 2014 1000 140,000 33
Leicester Royal
Infirmary
Teaching December 2011–July 2014 1000 150,000 41
Leighton Hospital Non-teaching June 2011–October 2013 460 82,000 12
Manchester Royal
Infirmary
Teaching July 2011–July 2014 650 100,000 41
Medway Maritime
Hospital
Non-teaching June 2011–April 2014 550 90,000 27
Musgrove Park
Hospital
Non-teaching August 2011–July 2014 700 56,000 29
New Cross Hospital Non-teaching September 2011–October 2013 700 111,000 8
Newham University
Hospital
Non-teaching September 2012–July 2013 234 125,000 10
North Devon District
Hospital
Non-teaching September 2012–July 2014 281 40,000 20
North Tyneside General
Hospital
Non-teaching September 2011–April 2012 450 60,000 1
Peterborough City
Hospital
Non-teaching March 2013–July 2014 611 90,475 24
Poole Hospital Non-teaching May 2011–June 2013 623 67,000 42
Queen Elizabeth
Hospital, Birmingham
Teaching July 2011–March 2012 and
October 2013–July 2014
1313 102,000 21
Queen Elizabeth
Hospital, Gateshead
Non-teaching September 2011–July 2014 600 87,000 30
Queen’s Medical
Centre
Teaching January 2013–July 2014 1300 185,000 25
Royal Berkshire
Hospital
Non-teaching August 2011–July 2014 660 100,000 55
Royal Bournemouth
Hospital
Non-teaching July 2011–June 2014 607 71,316 23
Royal Lancaster
Infirmary
Non-teaching May 2011–July 2014 428 56,000 21
Royal Preston Hospital Non-teaching June 2011–July 2014 708 74,852 22
Royal Surrey County
Hospital
Non-teaching March 2011–October 2013 550 71,175 15
Royal Sussex County
Hospital
Teaching September 2011–July 2014 850 110,000 29
Royal Victoria Infirmary Teaching May 2011–August 2011 and
June 2012–August 2013
1000 130,756 2
Salford Royal Hospital Non-teaching January 2012–July 2014 661 88,000 53
South Tyneside District
Hospital
Non-teaching June 2011–August 2012 400 74,000 4
Southend University
Hospital
Non-teaching July 2011–November 2011 700 89,965 1
Stafford Hospital Non-teaching June 2011–May 2013 299 46,761 15
RESULTS: SITES AND PATIENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
Participants: patients
In total, 6192 patients were screened between 15 February 2011 and 24 July 2014. Of these, 2415
(39.0%) met one or more exclusion criteria. There were 2517 (40.6%) patients who, although eligible for
inclusion in the trial, were not recruited. The most frequently reported reason for not recruiting eligible
patients was logistical issues, mainly no research staff being available, for example if the patient presented
at the ED outside usual office hours. Other reported reasons included refusal by the treating clinician to
recruit the patient; the patient declined to take part; or the patient was identified as eligible for the trial
outside the 2-hour window for obtaining consent and randomising (Figure 8).
The 1260 (20.3%) patients were recruited between 16 February 2011 and 24 July 2014, with 630
randomised to the EGDT group and 630 randomised to the usual-resuscitation group (Figure 9). There was
variation across the 56 sites in the rate of recruitment (Figure 10), the overall median recruitment rate
being 0.15 (IQR 0.10–0.22) patients per site per week, with a highest recruitment rate of 0.48 patients per
week. Patients were recruited over a relatively shorter time period than in ProCESS and ARISE (Figure 11).
Manual randomisation was required for three patients.
TABLE 5 Characteristics of participating sites (continued )
Site
Type of
hospital Recruitment period
Hospital
beds
Annual ED
presentations
Total patients
randomised
The Great Western
Hospital
Non-teaching October 2011–October 2012
and April 2013–November 2013
400 70,000 15
The Ipswich Hospital Non-teaching June 2011–April 2014 500 80,000 18
The James Cook
University Hospital
Non-teaching January 2012–July 2014 1000 104,000 28
The Queen Elizabeth
Hospital, King’s Lynn
Non-teaching May 2011–July 2014 489 55,000 71
The Royal Blackburn
Hospital
Non-teaching October 2012–March 2014 693 177,901 8
The Royal London
Hospital
Teaching September 2011–July 2014 680 150,000 49
Torbay Hospital Non-teaching February 2013–March 2014 400 117,896 3
University College
Hospital
Teaching March 2011–July 2014 665 129,000 33
University Hospital of
North Staffordshire
Teaching March 2011–July 2014 1180 128,000 21
Wansbeck General
Hospital
Non-teaching September 2011–April 2012 350 60,000 1
Whipps Cross
University Hospital
Non-teaching January 2013–July 2014 450 110,000 8
Whiston Hospital Non-teaching March 2011–July 2014 646 100,895 83
Worthing Hospital Non-teaching August 2011–October 2013 500 58,000 17
York Hospital Teaching October 2011–July 2014 700 85,000 15
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Met exclusion criteria (n = 2415)
• Had treating physician who deemed aggressive
   care unsuitable, n = 841
• Had do-not-attempt-resuscitation order, n = 794
• Were not able to commence EGDT within 1 hour of
   randomisation or complete 6 hours of EGDT, n = 167
• Required immediate surgery, n = 142
• Had contraindication to central venous
   catheterisation, n = 74
• Had major cardiac arrhythmia, n = 58
• Had haemodynamic instability due to active
   gastrointestinal haemorrhage, n = 57
• Were transferred from another in-hospital setting, n = 57
• Had seizure, n = 42
• Had acute cerebral vascular event, n = 25
• Had acute coronary syndrome, n = 25
• Had drug overdose, n = 24
• Had acute pulmonary oedema, n = 23
• Had advance directives restricting implementation of  
   EGDT, n = 16
• Were < 18 years, n = 16
• Were known to have a history of AIDS, n = 15
• Were previously enrolled in ProMISe, n = 15
• Had injury from burn or trauma, n = 8
• Had status asthmaticus, n = 6
• Had contraindication to blood transfusion, n = 5
• Were known to be pregnant, n = 5
Were eligible but did not undergo randomisation (n = 2517)
• Had study logistic issues, n = 995
• Were excluded by clinician, n = 449
• Declined to give consent, n = 354
• Were delayed referral, n = 343
• Were unable to give consent, n = 239
• Had other reasons, n = 112
• Had no reason given, n = 25
Were eligible for analysis (n = 625)
• Requested removal of all data, n = 3
• Were ineligible, n = 2
Were eligible for analysis (n = 626)
• Requested removal of all data, n = 1
• Were ineligible, n = 3
Underwent randomisation
(n = 1260)
Patients met inclusion criteria (n = 6192)
Were included in clinical primary 
outcome analysis (n = 623)
• Withdrew before 90 days, n = 2
Were included in clinical primary 
outcome analysis (n = 620)
• Withdrew before 90 days, n = 6
Were eligible for inclusion in cost-effectiveness
primary outcome analysis (n = 625)
• Not followed up at 1 year, n = 65
Were eligible for inclusion in cost-effectiveness
primary outcome analysis (n = 626)
• Not followed up at 1 year, n = 62
Were assigned to receive EGDT
(n = 630)
Returned EQ-5D at 
90 days (n = 356; 81%) 
and 339 were complete
Returned EQ-5D at 
90 days (n = 354; 81%) 
and 332 were complete
Returned EQ-5D at 1 year (n = 257; 77%)
and 244 were complete
Returned EQ-5D at 1 year (n = 250; 77%)
and 236 were complete
Were assigned to receive usual
resuscitation (n = 630)
FIGURE 8 Screening, randomisation and follow-up. AIDS, acquired immune deficiency syndrome.
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FIGURE 11 Recruitment of patients for ProMISe compared with ProCESS and ARISE.
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Patients were generally recruited into ProMISe during weekdays (Monday to Friday) and during usual office
hours (Figure 12); most of the recruiting sites reported having insufficient resources to enable screening
and recruitment at weekends and outside usual office hours.
Almost half of patients provided informed consent prior to randomisation (n= 624, 49.5%). For the
remaining patients, agreement was obtained from a personal (34.8%) or professional (2.9%) consultee or
from an independent clinician using emergency consent (12.8%) (Table 6). Four patients withdrew from
the trial, requesting the removal of all of their data from the analysis, and five patients were ineligible and
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FIGURE 12 Randomisation by (a) day of the week and (b) time of day.
TABLE 6 Informed consent, withdrawals and exclusions
Type of consent/agreement
Patients,
n (%)
Requested
removal of
all data, n
Ineligible:
excluded from
analysis, n
Withdrew
before
90 days, n
Informed consent from patient prior to randomisation 624 (49.5) 0 5 1
Agreement from a personal consultee 439 (34.8) 1 0 4
Agreement from a professional consultee 36 (2.9) 1 0 0
Agreement via emergency consent 161 (12.8) 2 0 3
Total 1260 (100) 4 5 8
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recruited in error, resulting in data on 1251 for initial analysis (n= 625 EGDT; n= 626 usual resuscitation).
Eight patients subsequently withdrew before 90 days, resulting in 1243 patients for analysis of outcomes
(n= 623, 99.7% EGDT; n= 620, 99.0% usual resuscitation). Owing to the truncation of follow-up,
127 patients were not followed up at 1 year (n= 65 EGDT; n= 62 usual resuscitation) (see Figure 8 and
Table 6). Follow-up was completed on 30 October 2014.
Characteristics of patients at baseline
The groups were well matched at baseline (Table 7). The criterion for refractory hypotension was met in
338 (54.1%) EGDT and 348 (55.6%) usual-resuscitation patients and for hyperlactataemia in 409 (65.4%)
EGDT and 399 (63.7%) usual-resuscitation patients. Intravenous fluid volume prior to randomisation was
similar [median 1950ml (IQR 1000–2500ml) EGDT, 2000ml (IQR 1000–2500ml) usual resuscitation]. The
median time from ED presentation to meeting inclusion criteria [1.3 (IQR 0.5–2.3) hours for EGDT and 1.3
(IQR 0.6–2.4) hours for usual resuscitation] and from ED presentation to randomisation [2.5 (IQR 1.8–3.5)
hours EGDT and usual resuscitation] was the same in both groups. Only two-thirds of patients in either
group were deemed as likely to be admitted to an ICU from ED (if not enrolled in the trial); those deemed
unlikely to be admitted were less severely ill.
The mean age of patients was similar in both groups (EGDT, 66.4 years; usual resuscitation, 64.3 years)
and more than half were male (57.0% EGDT, 58.6% usual resuscitation). The site of infection (most
commonly lungs) was well balanced. All patients received antimicrobials prior to randomisation.
Multiple imputation
Table 8 reports all the variables considered for multiple imputation and, for each variable, the number of
missing values and the imputation model chosen.
TABLE 7 Baseline characteristics of patients by treatment group
Characteristics EGDT (N= 625)
Usual resuscitation
(N= 626)
Refractory hypotension, n (%) 338 (54.1) 348 (55.6)
SBP (mmHg), mean (SD) 77.7 (11.0) 78.4 (10.2)
MAP (mmHg), mean (SD) 58.8 (15.8) 59.0 (10.7)
Hyperlactataemia, n (%) 409 (65.4) 399 (63.7)
Blood lactate concentration (mmol/l), mean (SD) 7.0 (3.5) 6.8 (3.2)
Intravenous fluids pre hospital to randomisation,a n/N (%) 612/625 (97.9) 606/625 (97.0)
Intravenous fluids pre hospital to randomisation (ml), median (IQR) 1950 (1000–2500) 2000 (1000–2500)
Intravenous fluids pre hospital,b n/N (%) 119/616 (19.3) 128/617 (20.7)
Intravenous fluids pre hospital (ml), median (IQR) 500 (250, 500) 500 (255, 500)
Intravenous fluids ED presentation to randomisation,b n/N (%) 607/625 (97.1) 599/625 (95.8)
Intravenous fluids ED presentation to randomisation (ml), median (IQR) 1600 (1000–2500) 1790 (1000–2500)
Blood products ED presentation to randomisation, n/N (%) 4/614 (0.7) 10/616 (1.6)
Blood products ED presentation to randomisation (ml), median (IQR) 922 (559–1000) 919 (500–1000)
Supplemental O2,
c n/N (%) 397/539 (73.7) 407/542 (75.1)
Time from ED presentation to inclusion criteria met (hours), mean (SD) 1.6 (1.3) 1.7 (1.4)
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TABLE 7 Baseline characteristics of patients by treatment group (continued )
Characteristics EGDT (N= 625)
Usual resuscitation
(N= 626)
Time from ED presentation to inclusion criteria met (hours), median (IQR) 1.3 (0.5–2.3) 1.3 (0.6–2.4)
Time from ED presentation to randomisation (hours), mean (SD) 2.7 (1.3) 2.8 (1.4)
Time from ED presentation to randomisation (hours), median (IQR) 2.5 (1.8–3.5) 2.5 (1.8–3.5)
Would have been admitted direct to ICU from ED if not enrolled into
ProMISe, n (%)
419 (67.0) 427 (68.2)
Yes (APACHE II scored), mean (SD) 20.5 (6.9) 19.0 (7.1)
No (APACHE II scored), mean (SD) 15.0 (6.1) 15.8 (6.5)
Age (years), mean (SD) 66.4 (14.6) 64.3 (15.5)
Age (years), median (IQR) 68 (58–78) 67 (54–76)
Male sex, n (%) 356 (57.0) 367 (58.6)
APACHE II score,d mean (SD) 18.7 (7.1) 18.0 (7.1)
APACHE II score,d median (IQR) 18 (13–23) 17 (13–22)
MEDS score,e mean (SD) 8.0 (3.4) 7.9 (3.3)
MEDS score,e median (IQR) 8 (6–10) 8 (6–10)
MEDS terminal illness, n (%) 11/622 (1.8) 14/626 (2.2)
MEDS respiratory difficulties, n (%) 510/620 (82.3) 499/618 (80.7)
MEDS septic shock, n (%) 277/624 (44.4) 305/622 (49.0)
MEDS platelets < 150 × 109/l, n (%) 144/585 (24.6) 144/585 (24.6)
MEDS bandforms > 5%, n (%) 52/54 (96.3) 64/70 (91.4)
MEDS lower respiratory infection, n (%) 220 (35.2) 196 (31.3)
MEDS nursing home resident, n (%) 18/622 (2.9) 14/626 (2.2)
MEDS altered mental status, n (%) 206/608 (33.9) 208/602 (34.6)
MEDS age > 65 years, n (%) 363 (58.1) 329 (52.6)
SOFA score,f mean (SD) 4.2 (2.4) 4.3 (2.4)
SOFA score,f median (IQR) 4 (2–5) 4 (3–6)
SOFA respiratory dysfunction, n (%) 323 (51.7) 357 (57.0)
SOFA neurological dysfunction, n (%) 196 (31.4) 200 (31.9)
SOFA cardiovascular dysfunction, n (%) 410 (65.6) 433 (69.2)
SOFA coagulation dysfunction, n (%) 144 (23.0) 144 (23.0)
SOFA hepatic dysfunction, n (%) 211 (33.8) 199 (31.8)
SOFA renal dysfunction,f n (%) 426 (68.2) 406 (64.9)
Any severe condition in the past medical history,
g n/N (%) 181/622 (29.1) 161/626 (25.7)
Severe liver disease 11/622 (1.8) 11/626 (1.8)
Severe renal disease 4/622 (0.6) 3/626 (0.5)
Severe respiratory disease 93/622 (15.0) 81/626 (12.9)
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TABLE 7 Baseline characteristics of patients by treatment group (continued )
Characteristics EGDT (N= 625)
Usual resuscitation
(N= 626)
Severe cardiovascular disease 22/622 (3.5) 17/626 (2.7)
Immunocompromised 84/622 (13.5) 70/626 (11.2)
Site of infection, n (%)
Lungs 228 (36.5) 207 (33.1)
Abdomen 40 (6.4) 51 (8.1)
Blood 97 (15.5) 86 (13.7)
Central nervous system 12 (1.9) 9 (1.4)
Soft tissue 39 (6.2) 39 (6.2)
Urinary tract 108 (17.3) 117 (18.7)
Other 21 (3.4) 37 (5.9)
Not sepsish 4 (0.6) 3 (0.5)
Unknown 76 (12.2) 77 (12.3)
Organism causing infection, n (%)
Gram positive 138 (22.1) 141 (22.5)
Gram negative 175 (28.0) 171 (27.3)
Fungus/yeast 14 (2.2) 19 (3.0)
Parasite 0 (0.0) 2 (0.3)
Virus 12 (1.9) 9 (1.4)
Mixed growth 7 (1.1) 12 (1.9)
Not sepsish 4 (0.6) 3 (0.5)
Unknown (not reported or no growth) 275 (44.0) 269 (43.0)
Antimicrobial change between ED admission and 72 hours, n/N (%) 359/615 (58.4) 342/617 (55.4)
MAP, mean arterial pressure; SBP, systolic blood pressure.
a Includes intravenous crystalloid and colloid > 20ml and all blood products.
b Includes intravenous crystalloid and colloid administration > 20ml.
c Supplemental O2 is based on recording of F iO2 > 0.21.
d The APACHE II score was calculated using the last recorded physiology data prior to randomisation and is not based on
data over a 24-hour time period.
e The MEDS score was calculated using the last recorded physiology data prior to randomisation.
f The SOFA score was calculated using the last recorded physiology data prior to randomisation. The SOFA renal score was
based on plasma creatinine concentration only (i.e. did not include urine output).
g Severe conditions in the past medical history defined according to APACHE II.
h Confirmed following randomisation.
DOI: 10.3310/hta19970 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 97
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Mouncey et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
43
TABLE 8 Variables considered for multiple imputation and form of imputation model
Variable Missing values,a n (%) Imputation model
Baseline variables
Treatment group 0 (0) None required
Age 0 (0) None required
Sex 0 (0) None required
Past medical history 3 (0.2) None requiredb
Site of infection 0 (0) None required
SOFA score 0 (0) None required
MEDS score 0 (0) None required
Admitted from nursing home 3 (0.2) None requiredb
Shortness of breath with light activity 3 (0.2) None requiredb
Altered mental status 41(3.3) Logistic regression
Septic shock 5 (0.4) Logistic regression
Respiratory difficulty 13 (1.0) Logistic regression
Low platelet count 81 (6.5) Logistic regression
Volume of intravenous fluid ED presentation to randomisation 3 (0.2) Predictive mean matching
Baseline blood lactate concentration 32 (2.6) Predictive mean matching
Baseline respiratory rate 5 (0.4) Predictive mean matching
Baseline heart rate 1 (0.1) Predictive mean matching
Baseline haemoglobin 31 (2.5) Predictive mean matching
Baseline white blood cell count 49 (3.9) Predictive mean matching
Resource use variables
Length of stay in critical care 0 (0) None required
Length of stay on general medical ward 0 (0) None required
Outpatient visits at 90 days 242 (27.3) Predictive mean matching
Acute hospital readmissions, 90 days to 1 year
Length of stay in critical care 135 (10.8) Predictive mean matching
Length of stay on general medical ward 135 (10.8) Predictive mean matching
Outpatient visits at 1 year 306 (38.5) Predictive mean matching
Mortality and quality-of-life variables
EQ-5D at 90 days 215 (24.3) Predictive mean matching
Mortality at 1 year 135 (10.8) Logistic regression
EQ-5D at 1 year 314 (39.5) Predictive mean matching
a For baseline variables, length of stay and mortality, the overall sample size was all randomised patients (n= 1251). For
other resource use and quality-of-life variables, the relevant sample sizes were those patients eligible for the 90-day
follow-up (n= 886) or 1-year follow-up (n= 794).
b When past medical history was missing, patients were assumed to have no past medical history.
RESULTS: SITES AND PATIENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
Chapter 4 Results: clinical effectiveness
Adherence to the protocol
Most patients randomised to EGDT (n= 545, 87.3%) had timely insertion of a PreSepTM central venous
oximetry catheter (Table 9). Two (0.3%) patients in the usual-resuscitation group had one inserted in error
but these were not used for monitoring ScvO2. The reasons for failure of insertion in the EGDT group were
that patients were determined either to no longer meet inclusion criteria or to now meet exclusion criteria
(n= 22); process of care (lack of equipment, staff, beds, communication, error; n= 20); technical or patient
difficulties (n= 18); clinician decision (n= 9); refusal by the patient (without withdrawal from the trial;
n= 5); and death before insertion (n= 2). No reason was provided for four patients. The mean first ScvO2
value recorded after catheterisation (at hour 1) was 70% (SD 12%). Standard central venous catheters (not
mandated) were inserted in 318 (50.9%) of the usual-resuscitation group and measurement of ScvO2 from
aspirated blood samples occurred in six patients. Arterial catheters (not mandated) were inserted in the
majority of patients (n= 462, 74.2% EGDT; n= 389, 62.2% usual resuscitation). EGDT was stopped
prematurely in 21 patients (median time to cessation, 3 hours) owing to withdrawal of active treatment
(n= 9); patient no longer considered to be septic (n= 5); error (n= 3); transfer to operating theatre (n= 1);
and refusal by the patient (n= 1). No reason was provided for two patients. Of the patients who died
within 6 hours (n= 17 EGDT; n= 18 usual resuscitation), five in the EGDT group and six in the
usual-resuscitation group had active treatment withdrawn prior to death.
TABLE 9 Interventions delivered during the intervention period
Interventions EGDT (N= 625) Usual resuscitation (N= 626)
Supplemental O2, n/N (%) 558/623 (89.6) 557/625 (89.1)
PreSep™ central venous oximetry catheter insertion, n/N (%) 545/624 (87.3) 2/625 (0.3)
Timing of insertion, n (%)
Before hour 1 459 (84.5) –
Hour 1 to hour 2 67 (12.3) –
Hour 2 to hour 3 15 (2.8) –
Hour 3 to hour 4 2 (0.4) –
Hour 4 to hour 5 0 (0.0) –
Hour 5 to hour 6 0 (0.0) –
Any CVC insertion, n/N (%) 575/624 (92.1) 318/625 (50.9)
Time from randomisation to insertion (hours), mean (SD) 1.2 (0.9) 1.8 (1.7)
Time from randomisation to insertion (hours), median (IQR) 1.1 (0.8–1.5) 1.4 (0.6–2.9)
Arterial catheter insertion, n/N (%) 462/623 (74.2) 389/625 (62.2)
Time from randomisation to insertion (hours), mean (SD) 1.3 (1.6) 1.2 (1.7)
Time from randomisation to insertion (hours), median (IQR) 1.1 (0.4–1.9) 1.0 (0.2–1.9)
Any intravenous fluid,a n/N (%) 609/623 (97.8) 604/625 (96.6)
Volume (ml), mean (SD) 2226.0 (1443.3) 2022.3 (1271.4)
continued
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TABLE 9 Interventions delivered during the intervention period (continued )
Interventions EGDT (N= 625) Usual resuscitation (N= 626)
Volume (ml), median (IQR) 2000 (1150–3000) 1784 (1075–2775)
Intravenous colloid,a n/N (%) 197/623 (31.6) 180/625 (28.8)
Volume (ml), mean (SD) 1061.5 (800.5) 913.4 (626.8)
Volume (ml), median (IQR) 1000 (500–1500) 750 (500–1000)
Intravenous crystalloid,a n/N (%) 584/623 (93.7) 597/625 (95.5)
Volume (ml), mean (SD) 1963.2 (1356.9) 1766.7 (1178.4)
Volume (ml), median (IQR) 1750 (999–2750) 1500 (900–2380)
Vasopressors, n/N (%) 332/623 (53.3) 291/625 (46.6)
Packed red blood cell transfusion, n/N (%) 55/623 (8.8) 24/625 (3.8)
Volume (ml), mean (SD) 426.3 (209.4) 539.5 (294.2)
Volume (ml), median (IQR) 309 (285–577) 535 (305–607)
Dobutamine, n/N (%) 113/623 (18.1) 24/625 (3.8)
Mechanical ventilation, n/N (%) 126/623 (20.2) 119/625 (19.0)
Sedatives, n/N (%) 138/623 (22.2) 130/625 (20.8)
Neuromuscular blocking agent, n/N (%) 53/623 (8.5) 40/625 (6.4)
Critical care admission, n/N (%) 551/625 (88.2) 467/626 (74.6)
Time from randomisation to admission (hours), mean (SD) 2.0 (2.3) 2.5 (5.7)
Time from randomisation to admission (hours), median (IQR) 1.2 (0.4–2.8) 1.2 (0.3–2.8)
Location of protocol delivery, n (%)
ED 64 (10.2) –
ICU 275 (44.0) –
Ward 10 (1.6) –
ED and ICU 235 (37.6) –
ED and ward 37 (5.9) –
ICU and ward 2 (0.3) –
ED, ICU and ward 1 (0.2) –
Review by consultant, n/N (%) 520/624 (83.3) 494/625 (79.0)
Specialty of most senior doctor to review the patient, n (%)
Emergency medicine 181 (29.0) 211 (33.8)
Critical care medicine 388 (62.2) 304 (48.6)
Acute medicine 39 (6.3) 92 (14.7)
Other 16 (2.6) 18 (2.9)
CVC, central venous catheter.
a Includes intravenous colloid and crystalloid > 20ml.
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Figure 13 shows the adherence with each element of the EGDT protocol across the 6-hour intervention
period. The bars plotted on each hour report the percentage of patients (of those meeting the previous
targets) who did not meet or met each physiological target at that hour, or for whom the relevant
physiological value was not recorded (within 15 minutes either side of the hour). The bars plotted between
each hour report the percentage of patients (of those who did not meet the physiological target at the
previous hour) that received the associated action either during the intervention period or after the
intervention period, or who no longer required the action as the target was subsequently met. Adherence
with the protocol was generally good, particularly for delivery of fluid and vasopressors, but there were
delays in obtaining packed red blood cells and dobutamine, such that the ScvO2 value had often resolved
spontaneously before these were delivered.
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FIGURE 13 Adherence to the EGDT protocol. (a) Target: CVP; action: fluids; (b) target: MAP/SBP; action:
vasopressors; and (c) target: ScVO2; action: PRBC transfusion (L) or dobutamine (R). Numbers at the foot of each bar
represent the denominator for the percentages in that bar. Each target is considered sequentially (i.e. those
meeting the target for CVP become the denominator for MAP/SBP and those meeting the target for MAP/SBP
become the denominator for ScvO2). Of the two smaller bars, (L) denotes the left-hand bar and (R) denotes the
right-hand bar. Thirty-two patients who no longer met eligibility criteria or declined the intervention were
excluded from the evaluation of adherence. CVP, central venous pressure; MAP, mean arterial pressure;
PRBC, packed red blood cells; SBP, systolic blood pressure.
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Figure 14 reports the protocol adherence compared with ProCESS and ARISE, according to the adherence
algorithms reported in their respective publications.23,24 For the comparison with ProCESS, adherence was
assessed at the end of the 6-hour intervention period only. Patients who died, were discharged or were
withdrawn from the intervention prior to 6 hours were excluded (47/625, 7.5%, for ProMISe; 35/439,
8.0%, for ProCESS). Overall adherence among the evaluable patients was similar for the two trials (85.6%
for ProMISe vs. 88.1% for ProCESS). The greatest difference was on failure to insert a central venous
catheter with ScvO2 monitoring capability; on all other measures, non-adherence for ProMISe was lower
than for ProCESS. For the comparison with ARISE, adherence was assessed hourly as the percentage of
patients meeting each physiological target (of those for whom the relevant physiological value was
recorded) and, for those with physiological values recorded at 2 consecutive hours, the percentage who
either met the target at the start or the end of the hour or received the associated action during the hour.
The percentage of patients meeting the physiological targets at each hour, for ProMISe compared with
ARISE, was similar for central venous pressure, higher for mean arterial pressure/systolic blood pressure and
lower for ScvO2. When reported as the percentage either meeting the target or receiving the associated
action, adherence was extremely high (and similar to ARISE) for both receipt of intravenous fluids and
receipt of vasopressors, but somewhat lower for receipt of packed red blood cells or dobutamine (although
this did reach a level of 89% by the final hour of the intervention period).
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FIGURE 14 Protocol adherence compared with ProCESS (a) and ARISE [(b), CVP; (c) i.v. fluids; (d) MAP or SBP;
(e) vasopressors; (f) ScvO2; and (g) PRBC and/or dobutamine]. For the comparison with ProCESS, the numbers of
evaluable patients were 578 (ProMISe) and 404 (ProCESS). For the comparison with ARISE, numbers at the foot of
each bar represent the denominator for the percentages in that bar. CVP, central venous pressure; i.v., intravenous;
MAP, mean arterial pressure; PRBC, packed red blood cells; SBP, systolic blood pressure. (continued )
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Delivery of care by treatment group
During the 6-hour intervention period, patients randomised to EGDT received more intravenous fluid than
those randomised to usual resuscitation (see Table 9). Hourly fluid volume decreased over the 6 hours but
patients in the usual-resuscitation group received a greater volume initially (Figure 15). In both groups,
crystalloid was used more frequently than colloid. More patients in the EGDT group received vasopressors
and dobutamine. Although more patients in the EGDT group received packed red blood cell transfusions,
larger volumes were transfused in the usual-resuscitation group. Administration of platelets and
fresh-frozen plasma was similar, although volumes of both were higher in the EGDT group. Physiological
values normalised slightly over the 6-hour intervention period in both groups (Figure 16). After 6 hours,
central venous pressure, mean arterial pressure, systolic blood pressure and haemoglobin, where measured
(with greater frequency in the EGDT group), were similar (Table 10).
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Between 6 and 72 hours, use of intravenous fluids was similar but usual-resuscitation patients received
higher volumes (Table 11). Intravenous colloid use was higher in the EGDT group but volumes were similar
in the two groups, intravenous crystalloid use was similar but volumes were higher in the usual-resuscitation
group and use of packed red blood cell transfusions was higher in the EGDT group but the volumes delivered
were higher in the usual-resuscitation group. Although the use of platelets and fresh-frozen plasma was
similar, the volume of platelets transfused was higher in the EGDT group and the volume of fresh-frozen
plasma was higher in the usual-resuscitation group. Vasopressor and dobutamine use remained higher in the
EGDT group. At 72 hours, physiological, biochemistry and SOFA values were similar (Table 12).
TABLE 10 Physiology measurements at the end of the intervention period
Physiology EGDT (n= 625) Usual resuscitation (n= 626)
CVP (mmHg), mean (SD) 11.2 (5.1) [496] 11.7 (6.1) [166]
MAP (mmHg), mean (SD) 76.5 (13.9) [518] 76.5 (14.3) [394]
SBP (mmHg), mean (SD) 113.1 (21.0) [573] 110.7 (22.4) [508]
ScvO2 (%), mean (SD) 74.2 (9.8) [497] –
Haemoglobin (g/dl), mean (SD) 11.0 (2.0) [384] 11.3 (2.3) [163]
CVP, central venous pressure; MAP, mean arterial pressure; SBP, systolic blood pressure.
The numbers in square brackets denote the number of patients for whom the physiological value was recorded (within
15 minutes either side of hour 6).
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Primary outcome: clinical effectiveness
At 90 days following randomisation, 184 (29.5%) patients randomised to EGDT had died, compared with
181 (29.2%) patients randomised to usual resuscitation, corresponding to an absolute risk reduction of
−0.3 (95% CI −5.4 to 4.7, p= 0.90) and a relative risk of 1.01 (95% CI 0.85 to 1.20; Table 13). This
difference remained non-significant after adjustment for baseline characteristics (adjusted odds ratio 0.95,
95% CI 0.74 to 1.24; p= 0.73; unadjusted odds ratio 1.02, 95% CI 0.80 to 1.30).
TABLE 13 Primary and secondary outcomes: clinical effectiveness
Outcome
EGDT
(N= 625)
Usual
resuscitation
(N= 626)
Effect estimate
(95% CI) p-value
Primary outcome
All-cause mortality at 90 days,
n/N (%)
184/623 (29.5) 181/620 (29.2) 1.01 (0.85 to 1.20)a 0.90
−0.3 (−5.4 to 4.7)b
1.02 (0.80 to 1.30)c
0.95 (0.74 to 1.24)d 0.73
Secondary outcomes
SOFA score at 6 hours,e
mean (SD)
6.4 (3.8) 5.6 (3.8) 0.8 (0.5 to 1.1)f,g < 0.001
SOFA score at 72 hours,e
mean (SD)
4.0 (3.8) 3.7 (3.6) 0.4 (−0.0 to 0.8)f,g 0.056
Receipt of advanced
cardiovascular support, n/N (%)
230/622 (37.0) 190/614 (30.9) 1.19 (1.02 to 1.40)a 0.026
Receipt of advanced respiratory
support, n/N (%)
179/620 (28.9) 175/615 (28.5) 1.01 (0.85 to 1.21)a 0.90
Receipt of renal support, n/N (%) 88/620 (14.2) 81/614 (13.2) 1.08 (0.81 to 1.42)a 0.62
Days alive and free from
advanced cardiovascular support
up to 28 days, mean (SD)
20.3 (11.9) 20.6 (11.8) −0.3 (−1.6 to 1.0)f 0.65
Days alive and free from
advanced respiratory support up
to 28 days, mean (SD)
19.6 (12.1) 19.8 (12.0) −0.2 (−1.5 to 1.1)f 0.75
Days alive and free from renal
support up to 28 days,
mean (SD)
20.6 (12.1) 20.6 (11.9) 0.0 (−1.3 to 1.4)f 0.96
ED length of stay (hours),
median (IQR)
1.5 (0.4–3.1) 1.3 (0.4–2.9) – 0.34
Survivors 1.4 (0.4–3.1) 1.3 (0.3–2.9) – 0.38
Non-survivors 3.7 (2.4–4.1) 2.4 (1.2–5.9) – 0.25
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Secondary outcomes: clinical effectiveness
For patients in the EGDT group, both the mean SOFA score at 6 hours (p< 0.001) and the proportion
receiving advanced cardiovascular support (p= 0.026) were significantly higher than for patients in the
usual-resuscitation group. The median total length of stay in critical care was significantly longer for
patients in the EGDT group than the usual-resuscitation group (p= 0.006). There were no significant
differences between the groups in any of the other secondary outcomes, including duration of survival
(log-rank test, p= 0.63; Cox proportional hazards model, adjusted hazard ratio 0.94, 95% CI 0.79 to 1.11;
p= 0.46) (Figure 17 and see Table 13).
TABLE 13 Primary and secondary outcomes: clinical effectiveness (continued )
Outcome
EGDT
(N= 625)
Usual
resuscitation
(N= 626)
Effect estimate
(95% CI) p-value
Critical care length of stay (days),
median (IQR)
2.6 (1.0–5.8) 2.2 (0.0–5.3) – 0.006
Survivors 2.9 (1.0–6.1) 2.8 (0.0–5.9) – 0.008
Non-survivors 1.6 (0.6–3.1) 1.2 (0.5–4.3) – 0.85
Acute hospital length of stay
(days), median (IQR)
9 (4–21) 9 (4–18) – 0.46
Survivors 11 (7–25) 11 (7–22) – 0.42
Non-survivors 2 (1–8) 2 (1–7) – 0.44
All-cause mortality at 28 days,
n/N (%)
155/625 (24.8) 152/621 (24.5) 1.01 (0.83 to 1.23)a 0.90
0.95 (0.73 to 1.25)d 0.73
All-cause mortality at acute
hospital discharge, n/N (%)
160/625 (25.6) 154/625 (24.6) 1.04 (0.86 to 1.26)a 0.74
0.98 (0.75 to 1.29)d 0.90
All-cause mortality at 1 year,
n/N (%)
224/558 (40.1) 233/558 (41.8) 0.96 (0.83 to 1.11)a 0.63
0.85 (0.66 to 1.09)d 0.20
a Relative risk.
b Absolute risk reduction.
c Unadjusted odds ratio.
d Adjusted odds ratio.
e SOFA renal score was based on plasma creatinine concentration only. Patients for whom the variables for SOFA renal
and coagulation scores were not recorded between randomisation and hour 6 had these values carried forward from
baseline, if recorded. A total of 181 patients who died or were discharged before 48 hours (84 EGDT, 97 usual
resuscitation) were not included in the SOFA score at 72 hours.
f Difference in means.
g Adjusted for baseline SOFA score.
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Safety monitoring
Thirty (4.8%) patients in the EGDT group and 26 (4.2%) patients in the usual-resuscitation group
experienced one or more serious adverse events within 30 days following randomisation (relative risk 1.16,
95% CI 0.69 to 1.93; p= 0.58; Table 14). The most commonly reported serious adverse events were
pulmonary oedema (four patients in the EGDT group and seven patients in the usual-resuscitation group)
and myocardial ischaemia (seven patients in the EGDT group and four patients in the usual-resuscitation
group). Three serious adverse events associated with EGDT (two pulmonary oedema and one arrhythmia)
were reported as probably related to the intervention, compared with four (in three patients) serious
adverse events (two pneumothoraces and one pulmonary oedema probably related, and one ventricular
fibrillation definitely related) reported as associated with usual resuscitation.
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FIGURE 17 Kaplan–Meier curves for survival to (a) 90 days and (b) 1 year following randomisation.
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Subgroup analyses of the primary outcome
There was no difference in the effect of EGDT on the primary outcome of all-cause mortality at 90 days
following randomisation according to the pre-specified subgroups defined by the degree of protocolised
care/usual resuscitation, age, MEDS score, SOFA score and time from ED presentation to randomisation
(p-values for test of interaction 0.39 to 0.72; Figure 18).
TABLE 14 Serious adverse events within 30 days following randomisation
Serious adverse events EGDT (N= 625) Usual resuscitation (N= 626)
Any serious adverse event, n (%) 30 (4.8) 26 (4.2)
Specified serious adverse events, n (%)
Pneumothorax 0 (0.0) 4 (0.6)
Haemo-pneumothorax 0 (0.0) 0 (0.0)
Bleeding 2 (0.3) 2 (0.3)
Thrombosis 2 (0.3) 0 (0.0)
Pulmonary embolus 4 (0.6) 2 (0.3)
Vascular catheter infection 0 (0.0) 0 (0.0)
Pulmonary oedema 4 (0.6) 7 (1.1)
Blood transfusion reaction 0 (0.0) 1 (0.2)
Myocardial ischaemia 7 (1.1) 4 (0.6)
Peripheral ischaemia 0 (0.0) 1 (0.2)
Unspecified serious adverse events, n (%)
Cardiac arrest 5 (0.8) 4 (0.6)
Cerebrovascular event 4 (0.6) 1 (0.2)
Arrhythmia 1 (0.2) 2 (0.3)
Othera 5 (0.8) 5 (0.8)
a Other serious adverse events (one patient each) were bronchopleural fistula; encephalitis; fresh blood in endotracheal
tube; hospital-acquired pneumonia; hypernatremia; myocardial infarction; perforation of ischaemic ileum; requirement
for emergency splenectomy; respiratory failure; worsening lactate; and deranged liver function tests.
Numbers do not add as some patients experienced more than one serious adverse event.
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Secondary analyses of the primary outcome
Eight patients were missing the primary outcome of all-cause mortality at 90 days following randomisation
(two in the EGDT group and six in the usual-resuscitation group). The effect of missing data on the results
was minimal. Sensitivity analyses making alternative extreme assumptions for the missing outcomes
reported relative risks of 0.99 and 1.03 (Table 15). Although the learning curve analysis suggested
increased odds of mortality for the first patient randomised to EGDT in each site, this effect was not
significant (p= 0.56; Figure 19 and see Table 15). Adjusting for non-adherence to the EGDT protocol
resulted in minimal change to the relative risk (see Table 15).
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FIGURE 19 Learning curve for delivery of EGDT. The y-axis is presented on a log scale.
TABLE 15 Secondary analyses of the primary outcome
Analysis
All-cause mortality at 90 days, n/N (%)
Incremental effect
(95% CI) p-value
EGDT
(n= 625)
Usual resuscitation
(n= 626)
Sensitivity analyses for missing data in the primary outcome
EGDT survive, usual resuscitation die 184/625 (29.4) 187/626 (29.9) 0.99 (0.83 to 1.17)a 0.90
EGDT die, usual resuscitation survive 186/625 (29.8) 181/626 (28.9) 1.03 (0.87 to 1.22)a 0.76
Learning curve analysis 0.56b
Asymptotic adjusted odds ratio – – 0.89 (0.69 to 1.15)c 0.34
Adherence-adjusted analysis – – 1.02 (0.78 to 1.32)a 0.90
a Relative risk.
b p-value for test of nonlinearity (i.e. for presence of a learning-curve effect).
c Adjusted odds ratio.
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Comparison with other early goal-directed therapy studies
Comparing the usual-resuscitation group for ProMISe with that from the original randomised controlled
trial of EGDT by Rivers et al.,6 patients in ProMISe were randomised, on average, slightly later than those in
the Rivers et al. trial (Table 16). Demographics were similar. Patients in ProMISe had slightly lower blood
pressure, blood lactate measurements and APACHE II scores. Patients in the usual-resuscitation group in
the Rivers et al.6 trial received considerably more fluid and packed red blood cell transfusions, and were
more likely to be mechanically ventilated; however, those in ProMISe received more vasopressors and
dobutamine. Hospital mortality was substantially higher in the Rivers et al.6 trial than in ProMISe.
Comparing the usual-resuscitation group for ProMISe with those from ProCESS23 and ARISE,24 time from
ED presentation to randomisation was similar but patients in ProMISe had a shorter length of stay in the
ED than those in ARISE (Table 17). Demographics were similar. The mean volume of fluid received prior to
randomisation was higher for ARISE than for ProCESS or ProMISe. Blood pressure and blood lactate
measurements were similar for ProMISe and ProCESS, but mean arterial pressure was slightly higher and
blood lactate was slightly lower for ARISE. This lower severity of illness for patients in ARISE was also
reflected in APACHE II scores, which were lowest for ARISE and highest for ProCESS. A greater proportion
of patients in ProMISe met both the refractory hypotension and the hyperlactataemia inclusion criteria. To
explore the hypothesis that the combination of both refractory hypotension and hyperlactataemia was
associated with higher mortality than either alone, we examined data from the Case Mix Programme, the
national clinical audit for adult critical care. Among 12,004 patients admitted to 183 adult general ICUs in
TABLE 16 Comparison of usual-resuscitation groups: Rivers et al.6 and ProMISe
Characteristics Rivers et al.6 ProMISe
Timing
ED presentation to randomisation (hours), mean (SD) 1.5 (1.7) 2.8 (1.4)
Baseline characteristics
Age (years), mean (SD) 64.4 (17.1) 64.3 (15.5)
Male (%) 50.4 58.6
SBP (mmHg), mean (SD) 109 (34) 97.0 (25.5)
MAP (mmHg), mean (SD) 76 (24) 64.7 (17.2)
Blood lactate concentration (mmol/l), mean (SD) 6.9 (4.5) 5.1 (3.5)
APACHE II score, mean (SD) 20.4 (7.4) 18.0 (7.1)
Interventions hour 0 to hour 6
Total intravenous fluids (ml), mean (SD) 3499 (2438) 2022 (1271)
Vasopressors (%) 30.3 46.6
Packed red blood cell transfusion (%) 18.5 3.8
Dobutamine (%) 0.8 3.8
Mechanical ventilation (%) 53.8 19.0
Outcomes
Hospital mortality (%) 46.5 24.6
MAP, mean arterial pressure; SBP, systolic blood pressure.
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TABLE 17 Comparison of usual-resuscitation groups: ProCESS, ARISE and ProMISe
Characteristics ProCESS23 ARISE24 ProMISe
Timing
ED presentation to randomisation (hours), mean (SD) 3.0 (1.6) – 2.8 (1.4)
ED presentation to randomisation (hours), median (IQR) – 2.7 (2.0–3.9) 2.5 (1.8–3.5)
ED length of stay (hours), median (IQR) – 2.0 (1.0–3.8) 1.3 (0.4–2.9)
Baseline characteristics
Age (years), mean (SD) 62.0 (16.0) 63.1 (16.5) 64.3 (15.5)
Male (%) 57.9 59.3 58.6
Pre-randomisation fluidsa (l), mean (SD) 2.1 (1.4) 2.6 (1.3) 2.0 (1.1)
SBP (mmHg), mean (SD) 99.9 (29.5) – 97.0 (25.5)
MAP (mmHg), mean (SD) 64.7 (15.6) 70.5 (16.0) 64.7 (17.2)
Blood lactate concentration (mmol/l), mean (SD) 4.9 (3.1) 4.2 (2.8) 5.1 (3.5)
Refractory hypotension only (%) 39.3 53.5 36.3
Hyperlactataemia only (%) 46.7 30.2 44.4
Both refractory hypotension and hyperlactataemia (%) 14.0 16.3 19.3
APACHE II score, mean (SD) 20.7 (7.5) 15.8 (6.5) 18.0 (7.1)
Interventions hour 0 to hour 6
Intravenous fluidsb (ml), mean (SD) 2279 (1881) 1713 (1401) 2022 (1271)
Vasopressorsc (%) 44.1 57.8 46.6
Dobutamine (%) 0.9 2.6 3.8
Packed red blood cell transfusion (%) 7.5 7.0 3.8
Mechanical ventilationd (%) 21.7 22.4 19.0
CVC insertione (%) 57.9 61.9 50.9
Outcomes
Hospital mortality (%) – 15.7 24.6
Discharge homef (%) 51.5 79.6 82.2
28-day mortality (%) – 15.9 24.5
90-day mortality (%) 33.7 18.8 29.2
CVC, central venous catheter; MAP, mean arterial pressure; SBP, systolic blood pressure.
a ProMISe includes intravenous crystalloid and colloid administration > 20ml and all blood product administration;
ProCESS includes intravenous crystalloid, colloid and blood product administration.
b ProMISe and ARISE include intravenous crystalloid and colloid administration > 20ml.
c ARISE includes vasopressor infusion at any dose for ≥ 30 minutes.
d ProCESS includes mechanical ventilation from ED presentation.
e ProCESS and ARISE include CVC insertion from ED presentation.
f ProCESS discharge home is reported at 60 days (two patients remained in hospital).
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England between February 2011 and June 2014 (the recruitment period of ProMISe) direct from the ED
with infection, meeting two or more SIRS criteria during the first 24 hours following admission, and with
hypotension (lowest systolic blood pressure < 90mmHg) and/or hyperlactataemia (highest blood lactate
≥ 4mmol/l), acute hospital mortality was around 30% for patients meeting a single criterion but almost
double for patients meeting both the refractory hypotension and the hyperlactataemia criteria (Table 18).
During the intervention period, the mean volume of fluid received by patients in the usual-resuscitation
group was highest for ProCESS and lowest for ARISE (see Table 17); however, a greater proportion of
patients in ARISE received vasopressors. Dobutamine use was highest in ProMISe and lowest in ProCESS
and the proportions of usual-resuscitation group patients receiving packed red blood cell transfusions in
ProCESS and ARISE were approximately double that in ProMISe. In all three trials, around 20% of patients
received mechanical ventilation, and the central venous catheter insertion rates varied from 51% in
ProMISe to 62% in ARISE. Reflecting the pattern seen in severity of illness scores, 90-day mortality for
usual-resuscitation group patients in ProCESS was slightly higher than in ProMISe (34% vs. 29%), whereas
for those in ARISE it was substantially lower (19%). Mortality in ARISE was similarly lower at other
comparable time points. Of patients discharged alive from hospital in both ProMISe and ARISE,
approximately 80% were discharged home, compared with only just over 50% of similar patients
in ProCESS.
TABLE 18 Acute hospital mortality for patients admitted to ICU from the ED with severe sepsis and refractory
hypotension and/or hyperlactataemia
Criteria met Admissions, n (%) Acute hospital mortality, n (%)
Refractory hypotension only 2186 (18.2) 687 (31.4)
Hyperlactataemia only 5339 (44.5) 1397 (26.2)
Both refractory hypotension and hyperlactataemia 4479 (37.3) 2485 (55.5)
Based on 12,004 patients admitted to 183 adult general ICUs in England participating in the Case Mix Programme
between February 2011 and June 2014.
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Chapter 5 Results: cost-effectiveness
Cost-effectiveness at 90 days following randomisation
Resource use up to 90 days
The average duration for the delivery of the EGDT protocol for the EGDT group was 5.8 hours in total, of
which 2.0 were in the ED. The delivery of the EGDT protocol used resources specific to the intervention
with respect to catheter insertion (PreSepTM central venous oximetry catheter and arterial catheter), packed
red blood cell transfusion, infusion of dobutamine and additional staff time required to implement the
protocol in the ED (Table 19). For the index hospital episode, the mean length of stay in critical care and
TABLE 19 Resource use up to 90 days following randomisation
Resource use up to 90 days EGDT (n= 625) Usual resuscitation (n= 626)
Interventionsa
PreSep™ central venous oximetry catheter, n (%) 545 (87) 2 (0)
Standard CVC, n (%) 48 (8) 316 (50)
Arterial catheter, n (%) 462 (74) 389 (62)
Blood products
Packed red blood cells (ml) 97 (267) 70 (262)
Platelets (ml) 16 (82) 15 (79)
Fresh-frozen plasma (ml) 58 (275) 59 (264)
Dobutamine total dose (mg) 183 (592) 88 (489)
Duration of protocol delivered in ED (hours) 2.0 (1.9) –
Duration of protocol delivered in total (hours) 5.8 (0.8) –
Additional staff time
Catheter insertion and monitor set-up (hours) 1.2 (0.3) 0.5 (0.4)
Monitoring (hours) 0.3 (0.3) –
Training (hours) 0.3 (0) –
Acute hospital length of stay
Index hospital admissiona
Length of stay in ED (hours) 2.3 (3.2) 1.9 (2.1)
Length of stay in critical care (days) 4.9 (7.8) 4.7 (8.9)
Length of stay on general medical ward (days) 10.5 (15.0) 9.6 (13.5)
Acute hospital readmissions,b n (%) 28 (4) 30 (5)
Length of stay in critical care (days) 0.3 (2.5) 0.4 (3.2)
Length of stay on general medical ward (days) 0.7 (4.2) 0.7 (4.5)
Total acute hospital length of stay up to 90 days 16.7 (19.2) 15.5 (17.8)
CVC, central venous catheter.
a Source: ProMISe data set.
b Source: Case Mix Programme database.32
Values are mean (SD), unless stated otherwise.
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on general medical wards was higher in the EGDT group than the usual-resuscitation group. The
proportion of patients who were readmitted and the mean length of stay following readmission were
similar between the treatment groups (see Table 19). The mean total length of stay in acute hospital
up to 90 days following randomisation was 16.7 days in the EGDT group versus 15.5 days in the
usual-resuscitation group.
Table 20 summarises the resource use reported from responses to the Health Services Questionnaire
administered at 90 days following randomisation for all patients randomised to each treatment group.
The mean number of inpatient days reported from admissions other than those involving critical care was
4.6 days for the EGDT group and 3.8 days for the usual-resuscitation group. The mean numbers of
outpatient visits and community care contacts up to 90 days were similar between the groups. Patients
in both groups reported low use of community health services over the 90 days following randomisation.
Total costs up to 90 days
The net effect of the higher average length of stay in critical care and on general medical wards was that
the EGDT group had higher mean total costs per patient than the usual-resuscitation group (Table 21).
At 90 days, the mean total costs per patient were £12,414 for the EGDT group and £11,424 for the
usual-resuscitation group.
TABLE 20 Resource use from the Health Services Questionnaire between discharge from hospital and 90 days
following randomisation
Resource use EGDT (N= 625), mean (SD) Usual resuscitation (N= 626), mean (SD)
Inpatient days (general medical) 4.6 (8.5) 3.8 (7.0)
Outpatient visits 0.9 (2.6) 1.1 (2.4)
GP contacts 1.2 (2.4) 1.1 (2.3)
Nurse contacts 0.7 (2.0) 0.7 (2.0)
Occupational therapist contacts 0.2 (1.4) 0.3 (2.2)
Health visitor contacts 0.2 (1.6) 0.4 (2.4)
Clinical psychologist contacts 0.02 (0.2) 0.01 (0.3)
Speech therapist contacts 0.01 (0.3) 0.04 (2.7)
Physiotherapist contacts 0.4 (2.3) 0.4 (2.7)
Dietitian contacts 0.1 (0.9) 0.1 (0.5)
GP, general practitioner.
For patients with missing values who were known to be alive at 90 days, we applied imputed means for each item of
resource use.
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Health-related quality of life at 90 days
The distribution of responses to each dimension of the EQ-5D questionnaires, administered at 90 days
following randomisation, is reported by treatment group in Table 22. The distribution of responses was
similar between the groups. The resultant mean EQ-5D utility scores and QALYs were also similar between
the treatment groups (Table 23).
Cost-effectiveness at 90 days
The incremental QALY gain for EGDT versus usual resuscitation was negative, but with 95% CIs that
included zero (see Table 23). The average costs were higher for the EGDT group, but this difference was
not statistically significant. The INB for EGDT versus usual resuscitation was negative at −£1000
(95% CI −£2720 to £720; see Table 23).
When the uncertainty in the incremental costs and QALYs is represented on the cost-effectiveness plane,
the majority of the points are in those quadrants that show EGDT has, on average, higher costs (Figure 20).
The probability that EGDT is more cost-effective than usual resuscitation, given the data, is never greater than
20%, irrespective of how much society is willing to pay for a QALY gain (Figure 21).
TABLE 21 Costs (£) up to 90 days following randomisation
Resource use categories EGDT (N= 625), mean (SD)
Usual resuscitation (N= 626),
mean (SD)
Interventiona
Monitor and consumables 206 (70) 33 (26)
Blood products 83 (208) 66 (207)
Drugs (dobutamine) 8 (24) 4 (19)
Additional staff time costs
Catheter insertion and monitor set-up 64 (18) 29 (21)
Monitoring 16 (16) –
Training 17 (0) –
Hospital costs
Index hospital admissiona
ED 62 (85) 53 (56)
Critical care 7255 (12,045) 6852 (13,529)
General medical ward 2788 (3983) 2532 (3586)
Readmission costs
Critical careb 467 (3577) 626 (4500)
General medicalb,c 196 (1132) 178 (1187)
Outpatient and community costsc,d 1252 (2848) 1051 (2660)
Total costs up to 90 daysd 12,414 (14,970) 11,424 (15,727)
a Source: ProMISe data set.
b Source: Case Mix Programme database.32
c Source: Health Services Questionnaire.
d Results reported after applying multiple imputation to handle missing data.
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TABLE 22 Health-related quality of life (EQ-5D-5L) responses for patients who were alive and fully completed the
questionnaire at 90 days following randomisation
EQ-5D-5L dimension EGDT (N= 339a), n (%) Usual resuscitation (N= 332a), n (%)
Mobility
No problems 101 (30) 102 (31)
Slight problems 44 (13) 51 (15)
Moderate problems 86 (25) 71 (21)
Severe problems 75 (22) 74 (22)
Extreme problems 33 (10) 34 (10)
Self-care
No problems 173 (51) 171 (52)
Slight problems 44 (13) 40 (12)
Moderate problems 68 (20) 71 (21)
Severe problems 30 (9) 25 (8)
Extreme problems 24 (7) 25 (8)
Usual activities
No problems 81 (24) 87 (26)
Slight problems 61 (18) 62 (19)
Moderate problems 83 (24) 82 (25)
Severe problems 62 (18) 51 (15)
Extreme problems 52 (15) 50 (15)
Pain/discomfort
No problems 93 (27) 95 (29)
Slight problems 91 (27) 81 (24)
Moderate problems 81 (24) 89 (27)
Severe problems 50 (15) 53 (16)
Extreme problems 24 (7) 14 (4)
Anxiety/depression
No problems 152 (45) 146 (44)
Slight problems 74 (22) 79 (24)
Moderate problems 72 (21) 70 (21)
Severe problems 23 (7) 22 (7)
Extreme problems 18 (5) 15 (5)
a Results are presented for patients with complete information; the numbers of complete responses/eligible patients at
90 days are as follows: EGDT 339/441 (77%), usual resuscitation 332/445 (75%).
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TABLE 23 Cost-effectiveness at 90 days
End point
EGDT (n= 625),
mean (SD)
Usual resuscitation
(n= 626), mean (SD)
Incremental effect
(unadjusted),
mean (95% CI) p-value
EQ-5D-5L utility score (survivors) 0.609 (0.319) 0.613 (0.312) −0.004 (−0.051 to 0.044) 0.88
QALYs 0.054 (0.048) 0.054 (0.048) −0.001 (−0.006 to 0.005) 0.85
Costs (£) 12,414 (14,970) 11,424 (15,727) 989 (−726 to 2705) 0.26
Incremental net benefit (£)a −1000 (−2720 to 720) 0.25
Results are reported after applying multiple imputation to handle missing data.
a Incremental net benefit is calculated, according to NICE methods guidance, by multiplying the mean QALY gain (or loss)
by £20,000, and subtracting from this the incremental cost.
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The estimated INB were similar for the scenarios considered in the sensitivity analyses (Figure 22). For
example, the INB remains around −£1000 whether EGDT is provided in the ED or in critical care. Similarly,
excluding readmissions that were reported from responses to the Health Services Questionnaire, to avoid
any risk of double counting, had only a small impact on the mean INB (−£800 vs. −£1000).
The results of the subgroup analyses are presented in Table 24, and show that the incremental QALYs
were similar across all subgroups. Although there were some subgroups for which the incremental costs of
EGDT were negative and hence the INBs were positive, the statistical uncertainty surrounding these findings
was high. Hence for each subgroup, as for the overall results, the 95% CIs around the INB included zero.
Adjusting for adherence to the EGDT protocol decreased the INB to −£1438, but the 95% CI still included
zero (see Table 24).
– 3500 – 2500 – 1500 – 500 0 500 15001000– 3000 – 2000 – 1000
Incremental net benefits at £20,000 per QALY gain
(EGDT vs. usual resuscitation)
Distributional assumptions
Baseline covariates
Excluding readmissions
Location of EGDT protocol delivery – critical care
Location of EGDT protocol delivery – ED
Staff training time – 30 minutes
Staff training time – 15 minutes
Staff monitoring time – 15 minutes per hour
Staff monitoring time – 5 minutes per hour
Equipment costs for the intervention
Base case
FIGURE 22 Sensitivity analyses for the incremental net benefit at 90 days following randomisation according to
alternative assumptions, compared with the base case. The vertical dashed line indicates incremental net benefit in
the base-case analysis. The solid vertical line indicates no difference in net monetary benefits between the
treatment groups.
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Cost-effectiveness at 1 year following randomisation
(primary outcome)
Resource use up to 1 year
Acute hospital length of stay up to 1 year following randomisation is presented in Table 25. A higher
proportion of patients in the EGDT group had an index hospital admission or readmission that continued
beyond day 90. Between 90 days and 1 year following randomisation, the mean number of days in critical
care, on general medical wards and in total was lower for the EGDT group than for the usual-resuscitation
group. The mean total acute hospital length of stay up to 1 year following randomisation was 18.7 days
in the EGDT group, compared with 18.2 days in the usual-resuscitation group.
Table 26 reports results from responses to the Health Services Questionnaire administered at 1 year
following randomisation, concerning resource use between 90 days and 1 year. The mean number of
inpatient days reported from admissions other than those involving critical care was 6.3 days for the EGDT
TABLE 24 Cost-effectiveness at 90 days: subgroup and secondary analyses
Subgroup
Incremental cost (£)
(95% CI)
Incremental QALYs
(95% CI)
Incremental net benefit (£)
(95% CI)
Degree of protocolised resuscitation in usual-resuscitation group
Low 806 (−1213 to 2825) 0.002 (−0.004 to 0.009) −765 (−2789 to 1259)
High 1655 (−1822 to 5131) −0.005 (−0.017 to 0.006) −1764 (−5247 to 1719)
Age (years)
18–56 3253 (−155 to 6662) −0.001 (−0.012 to 0.011) −3265 (−6684 to 154)
57–67 398 (−3021 to 3818) 0.003 (−0.008 to 0.014) −329 (−3758 to 3100)
68–77 −1511 (−4884 to 1862) −0.003 (−0.015 to 0.008) 1444 (−1943 to 4831)
78–95 2359 (−1112 to 5830) 0.003 (−0.008 to 0.015) −2296 (−5777 to 1185)
MEDS score
0–4 2129 (−2644 to 6902) 0.002 (−0.014 to 0.018) −2089 (−6864 to 2686)
5–6 2700 (−815 to 6215) 0.002 (−0.009 to 0.014) −2652 (−6173 to 869)
7–9 −250 (−3308 to 2807) 0.005 (−0.005 to 0.015) 351 (−2715 to 3417)
10–20 196 (−2934 to 3326) −0.009 (−0.019 to 0.001) −377 (−3514 to 2760)
SOFA score
0–2 1947 (−1482 to 5375) 0.002 (−0.009 to 0.014) −1898 (−5327 to 1531)
3–4 623 (−2351 to 3598) 0.001 (−0.009 to 0.011) −603 (−3580 to 2374)
5 −1506 (−5705 to 2692) −0.007 (−0.021 to 0.006) 1359 (−2848 to 5566)
6–14 2658 (−701 to 6016) −0.004 (−0.014 to 0.007) −2736 (−6099 to 627)
Time from ED presentation to randomisation (hours)
0.2–1.8 1291 (−2114 to 4697) −0.002 (−0.013 to 0.009) −1322 (−4734 to 2090)
1.8–2.5 2849 (−515 to 6214) 0.004 (−0.007 to 0.015) −2776 (−6147 to 595)
2.5–3.5 1123 (−2344 to 4590) −0.003 (−0.014 to 0.009) −1179 (−4655 to 2297)
3.5+ −1453 (−4882 to 1976) −0.001 (−0.012 to 0.01) 1426 (−2008 to 4860)
Adherence adjusted analysis 1423 (−1042 to 3888) −0.001 (−0.009 to 0.007) −1438 (−3909 to 1033)
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TABLE 25 Acute hospital length of stay up to 1 year following randomisation
Acute hospital length of stay up to 1 year EGDT (N= 625)
Usual resuscitation
(N= 626)
Total acute hospital length of stay up to 90 daysa,b 16.7 (19.2) 15.5 (17.8)
Acute hospital length of stay 90 days to 1 year
Continuing index hospital admission,a n (%) 13 (2.1) 9 (1.4)
Length of stay in critical care (days) 0 (0) 0.01 (0.1)
Length of stay on general medical ward (days) 0.5 (5.6) 0.6 (10.0)
Acute hospital readmissions,b n (%) 40 (6.4) 46 (7.3)
Length of stay in critical carec (days) 0.2 (1.5) 0.3 (2.0)
Length of stay on general medical wardc (days) 1.3 (6.6) 1.8 (10.3)
Total acute hospital length of stay up to 1 year 18.7 (24.5) 18.2 (26.8)
Values are mean (SD), unless stated otherwise.
a Source: ProMISe data set.
b Source: Case Mix Programme database.32
c Results reported after applying multiple imputation to handle missing data.
TABLE 26 Resource use from the Health Services Questionnaire between 90 days and 1 year
following randomisation
Resource use
EGDT (n= 625),
mean (SD)
Usual resuscitation
(n= 626), mean (SD)
Inpatient days (general medical) 6.3 (9.0) 6.6 (11.9)
Outpatient visits 1.6 (3.7) 1.8 (4.5)
GP contacts 1.7 (3.3) 1.6 (3.4)
Nurse contacts 1.5 (4.1) 1.7 (4.8)
Occupational therapist contacts 0.2 (1.0) 0.3 (1.2)
Health visitor contacts 0.3 (4.1) 0.2 (1.6)
Clinical psychologist contacts 0.03 (0.3) 0.04 (0.4)
Speech therapist contacts 0.05 (0.6) 0.05 (0.5)
Physiotherapist contacts 0.4 (2.0) 0.6 (3.2)
Dietitian contacts 0.1 (0.7) 0.2 (1.1)
GP, general practitioner.
For patients with missing values who were known to be alive at 1 year, we applied imputed means for each item of
resource use.
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group and 6.6 days for the usual-resuscitation group. The mean numbers of outpatient visits and
community care contacts between 90 days and 1 year were similar between the groups. Overall, both
groups reported low use of community health services over 1 year following randomisation.
Total costs up to 1 year
Table 27 reports the total costs up to 1 year following randomisation, across all of the resource use items
recorded. At 1 year, the mean total costs per patient were £15,139 for the EGDT group and £14,375 for
the usual-resuscitation group.
Health-related quality of life at 1 year
The distribution of responses to each dimension of the EQ-5D questionnaires, administered at 1 year
following randomisation, is reported by treatment group in Table 28. At 1 year, a lower proportion of
patients in the EGDT group than in the usual-resuscitation group reported ‘no problems’ for each
dimension of the EQ-5D, with a higher proportion of patients in the EGDT group reporting ‘severe
problems’ or ‘extreme problems’ for each dimension of health. The mean EQ-5D utility score of those
patients who were alive at 1 year post randomisation was higher in the usual-resuscitation group (0.653)
than in the EGDT group (0.620; Table 29).
Cost-effectiveness at 1 year
At 1 year following randomisation, a slightly higher proportion of patients in the EGDT group were alive
than in the usual-resuscitation group (see Secondary outcomes: clinical effectiveness). The net effect of
the EGDT group having higher survival but a lower average EQ-5D utility score resulted in similar 1-year
QALYs between the treatment groups (see Table 29). The mean total cost was higher in the EGDT group,
with an incremental cost of £764 (95% CI −£1402 to £2930). Hence the INB for EGDT versus usual
resuscitation was negative at −£725 (95% CI −£3000 to £1550). The distribution of incremental costs and
QALYs in the cost-effectiveness plane is shown in Figure 23.
TABLE 27 Costs (£) up to 1 year following randomisation
Resource use categories EGDT (n= 625), mean (SD)
Usual resuscitation (n= 626),
mean (SD)
Total costs up to 90 daysa,b,c,d 12,414 (14,970) 11,424 (15,727)
Hospital costs 90 days to 1 year
Continuing index hospital admissiona
Critical care 0 (0) 15 (281)
General medical ward 144 (1471) 148 (2666)
Acute hospital readmissions
Critical careb 607 (2233) 575 (2678)
General medical wardb,c 340 (1740) 490 (2727)
Outpatient and community costsc,d 1634 (3546) 1722 (4406)
Total costs up to 1 yeard 15,139 (18,345) 14,375 (19,179)
a Source: ProMISe data set.
b Source: Case Mix Programme database.32
c Source: Health Services Questionnaire.
d Results reported after applying multiple imputation to handle missing data.
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TABLE 28 Health-related quality of life (EQ-5D-5L) responses for patients that were alive and fully completed the
questionnaire at 1 year following randomisation
EQ-5D-5L dimension EGDT (N= 244a), n (%) Usual resuscitation (N= 236a), n (%)
Mobility
No problems 65 (26.6) 81 (34.3)
Slight problems 40 (16.4) 38 (16.1)
Moderate problems 69 (28.3) 47 (19.9)
Severe problems 49 (20.1) 55 (23.3)
Extreme problems 21 (8.6) 15 (6.4)
Self-care
No problems 124 (50.8) 141 (59.8)
Slight problems 33 (13.5) 27 (11.4)
Moderate problems 49 (20.1) 38 (16.1)
Severe problems 21 (8.6) 22 (9.3)
Extreme problems 17 (7.0) 8 (3.4)
Usual activities
No problems 69 (28.3) 88 (37.3)
Slight problems 49 (20.1) 42 (17.8)
Moderate problems 55 (22.5) 50 (21.2)
Severe problems 46 (18.9) 39 (16.5)
Extreme problems 25 (10.3) 17 (7.2)
Pain/discomfort
No problems 71 (29.1) 81 (34.3)
Slight problems 50 (20.5) 45 (19.1)
Moderate problems 71 (29.1) 57 (24.2)
Severe problems 41 (16.8) 43 (18.2)
Extreme problems 11 (4.5) 10 (4.2)
Anxiety/depression
No problems 104 (42.6) 120 (50.9)
Slight problems 57 (23.4) 50 (21.2)
Moderate problems 55 (22.5) 39 (16.5)
Severe problems 19 (7.8) 22 (9.3)
Extreme problems 9 (3.7) 5 (2.1)
a Results are presented for patients with complete information; the numbers of complete responses/eligible patients at
1 year are as follows: EGDT 244/334 (73%), usual resuscitation 236/325 (73%).
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The cost-effectiveness acceptability curve (Figure 24) shows that at 1 year the probability that EGDT is
more cost-effective than usual resuscitation, given the data, is below 30% at the £20,000 willingness-to-
pay threshold stipulated by NICE.
The estimated INBs were similar for the scenarios considered in the sensitivity analyses (Figure 25). This
shows that the base-case results are robust to alternative assumptions.
The estimated INBs were similar across all pre-specified subgroups (Table 30). Although there were some
subgroups for whom EGDT was cost-saving and hence their INBs were positive, there was high statistical
uncertainty around surrounding these findings. Hence for each subgroup, as for the overall results, there is
high statistical uncertainty surrounding INBs.
TABLE 29 Cost-effectiveness at 1 year (primary outcome)
End point EGDT (n= 625)
Usual resuscitation
(n= 626)
Incremental effect
(unadjusted), mean
(95% CI) p-value
EQ-5D-5L utility score (survivors) 0.620 (0.307) 0.653 (0.323) −0.032 (−0.085 to 0.020) 0.23
QALYs 0.352 (0.323) 0.351 (0.329) 0.002 (−0.036 to 0.040) 0.92
Costs (£) 15,139 (18,345) 14,375 (19,179) 764 (−1402 to 2930) 0.49
Incremental net benefit (£)a −725 (−3000 to 1550) 0.53
a Incremental net benefit is calculated, according to NICE methods guidance, by multiplying the mean QALY gain (or loss)
by £20,000, and subtracting from this the incremental cost.
Values are mean (SD), unless stated otherwise. Results are reported after applying multiple imputation to handle
missing data.
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Lifetime incremental cost-effectiveness
Long-term survival
The Kaplan–Meier survival curves show that when the time horizon was extended beyond 1 year, for those
with survival data available, the probability of survival remained similar between treatment groups (Figure 26).
To calculate QALYs over 20 years, the long-term survival for each patient was estimated by combining the
observed survival for each patient up to 1 year with their predicted survival from 1 year to 20 years. We
compared alternative parametric extrapolation approaches to predict longer-term survival of patients
recruited to ProMISe. Figure 27 considers alternative parametric extrapolations for survival, using the
observed survival data after day 30. The survival data were pooled across the treatment groups, given that
there was no evidence of an effect of treatment group on survival. Of the alternative survival functions,
log-normal appeared to fit the observed data best in that it reported the lowest Akaike information criteria
and Bayesian information criteria (Table 31). However, the Gompertz function offered the most plausible
projections of future survival (see Figure 27 and Table 31), in that the levels of survival remained constant
TABLE 30 Cost-effectiveness at 1 year: subgroup and secondary analyses
Subgroup
Incremental cost (£)
(95% CI)
Incremental QALYs
(95% CI)
Incremental net benefit (£)
(95% CI)
Degree of protocolised resuscitation in usual-resuscitation group
Low 801 (−1718 to 3319) 0.014 (−0.03 to 0.058) −525 (−3172 to 2122)
High 739 (−3562 to 5040) −0.017 (−0.093 to 0.059) −1084 (−5578 to 3410)
Age (years)
18–56 3643 (−626 to 7913) 0.011 (−0.064 to 0.086) −3422 (−7932 to 1088)
57–67 257 (−3977 to 4490) 0.025 (−0.049 to 0.098) 238 (−4234 to 4710)
68–77 −1924 (−6101 to 2252) −0.028 (−0.104 to 0.047) 1357 (−3042 to 5756)
78–95 2038 (−2227 to 6302) 0.041 (−0.035 to 0.116) −1226 (−5720 to 3268)
MEDS score
0–4 1972 (−3966 to 7909) 0.015 (−0.088 to 0.118) −1670 (−7866 to 4526)
5–6 2401 (−1931 to 6733) 0.008 (−0.068 to 0.084) −2241 (−6789 to 2307)
7–9 −909 (−4684 to 2866) 0.045 (−0.022 to 0.112) 1806 (−2160 to 5772)
10–20 615 (−3305 to 4534) −0.047 (−0.114 to 0.021) −1551 (−5636 to 2534)
SOFA score
0–2 1579 (−2755 to 5913) 0.020 (−0.055 to 0.095) −1183 (−5694 to 3328)
3–4 696 (−3033 to 4425) 0.007 (−0.059 to 0.072) −566 (−4450 to 3318)
5 −2836 (−8057 to 2384) −0.036 (−0.127 to 0.056) 2118 (−3332 to 7568)
6–14 2769 (−1401 to 6939) −0.016 (−0.087 to 0.055) −3097 (−7446 to 1252)
Time from ED presentation to randomisation (hours)
0.2–1.8 1739 (−2507 to 5985) −0.010 (−0.085 to 0.065) −1940 (−6387 to 2507)
1.8–2.5 3576 (−633 to 7786) 0.032 (−0.043 to 0.107) −2934 (−7350 to 1482)
2.5–3.5 1111 (−3225 to 5446) −0.005 (−0.082 to 0.071) −1215 (−5785 to 3355)
3.5+ −3535 (−7762 to 692) −0.007 (−0.083 to 0.068) 3388 (−1037 to 7813)
Adherence adjusted analysis 1099 (−2013 to 4211) 0.003 (−0.051 to 0.057) −1042 (−4312 to 2228)
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over time from 5 years following randomisation onwards. The parametric models predicted excess
mortality in patients recruited to ProMISe compared with the age-/sex-matched general population.
In the base case, we applied death rates according to the most plausible parametric model (i.e. Gompertz)
between year 2 and year 15. At year 16, predicted survival overlaps with age-/sex-matched survival and,
therefore, from year 16 onwards we applied age-/sex-matched general population death rates.
Long-term health-related quality of life
The lifetime cost-effectiveness analysis required health-related quality of life to be estimated over time.
We used health-related quality of life from ProMISe and also from the age-/sex-matched general
population to predict the long-term quality of life of patients recruited to ProMISe. There was a difference
in the mean quality of life between the treatment groups at 1 year (0.62 for EGDT and 0.65 for usual
resuscitation), which was maintained for the period over which the excess rate of mortality was applied
(years 2–15). In the base case, we applied age-/sex-matched general population quality of life for years
2–15, but applying decrements of 21% (EGDT) and 17% (usual resuscitation) to allow for the relative
differences in quality of life observed between the treatment groups at 1 year to be maintained.
Long-term costs
To project lifetime costs attributable to the initial episode of severe sepsis, we considered mean inpatient,
outpatient and community costs up to 1 year estimated from the Health Services Questionnaires.
The mean cost for each intervention group was calculated for those patients who survived at least up to
1 year. These mean costs were used to impute mean costs between year 1 and year 15. For each group,
these mean costs were similar (£4221 for EGDT and £4216 for usual resuscitation). After year 15 it was
assumed that there were no further readmission costs that were attributable to the original episode of
severe sepsis.
Lifetime incremental cost-effectiveness
Table 32 presents the resultant lifetime QALYs, lifetime costs and INB according to the base-case
assumptions. Overall, at the NICE-stipulated threshold of £20,000 per QALY the INB was negative,
but with a wide 95% CI that included zero. The distribution of incremental costs and QALYs in the
cost-effectiveness plane is shown in Figure 28.
The cost-effectiveness acceptability curve shows that that the probability of EGDT of being cost-effective
compared with usual resuscitation is never > 50% irrespective of how much society is willing to pay for a
QALY gain (Figure 29).
The sensitivity analyses on the long-term results suggest that these findings are robust to alternative
assumptions including those applied to extrapolation of long-term survival, quality of life for survivors and
costs (Figure 30). For example, a large versus smaller decrement in quality of life over 15 years had only
marginal impact on the mean INB.
TABLE 31 Fit of alternative parametric survival functions applied to the ProMISe data set after day 30
Distribution AIC BIC
Gompertz 1658.0 1687.1
Log-normal 1642.4 1671.5
Logistic 1644.5 1673.5
Weibull 1645.8 1674.8
Exponential 1691.0 1715.2
AIC, Akaike information criterion; BIC, Bayesian information criterion.
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TABLE 32 Lifetime cost-effectiveness
End point EGDT (n= 625)
Usual resuscitation
(n= 626)
Incremental effect
(unadjusted), mean
(95% CI) p-value
QALYs 4.584 (3.546) 4.582 (3.720) 0.002 (−0.411 to 0.414) 0.99
Costs (£) 33,620 (25,012) 32,142 (25,798) 1478 (−1434 to 4390) 0.32
Incremental net benefit (£)a −1446 (−8102 to 5210) 0.67
a Incremental net benefit is calculated according to NICE methods guidance, by multiplying the mean QALY gain (or loss)
by £20,000, and subtracting from this the incremental cost.
Values are mean (SD), unless stated otherwise. Results are reported after applying multiple imputation to handle
missing data.
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The results of the subgroup analysis presented in Table 33 show that there were some differences in the
direction of mean incremental effects but high statistical uncertainty surrounds these findings. Across
subgroups, incremental QALYs were small. Although there were some subgroups of patients for whom the
incremental costs of EGDT were negative, and hence the INBs were positive, 95% CIs around these INBs
included zero. Hence for each subgroup, as for the overall result, cost-effectiveness estimates were
surrounded by high statistical uncertainty.
TABLE 33 Lifetime incremental cost-effectiveness: subgroup and secondary analyses
Subgroup
Incremental cost (£)
(95% CI)
Incremental QALYs
(95% CI)
Incremental net benefit (£)
(95% CI)
Degree of protocolised resuscitation in usual-resuscitation group
Low 1905 (−1495 to 5305) 0.104 (−0.38 to 0.587) 168 (−7630 to 7966)
High 965 (−4874 to 6805) −0.131 (−0.968 to 0.706) −3589 (−17,056 to 9878)
Age (years)
18–56 4881 (−736 to 10,498) 0.096 (−0.715 to 0.907) −2957 (−16,236 to 10,322)
57–67 1357 (−4289 to 7003) 0.114 (−0.692 to 0.919) 915 (−12,166 to 13,996)
68–77 −1945 (−7570 to 3681) −0.201 (−1.007 to 0.606) −2069 (−15,097 to 10,959)
78–95 4635 (−1113 to 10,383) 0.521 (−0.309 to 1.351) 5787 (−7640 to 19,214)
MEDS score
0–4 3344 (−4654 to 11,343) 0.139 (−1.006 to 1.284) −560 (−19,050 to 17,930)
5–6 3759 (−2120 to 9638) 0.139 (−0.700 to 0.977) −985 (−14,470 to 12,500)
7–9 819 (−4262 to 5900) 0.280 (−0.441 to 1.001) 4788 (−6840 to 16,416)
10–20 −140 (−5456 to 5176) −0.361 (−1.104 to 0.383) −7077 (−18,979 to 4825)
SOFA score
0–2 3008 (−2798 to 8814) 0.151 (−0.661 to 0.963) 4 (−13,077 to 13,085)
3–4 1886 (−3143 to 6915) 0.114 (−0.591 to 0.819) 386 (−10,938 to 11,710)
5 −3279 (−10,351 to 3793) −0.312 (−1.300 to 0.677) −2952 (−18,774 to 12,870)
6–14 1792 (−3854 to 7439) −0.369 (−1.163 to 0.426) −9164 (−21,917 to 3589)
Time from ED presentation to randomisation (hours)
0.2–1.8 2471 (−3280 to 8223) 0.005 (−0.819 to 0.829) −2371 (−15,643 to 10,901)
1.8–2.5 6390 (707 to 12,073) 0.523 (−0.276 to 1.323) 4074 (−8777 to 16,925)
2.5–3.5 693 (−5140 to 6525) −0.279 (−1.130 to 0.571) −6275 (−20,079 to 7529)
3.5+ –3759 (–9472 to 1953) –0.230 (–1.052 to 0.591) –847 (–14,099 to 12,405)
Adherence adjusted analysis 2126 (–2056 to 6307) 0.002 (–0.591 to 0.595) –2079 (–11,654 to 7496)
RESULTS: COST-EFFECTIVENESS
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Chapter 6 Discussion and conclusions
Principal findings
Among adults identified with early signs of septic shock presenting to the ED of one of 56 NHS hospitals
in England and receiving 6 hours of protocolised resuscitation, there was no significant difference in
mortality at 90 days when compared with usual resuscitation (relative risk 1.01, 95% CI 0.85 to 1.20).
Although mortality was lower than anticipated, our results rule out, with 95% confidence, a relative risk
reduction with EGDT of > 15%. On average, EGDT increased costs and, given similar QALYs across groups,
INB at 1 year was negative (−£725, 95% CI −£3000 to £1550). The probability that EGDT is cost-effective
(at a willingness to pay of £20,000 per QALY) is below 30%. Sensitivity analyses found that this conclusion
is robust to alternative assumptions to those made in the base-case analysis.
There was no significant interaction between treatment effect and mortality at 90 days across pre-specified
subgroups on the basis of degree of protocolisation of usual resuscitation, age, MEDS score, SOFA score or
time to randomisation. More patients receiving EGDT were admitted to ICU, resulting in significantly more
days spent in critical care in this group. Treatment intensity was greater for the EGDT group, driven by
adherence to the protocol, and indicated by the increased use of central venous catheters, intravenous
fluids, vasoactive drugs and packed red blood cell transfusions. Increased treatment intensity was reflected
by significantly higher SOFA scores and more advanced cardiovascular support days in critical care for
the EGDT group. There were no significant differences in any other secondary outcomes including
health-related quality of life, measured in health-state utility values, which was substantially poorer in this
severely ill patient group at both 90 days (0.61) and 1 year (0.62–0.65) than for the age-/sex-matched
general population (0.80).58 At 12 months post randomisation, approximately 30% of responders reported
‘severe’ or ‘extreme’ problems with mobility or undertaking usual activities, indicating substantial ongoing
morbidity for this patient group.
Strengths
ProMISe was set in a real-world context, in a large, representative, mixed sample of approximately
one-quarter of NHS hospitals in England, and was pragmatic, with staff and locations for delivery of the
protocol determined locally, as would be the case if the intervention were to be adopted into routine NHS
care. Site set-up was rapid, resulting in our trial recruiting its full sample of 1260 patients over a relatively
shorter time period than the two similar studies already reported from the USA and Australasia; minimising
the potential for other changes in treatments to impact on the trial.
Loss to follow-up was minimal and all analyses were conducted according to a pre-specified, published
statistical analysis plan including, given the complex intervention, adjusted analyses to address the degree
of adherence to EGDT and the possibility of the existence of a learning curve for its delivery.
Unlike the previous studies, our trial reported on quality of life at 90 days and 1 year post randomisation
and our results include an integrated analysis of the cost-effectiveness of EGDT. This prospectively
designed economic evaluation ensured that resource use data were collected on both primary admissions
and readmissions for each patient randomised. The resource use measurement harnessed information from
three sources: the case report forms, linked data from the Case Mix Programme database and responses to
follow-up Health Service Questionnaires. This approach enabled detailed resource use measurement for
those events that were anticipated to be the key drivers of the incremental costs of EGDT versus usual
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resuscitation. The cost-effectiveness analysis also measured quality of life with the EQ-5D-5L;59 this version
of the EQ-5D instrument was anticipated to be sensitive to differences in health status between the
treatment groups. To address missing data, we undertook the recommended approach of multiple
imputation and imputed missing values, conditional on all the information observed.
Limitations
As with all studies enrolling patients presenting as emergencies, recruitment was more challenging at
weekends and out-of-office hours. As a result of this, together with other logistical issues, only around
one-third of eligible patients were recruited. However, there were no important differences in baseline
characteristics between patients recruited during usual working hours or at weekends and out-of-office
hours. In addition, exclusion by a clinician was comparatively rare.
With recruitment rates much lower – and eligible patients missed – at nights and at weekends, alongside
a number of sites undergoing a period of suspension or closing early to recruitment owing to lack of
available resources, the trial recruited behind the planned schedule. Owing to the short time-windows to
recruit and commence treatment in randomised controlled trials in emergency and critical care settings,
it is vital that research infrastructure within the NHS is delivered 24 hours per day, 7 days per week.
The intervention could not be blinded to those caring for patients but the risk of bias was minimised through
central randomisation to ensure allocation concealment and the use of a primary outcome not subject to
observer bias. The mortality observed in the usual-resuscitation group was lower than anticipated as the basis
for the sample size calculation (29.2% vs. 40%). This was also true for both ProCESS (60-day in-hospital
mortality, 18.9% observed, 30–46% anticipated23) and ARISE (90-day mortality, 18.8% observed, 38%
anticipated24). However, unlike both ProCESS and ARISE, based on the 95% CI, our results were able to rule
out with 95% confidence, in our setting of NHS EDs, the relative risk reduction in 90-day mortality of 20%
that was the basis for our sample size calculation. Although able to provide, relatively, the most precise
overall estimate of effect, we have limited power to address many important subgroups for either the clinical
effectiveness or the cost-effectiveness.
The long-term cost-effectiveness analysis was inevitably required to make assumptions, in particular about
the mortality, quality of life and cost in the time period beyond the observed data. The study made
maximum use of the available trial data to inform these assumptions. For example, the analysis of the
mortality data found that mortality was similar between the treatment groups at each time point, and
that there was excess mortality versus the age-/sex-matched general population for up to 15 years post
randomisation. These findings informed the assumptions made in the base-case analysis concerning the
long-term survival extrapolation. The study made these and other requisite structural assumptions
transparent and subjected them to extensive sensitivity analyses.
Our findings in context
Rivers et al.6
Unlike the original Rivers et al. trial,6 we did not observe a significant reduction in mortality at hospital
discharge. There are many possible reasons for this. First, there may be bias in a small, single-centre trial,
leading to an inflated effect. Second, in the intervening years, both presenting patients and usual
resuscitation has changed; all patients in our trial received antibiotics prior to randomisation and, comparing
the usual-resuscitation groups, patients in our trial appeared less sick (with lower baseline serum lactate,
lower APACHE II scores and a lower rate of initiation of mechanical ventilation in the first 6 hours), received
much lower volumes of fluid, more vasoactive drugs and experienced lower hospital mortality.
DISCUSSION AND CONCLUSIONS
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ProCESS and ARISE
Our results, both for adherence and outcomes, are comparable with those from the ProCESS23 and ARISE24
studies from the USA and Australasia, respectively. Of note is that a greater proportion of patients in our
trial met the inclusion criteria for both refractory hypotension and hyperlactataemia, associated with higher
mortality, than met either criterion alone. The rate of death at 90 days in our trial was slightly lower than
ProCESS but higher than ARISE.
Economic evaluation
Previous cost-effectiveness analyses have reported that EGDT is cost-effective relative to usual
resuscitation.9,11,54,60,61 However, almost all these studies relied solely on observational data,9,11,60,61 and so
the finding that EGDT was associated with improved survival, and higher QALYs, could reflect confounding
by indication. Neither ProCESS nor ARISE undertook a fully integrated cost-effectiveness analysis. A key
advantage is that individual-level data on quality of life and resource use were collected prospectively.
The quality-of-life data were collected at 90 days and 1 year following randomisation with EQ-5D-5L59 and
hence the cost-effectiveness analysis was able to incorporate any differences in quality of life between the
treatment groups into the final measures of cost-effectiveness.
A previous cost-effectiveness analysis, based on the mortality reduction reported in the Rivers’ trial,6
projected that EGDT would lead to a gain in QALYs and a reduction in hospital costs of 22%.54 In contrast,
our analysis of the individual patient resource use data from the trial found that EGDT led to a small
average increase in both intervention costs and the use of critical care and general medical ward resources.
Our cost analysis also allowed for the additional training and monitoring costs of providing EGDT in the
NHS – relatively minor costs. When combined with no difference in patient outcomes this led to a very low
probability of EGDT being cost-effective. The quality-of-life estimates were similar to previous estimates for
patients surviving sepsis and sepsis shock,62,63 and to a previous study of general ICU survivors.64
Trends in outcomes
Mortality for patients with severe sepsis has been reported to be decreasing in a number of settings.3,65–67
Although this may, in part, be a dilution effect due to increased recognition and changes in clinical
coding,68,69 it is also likely that increased global awareness and a focus on early identification and
treatment, for example, early administration of antibiotics, have contributed to improved outcomes.
It is of note, however, that the reported downwards trend in mortality has been ongoing since before the
Rivers et al.6 trial and Surviving Sepsis Campaign,70 and that similar trends have been reported among
critically ill patients without sepsis.3
Implications for health care
Our results suggest that usual resuscitation has evolved over the fifteen years since the Rivers et al.6 trial;
NHS hospitals now achieve similar levels of in-hospital survival to those achieved with EGDT in the
Rivers et al.6 trial for patients with septic shock identified early and receiving intravenous antibiotics and
adequate fluid resuscitation. The addition of continuous ScvO2 monitoring and strict protocolisation of care
was, on average, more costly and did not improve outcomes.
Although adherence to the EGDT protocol in ProMISe was similar in most respects with both ProCESS and
ARISE, it is of note that the adherence with administration of packed red blood cells was generally low and
occurred considerably slower than for other interventions. The lower adherence may reflect concerns over
the relatively high haemoglobin threshold for blood transfusion in the EGDT protocol, as more recent
research evidence suggests that lower transfusion thresholds may be preferable,71 but the long time lag
from reaching the transfusion threshold to administration of blood may warrant local investigation to
ensure adequate processes are in place for rapid provision of blood products when required.
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Recommendations for research
Recommendation 1: an individual patient data meta-analysis of the three
completed trials should be conducted
Our results complete the planned trio of evaluations of EGDT across the USA, Australasia and England.
These three large studies, each with their own strengths and weaknesses, have indicated that EGDT is not
superior to usual resuscitation. Recognising that each of the three individual, large trials has limited
power for evaluating potentially important subgroups, the harmonised approach adopted provides
the opportunity to conduct an individual patient data meta-analysis, enhancing both knowledge
and generalisability.
Recommendation 2: further research to consider alternative definitions of
adherence to the resuscitation protocol should be conducted
Both the clinical effectiveness and cost-effectiveness analyses reported estimates that were adherence-adjusted
as part of pre-specified secondary analyses. However, further research to consider alternative definitions of
adherence to the EGDT resuscitation protocol are warranted. In particular, future research could apply
differential weights for adherence to the different elements of the EGDT resuscitation protocol, or to particular
time points within the 6-hour intervention period. Hence subsequent research could report whether EGDT was
clinically effective or cost-effective when these alternative definitions of adherence were met.
DISCUSSION AND CONCLUSIONS
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Appendix 1 Patient information sheet
 
[To go on your hospital Trust’s Headed paper] 
 
 
 
Patient Information Sheet 
 
 
Protocolised Management In Sepsis (ProMISe): a multi-centre, randomised controlled trial of the 
clinical and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic 
shock 
 
Introduction 
We would like to invite you to take part in a clinical trial which considers the benefit of early, goal-
directed, protocolised resuscitation compared to usual resuscitation in patients with severe sepsis 
or septic shock. 
 
Before you decide, it is important that you understand why the trial is being done and what it 
involves. One of our team will go through the information sheet with you and answer any 
questions you have.  Please feel free to talk to others about the trial if you wish 
and please don’t hesitate to ask us if there is anything that is unclear. 
 
Background 
The usual resuscitation for severe sepsis in the United Kingdom involves treatment with antibiotics,
fluids given into a vein, and medication to support the blood pressure, the heart and lung function.
In the United States (US), a trial performed at one hospital found that usual resuscitation for
severe sepsis worked better with a treatment plan guided by central blood oxygen levels during
the first six hours of hospital treatment.  This treatment plan is early, goal-directed, protocolised
resuscitation. 
 
What is the purpose of this trial? 
When a person has a severe infection, their body may react by producing an ‘inflammatory 
response’, which can damage important organs, such as the heart and lungs to the point where
they no longer function properly.  When infection causes organ failure, it is called severe sepsis.  If
severe sepsis results in low blood pressure, it is referred to as septic shock.   
 
ProMISe Patient Information Sheet, version 1.1, dated 26/07/2010 
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 The purpose of this trial is to investigate whether early, goal-directed, protocolised resuscitation
results in more people recovering from severe sepsis or septic shock when compared with usual
resuscitation.  Early, goal-directed, protocolised resuscitation is a structured series of steps or
elements that must be initiated as soon as possible, and completed over a six-hour period. This is
referred to as the ‘trial protocol’ in the rest of the document. Usual resuscitation is less structured
in that the doctor may provide some of the same elements, but does not necessarily follow a
structured series of steps or elements in a time dependent manner.  
 
The trial, which took place in the US (see background), showed that early, goal-directed,
protocolised resuscitation is better than usual resuscitation, but this trial only involved a small
number of patients, and therefore, more research is needed.  Doctors don’t know if early, goal-
directed, protocolised resuscitation will be better than usual resuscitation, so this trial will help to
determine if early, goal-directed, protocolised resuscitation should be used routinely in this
country. 
 
Why have I been asked to take part in the trial? 
You are eligible to participate in this trial because you have severe sepsis or septic shock, and have
been admitted through the Emergency Department in your hospital.  
 
Do I have to take part? 
Joining the trial is entirely voluntary. Once you have read this information sheet, if you agree to
take part, we will ask you to sign a consent form. You are free to withdraw at any time, without
giving a reason, and this will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
In order to find out which of the resuscitation methods is best, each patient will be put into one of
two groups (early, goal-directed, protocolised resuscitation or usual resuscitation). The results will
be compared to see which one is better.  
 
ProMISe is a ‘randomised controlled trial’, which means that, each patient is randomly put into one
of the two groups. The groups are selected by a computer that will decide on a chance basis (as if 
it were tossing a coin) whether you will receive early, goal-directed, protocolised resuscitation or
usual resuscitation. Your progress will be closely followed to see which resuscitation method turns
out to be the most beneficial.  There is equal likelihood that you will receive either early, goal-
directed, protocolised resuscitation or usual resuscitation.  Neither you nor the doctor can decide
which resuscitation method you will receive. 
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 Whether you receive early, goal-directed, protocolised resuscitation or usual resuscitation, you will 
be provided with all other standard care as necessary, such as antibiotics or surgery. We will collect
information about your progress throughout your hospital stay.  
 
Many people who develop severe sepsis or septic shock routinely require a central venous catheter
(CVC). This involves a doctor inserting a tube (catheter) into a large vein, usually in the neck, or
near the collarbone to provide drugs, fluids or other products required during standard sepsis
treatment. Treatment can include giving fluid into the vein; medications to support the blood 
pressure and heart; and a possible blood transfusion. The patient may also have an arterial
catheter, which is a smaller tube that will be inserted into your artery in the wrist or groin and 
connected to a monitor to measure blood pressure. Additional treatment to support breathing may
include supplemental oxygen and a machine to help the patient breathe. 
 
Early, goal-directed, protocolised resuscitation  
If you are assigned to receive early, goal-directed, protocolised resuscitation, you will be cared for
by the hospital’s ProMISe Trial Team in conjunction with the team who will provide your ongoing 
care.  You will receive resuscitation which follows the trial protocol for six hours. All patients will
have a specialised CVC placed. The specialised CVC measures the oxygen level in blood returning 
from the tissues to the heart (central blood oxygen levels).  These levels are monitored and
treated accordingly. This specialised central catheter is used routinely. Many patients may have an
arterial catheter to monitor blood pressure. The treating clinician(s) will use the information from
these to treat you, and will include many of the standard sepsis treatments mentioned above, but 
according to the trial protocol. Each element in the trial protocol is to be given at the discretion of 
the treating clinician(s). Once a total of six hours of early, goal-directed, protocolised resuscitation
has been completed, you will be given standard care at the discretion of the treating clinician(s) in
accordance with current best practice.  
 
Usual resuscitation 
If you are assigned to receive usual resuscitation, you will continue to be monitored and treated by
the hospital’s usual clinical team in accordance with the hospital’s current standard resuscitation
practice. You will often have a CVC and an arterial catheter placed, if the treating clinician(s)
deems this is needed for your treatment.  
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 ProMISe patient schedule 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
What are the possible disadvantages and risks of taking part? 
All medical procedures, regardless of trial participation, involve some risk of injury.  In addition,
there may be risks associated with this trial that are presently unknown or unforeseeable.  In spite 
of all reasonable precautions, you might develop medical complications from participating in this 
trial. The most predictable risks are from the insertion of a CVC and an arterial catheter. These
catheters are commonly inserted as part of usual resuscitation, but the CVC will always be
inserted, and the arterial catheter will often be inserted, as part of early, goal-directed,
protocolised resuscitation. 
 
CVC complications 
The most common complication is infection which occurs in less than one in 20 patients.  The most
serious complications are puncture of the lung, causing collection of air into the chest, or puncture 
of an artery causing blood to collect in the chest. These are rare and occur in less than one in a 
hundred patients.  Other complications include injury to the blood vessel causing bruising and/ or 
bleeding or a blood clot inside the blood vessel (thrombosis). These are treatable and all patients 
will be assessed for the presence of any of these complications. 
 
 
 
 
Patient admitted to Emergency Department 
Randomisation 
Early, goal-directed, 
protocolised resuscitation  
(six hour trial protocol) 
Usual resuscitation 
All other care at the discretion of the 
treating clinician(s) 
3 months 
General health and wellbeing questionnaires (postal) 
12 months 
General health and wellbeing questionnaires (postal) 
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 Arterial catheter complications 
Complications from arterial catheters are rare, but may include bleeding, infection or a lack of 
blood flow to tissue supplied by the artery, which is nearly always correctable by removal of the
catheter. 
 
Other trial treatments 
There are specific risks associated with each of the individual standard treatments used routinely
for patients with severe sepsis or septic shock.  These treatments are commonly used in critically 
ill patients and side effects can include: 
Fluid infusions:  giving fluid into a vein can cause fluid overload where the patient temporarily has 
too much fluid for their blood vessels and heart to cope with easily.  This is reversible by slowing 
the speed at which the fluid is given, discontinuation, and sometimes by giving other medications. 
Blood transfusion: can contribute to fluid overload, cause a reaction to the blood itself (rare) and
spread viral disease. All blood is screened prior to administration. 
Drugs: medication given to support the heart can cause abnormal heart rhythm or rarely, a 
decreased blood supply to the heart and extremities. 
All patients are monitored closely for development of any side effects from treatments, which will 
be immediately treated by decreasing the dose or stopping the treatment altogether. 
 
What are the possible benefits of taking part? 
We cannot promise that participation in the trial will benefit you during your hospital stay but the 
information we get from this trial may help improve the way in which we care for patients with 
severe sepsis or septic shock in the future.  
 
If you receive early, goal-directed, protocolised resuscitation you will be cared for by the hospital’s
ProMISe Trial Team in conjunction with the team who will provide your ongoing care and may
receive closer observation and additional nursing attention. Early, goal-directed protocolised
resuscitation may or may not improve your chances of recovery when compared to usual
resuscitation; at present there is no evidence to suggest that early, goal-directed, protocolised
resuscitation is harmful. 
 
What happens when the trial stops? 
Once the trial has finished you will receive usual medical care up to and following discharge from 
hospital. However, at 3 months and 12 months after recruitment to the trial you will be contacted 
by post, by a researcher from ICNARC, to ask that you complete some questions on your general 
health and wellbeing.  These questionnaires will take around 15-20 minutes to complete.  
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 What if something goes wrong? 
If you are harmed due to someone’s negligence or wish to complain about any aspect of the way
you have been approached or treated during the course of this trial, contact the Hospital’s Patien
Advice & Liaison Service (PALS) for further information. 
 
Will my taking part in this trial be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. All information that is collected about you during the course of the trial will be kept
strictly confidential. Where possible, any information about you which leaves the hospital will have 
your name and address removed so that you cannot be recognised from it. As some patients may
lose touch with their hospital, we will need to collect important basic information from national
records held by the NHS Medical Research Information Service (MRIS). To ensure we identify you 
correctly on the MRIS database, we will ask the hospital staff for your name, date of birth, post
code and NHS number. In addition, ICNARC will also be given your address and telephone 
number, in order to send the questionnaires (mentioned above) to your home. Your GP will also be
notified that you have agreed to participate in this trial. The information will be stored securely
and in strict confidence at ICNARC. Procedures for handling, processing, storing and destroying
data [add relevant NHS Trust here] and at ICNARC are compliant with the Data Protection Act 
1998. 
 
What will happen to the results of the trial? 
The trial is estimated to take two years, commencing in late 2010. It is hoped to publish the 
results by mid 2014. If you would like a copy of the published results, please contact the Principal 
Local Investigator (details below). 
 
Funding and organisation of the trial 
This trial is being funded by the National Institute for Health Research, Health Technology 
Assessment programme.  The trial is being Sponsored and managed by ICNARC. 
 
Who has reviewed the trial 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This trial has been reviewed and given a favourable opinion 
by the North West London Research Ethics Committee 1.  
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Thank you for taking the time to read this information: 
 
 
Local research contact details: 
 
Please contact the Consultant leading the trial at your unit for further 
information: 
- [Insert name and contact number of Local Principal Investigator] 
 
Alternate contacts include: 
- [Nurse – name and contact] 
- ProMISe Team @ ICNARC – 020 7269 9277 
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Appendix 2 Short patient information sheet
 
[To go on your hospital Trust’s Headed paper] 
 
 
 
Patient Information Sheet - short 
 
 
Protocolised Management In Sepsis (ProMISe): a multi-centre, randomised controlled trial of the 
clinical and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic 
shock 
 
Introduction 
When a person has a severe infection, their body may react by producing an ‘inflammatory 
response’, which can damage important organs, such as the heart and lungs to the point where 
they no longer function properly.  When infection causes organ failure, it is called severe sepsis.  If
severe sepsis results in low blood pressure, it is referred to as septic shock.  The usual
resuscitation for severe sepsis in the United Kingdom involves treatment with antibiotics, fluids
given into a vein, and medication to support the blood pressure, the heart and lung function.  In
the United States, a small trial performed at one hospital found that usual resuscitation for severe
sepsis worked better with a treatment plan guided by central blood oxygen levels during the first
six hours of hospital treatment.  This treatment plan is early, goal-directed, protocolised
resuscitation. This trial only involved a small number of people and more research is needed. 
 
What is the purpose of the ProMISe trial? 
We would like you to take part in a clinical trial to investigate whether early, goal-directed,
protocolised resuscitation results in more people recovering from severe sepsis or septic shock
when compared with usual resuscitation.  Early, goal-directed, protocolised resuscitation is a
structured series of steps or elements that must be initiated as soon as possible, and completed
over a six-hour period. Usual resuscitation is less structured in that the doctor may provide some
of the same elements, but does not necessarily follow a structured series of steps or elements in a
time dependent manner.  
 
Why have I been asked to take part in the trial? 
You are eligible to participate in this trial because you have severe sepsis or septic shock, and have
been admitted through the Emergency Department in your hospital. Joining the trial is entirely  
 
Patient Information Sheet - short, version 1.0, 21/11/2011 
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voluntary. Once you have read this information sheet, if you agree to take part, we will ask you to 
sign a consent form. You are free to withdraw at any time, without giving a reason, and this will no
affect the standard of care you receive. 
 
What will happen to me if I take part? 
In order to find out which of the resuscitation methods is best, each patient will be randomly put 
into one of two groups (early, goal-directed, protocolised resuscitation or usual resuscitation) – as i
tossing a coin. The results will be compared to see which one is better.  There is equal likelihood 
that you will receive either early, goal-directed, protocolised resuscitation or usual resuscitation.  
Neither you nor the doctor can decide which resuscitation method you will receive. Whether you 
receive early, goal-directed, protocolised resuscitation or usual resuscitation  (details below), you will
be provided with all other standard care as necessary, such as antibiotics or surgery. We will collect
information about your progress throughout your hospital stay.  
 
· Early, goal-directed, protocolised resuscitation: you will receive resuscitation which 
follows the trial protocol for six hours. All patients will have a specialised central venous 
catheter (CVC) placed into a large vein, usually in the neck, to measure the oxygen level in 
the blood.  These levels are monitored and treated accordingly. This specialised CVC is 
used routinely. You may also have an arterial catheter (a small tube) inserted into an artery 
in your wrist or groin to monitor blood pressure. Once a total of six hours of early, goal-
directed, protocolised resuscitation has been completed, you will be given standard care at 
the discretion of the treating clinician(s) in accordance with current best practice.  
 
· Usual resuscitation: you will continue to be monitored and treated by the hospital’s 
usual clinical team in accordance with the hospital’s current standard resuscitation practice. 
You may have a CVC and an arterial catheter inserted if the treating clinician(s) deems this 
is needed for your treatment.  
 
What are the possible disadvantages and risks of taking part? 
All medical procedures, regardless of trial participation, involve some risk of injury.  In addition,
there may be risks associated with this trial that are presently unknown or unforeseeable.  
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· CVC complications: the most common complication is infection which occurs in 
less than one in 20 patients.  The most serious complications are puncture of the 
lung, causing collection of air into the chest, or puncture of an artery causing blood 
to collect in the chest. These are rare and occur in less than one in a hundred 
patients.  Other complications include injury to the blood vessel causing bruising 
and/ or bleeding or a blood clot inside the blood vessel (thrombosis). These are 
treatable and all patients will be assessed for the presence of any of these 
complications. 
 
· Arterial catheter complications: these are rare, but may include bleeding, 
infection or a lack of blood flow to tissues supplied by the artery, which is nearly 
always correctable by removal of the catheter. 
 
What are the possible benefits of taking part? 
We cannot promise that participation in the trial will benefit you during your hospital stay 
but the information we get from this trial may help improve the way in which we care for 
patients with severe sepsis or septic shock in the future.  
 
What if something goes wrong? 
If you are harmed due to someone’s negligence or wish to complain about any aspect of the
way you have been approached or treated during the course of this trial, contact the 
Hospital’s Patient Advice & Liaison Service (PALS) for further information. 
 
Who has reviewed the trial? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your interests. This trial has been reviewed and given a 
favourable opinion by the North West London Research Ethics Committee 1.  
 
Please also read the ProMISe Patient Information Sheet which has more detailed 
information about the ProMISe Trial. 
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Appendix 3 Case report form
 
Refractory hypotension or hypoperfusion:Known or presumed infection:
Two, or more SIRS criteria: Yes Y
Yes Y
Presentation at ED:
Time met final physiological inclusion criteria:
Time:
Consent process used:
Date: Time: (24-hour clock)D D M M 2 0 Y Y H H : M M
Today Yesterday1 2 (24-hour clock)H H : M M
(24-hour clock)H H : M M
Patient consent Personal Consultee1 2
Professional Consultee
Emergency consent
3
4
Signature:Completed by:
Antimicrobial(s) initiated: Yes Y
No N
No N
No N
No N
No N
No N
No N
No NAge less than 18 years:
Known pregnancy: 
Primary diagnosis of; an acute cerebral 
vascular event, acute coronary syndrome, 
acute pulmonary oedema, status asthmaticus, 
major cardiac arrhythmia (as part of primary 
diagnosis), seizure, drug overdose, 
injury from burn or trauma:
No N
No NHaemodynamic instability due to active 
gastrointestinal haemorrhage:
Requirement for immediate surgery: 
Known history of AIDS:
Advanced directives restricting implementation 
of the protocol:
Contraindication to central venous catheterisation:
Contraindication to blood transfusion: 
Attending physician deems aggressive care 
unsuitable:
Transferred from another in-hospital setting:
Not able to commence protocol within one 
hour of randomisation:
Do-Not-Attempt-Resuscitation (DNAR) status: No N
No N
No N
Not able to complete six hours of protocol 
treatment from commencement: No N
Met once, in any order, within six hours from presentation at ED
Yes Y
Randomisation (T0)
Date: Time: (24-hour clock)D D M M 2 0 Y Y H H : 0 0First “golden” hour (T1)
Trial number: Treatment allocation:
Early, goal-directed, protocolised resuscitation
Usual resuscitation
E
U
Does the patient have any other treatment limitations?
(see: overleaf for guidance)
Yes Y NNo
If yes, please specify
Not requested in call to 
Randomisation Service
You now have two hours to consent and randomise the patient
N.B. If during screening, a patient is found to be participating in another interventional study/trial, then please contact 
the ICNARC CTU on 020 7269 9295 to discuss their participation in ProMISe
ProMISe CRF booklet v3.1, 10/09/2013                                                                                                                                               promise@icnarc.org
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 Randomisation – Eligibility  
 
 
Overleaf, to be completed once consent/agreement is obtained and before calling the Randomisation Service 
 
Time of presentation at ED  
• Presentation at ED – day the patient physically presented at ED 
 
• Time – time the patient physically presented at ED 
 
Inclusion  
All should be ticked ‘Yes’ to be eligible 
 
• Two, or more SIRS criteria 
 
SIRS criteria Results 
Core temperature ≤ 36°C or ≥ 38°C  
Heart rate ≥ 90 beats min-1  
Respiratory rate ≥ 20 breaths min-1    
or Hyperventilaton PaCO2 < 4.3 kPa or  mechanical ventilation for acute process  
White blood cell count ≤ 4x109 l-1 or ≥ 12×109 l-1  
or Immature neutrophils (bands) > 10%  
 
• Refractory hypotension or hypoperfusion 
 
Physiology Results 
Refractory hypotension MAP < 65 mmHg  or  SBP < 90 mmHg  
or Hypoperfusion blood lactate ≥ 4 mmol l-1  
 
Exclusion 
All should be ticked ‘No’ to be eligible 
 
Treatment limitations 
• Does the patient have any other treatment limitations? – these are treatment limitations which do not 
prevent delivery of the early, goal-directed, protocolised resuscitation (obviously, ones that do, 
exclude the patient from ProMISe), e.g.   
 a patient whose treatment limitation precludes the use of inotropic agents would be excluded 
from ProMISe 
 a patient whose treatment limitation precludes the use of mechanical ventilation would be 
eligible for ProMISe, because the early, goal-directed, protocolised resuscitation requires that 
mechanical ventilation only be considered 
 
Consent 
• Consent process used – 
 Patient consent – the patient provided informed consent 
 Personal Consultee – a relative or friend provided agreement 
 Professional Consultee – an Independent Mental Capacity Advocate provided agreement  
 Emergency consent – an independent doctor was consulted and agreed  
 
Antimicrobial(s) 
• Antimicrobial(s) initiated – first dose must be initiated before randomisation 
 
 
Randomisation 
 
Randomisation Service – 020 8099 7784 
Study number – 2016 
Investigator number – XXX 
 
• Trial number – provided by the Randomisation Service 
 
• Treatment allocation – provided by the Randomisation Service 
 
• Randomisation (T0) – complete date and time provided by the Randomisation Service 
 
• First “golden” hour (T1) – date and time provided by the Randomisation Service 
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Protocolised Management In Sepsis
A multi-centre, randomised controlled trial 
of the clinical and cost-effectiveness of 
early, goal-directed, protocolised resuscitation 
for emerging septic shock
Early, goal-directed, protocolised resuscitation
Usual resuscitation
E
U
D D M M 2 0 Y YDate: Time: H H : M M
D D M M 2 0 Y YDate: Time: H H : 0 0
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Signature:
Completed by:
Date completed:
°C
Heart rate: 
Temperature:
Known or presumed infection:
Lactate:
PaCO2:
Mechanical ventilation:
White blood count:
Immature neutrophils (bandforms): %
First dose of IV antimicrobial(s) initiated:
IV antimicrobial(s) initiated:
Respiratory rate: 
Blood pressure (after fluid challenge) - 
beats min-1
109 l-1
mmol l-1
breaths min-1
mmHg
.
.
Yes NoY N
D D M M 2 0 Y Y
.
MAP: mmHg SBP:
Yes NoY N
kPa mmHgK M
Yes NoY N
.
or
For
SIRS 
criteria
Would patient be admitted direct to ICU from ED if not enrolled into ProMISe? Yes NoY N
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Date of birth:
First name:
Surname:
NHS number:
Hospital number:
If address not known
Telephone number:
House number/name:
Surname:
Treating clinician responsible for patient
Title:
First name:
Surname:
Gender:
Address 1:
Address 2:
Postcode:
City:
County:
Country:
House number/name:
Address 1:
Address 2:
Postcode:
City:
County:
Country:
Initials:
Mobile number:
Other number:
Signature:
Completed by:
Date completed:
Practice name:
D D M M 1 9 Y Y
Title:
Abroad
Homeless
Military
No fixed abode
A
H
M
N
D D M M 2 0 Y Y
Residence/status:
Male FemaleM F
Estimated age:or
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kPa mmHgK M
Obeys commands:
Date completed:
μmol l-1
x109 l-1
Bilirubin:
Platelets:
Creatinine:
Lactate:
Haemoglobin:
μmol l-1
mmol l-1
PaO2:
FiO2:
SpO2:
CVP:
MAP:
SBP/DBP:
ScvO2:
Respiratory rate: breaths min-1
%
mmHg
mmHg
mmHg
%
Temperature:
Heart rate:
Arterial pH:
oC
beats min-1
Sodium:
Potassium:
White blood count:
mmol l-1
mmol l-1
x109 l-1
Signature:
Completed by:
Pre-sedation:
Motor response
PaCO2:
.
Spontaneous:
To speech: 3
No response:
2
1
Localises to painful stimuli:
6
5
Withdrawal to painful stimuli:
Abnormal flexion:
4
3
Extends to painful stimuli:
No response:
2
1
Oriented: 5
Confused:
Inappropriate words:
4
3
Incomprehensible sounds:
No response:
2
1
%
Immature neutrophils 
(bandforms):
g dl-1
.
.
.
.
.
Vasoactives administered:
If yes
Dobutamine:
Dopamine:
Epinephrine:
Norepinephrine:
Yes NoY N
Total GCS:
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
Not recorded (NR)
NR
Not recorded (NR)
kPa mmHgK M
.
Eye opening response
4
.
Yes Y
≤5 μg kg-1 min-1
>5 μg kg-1 min-1
L
M
Yes Yes Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Yes Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
IV fluid (total volume)
Pre-hospital: ED presentation to randomisation:ml ml
ED presentation to randomisation:ml
Blood products (total volume)
Pre-hospital: ml
Not recorded: NR
NR
Verbal response
Y
Yes NoY N
.
.
Rate
Rate
Rate
or
D D M M 2 0 Y Y
To painful stimuli:
>15 μg kg-1 min-1 U
Mechanical ventilation: Yes NoY N
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Upper GI bleeding (due to portal hypertension): 
If yes
Respiratory
Shortness of breath with light activity:
Home ventilation:
Does the patient have any of the listed comorbidities?
Signature:
Completed by:
Date completed:
Yes NoY N
Liver
Cirrhosis:
Portal hypertension:
Y
Y
Hepatic failure or encephalopathy:
Y
Y
Leukaemia:
Haematological/oncological
AIDS:
Lymphoma:
Y
Y
Myeloma:
Y
YMetastatic disease:
Y
Renal
Chronic renal replacement therapy 
for irreversible renal disease: 
(haemodialysis, haemofiltration and peritoneal dialysis) 
Y Y
Y
Cardiovascular
Fatigue, claudication, dyspnoea or angina at rest: 
(New York Heart Association Functional Class IV)
Y
Neurological
Altered mental state: Y
Immunological
Therapy supressing resistance to infection: 
(e.g. steroids, chemotherapy, radiotherapy, etc.)
Y
Specify other:
Other
Admitted from a Nursing Home: Y
Other: Y
D D M M 2 0 Y Y
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CVC with ScvO2 monitoring capability:
CVC without ScvO2 monitoring capability:
Arterial line: 
(24-hour clock)
Date of insertion:
Time of insertion:
Signature:
Completed by:
Date completed:
If yes
D D M M 2 0 Y Y
H H : M M
PreSep catheter batch number:
(24-hour clock)
Date of insertion:
Time of insertion:
If yes
H H : M M
(24-hour clock)
Date of insertion:
Time of insertion:
If yes
H H : M M
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
Yes NoY N
Yes NoY N
Yes NoY N
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
118
  
(24-hour clock)
→
→
Opioid:
Propofol:
Other:
B
D
P
O
Benzodiazepine:
Colloid:
(exclude blood products)
Dopamine:
Dopexamine:
Epinephrine:
Norepinephrine:
Other:
PRBC:
Other blood products: 
Platelets:
FFP:
Albumin (20%):
Dobutamine:
Mechanical ventilation:
Other: 
Phenylephrine:
Specify other:
Highest FiO2:
Signature:
Completed by:
Date completed:
Crystalloid:
Vasoactive agents:
Sedated:
Neuromuscular blocking agent:
CVP: mmHg
MAP:
SBP:
ScvO2: 
mmHg
mmHg
%
If yes
If yes
T0 = time of randomisation and T1 = time of randomisation plus one “golden” hour 
e.g. patient randomised at 18:25, T1 = 20:00, patient randomised at 19:04, T1 = 21:00 
If yes
Yes Y
Yes NoY N
.
Yes NoY N
Supplemental O2: Yes Y
Yes NoY N
Yes NoY N
NR
NR
NR Haemoglobin: g dl-1
. NR
NR
D D M M 2 0 Y Y
Not recorded (NR) Not recorded (NR)
N
Specify other:
No
→Yes Y
→Yes Y .
Max. infusion rate
→Yes Y .
→Yes Y .
→Yes
→Yes Y .
→Yes Y .
→Yes Y NNo
→Yes Y
→Yes Y
→Yes Y
→Yes Y
→Yes Y .
Max. infusion rate
l min-1
.
Specify other:
ml
ml
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
ml
ml
ml
ml
ml
μg kg-1 min-1
Yes NoY N
Sedative(s):
NNo
H H : 0 0
Y
IV fluid(s):
If yes
Yes NoY N
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(24-hour clock)
→
→
Opioid:
Propofol:
Other:
B
D
P
O
Benzodiazepine:
Colloid:
(exclude blood products)
Dopamine:
Dopexamine:
Epinephrine:
Norepinephrine:
Other:
PRBC:
Other blood products: 
Platelets:
FFP:
Albumin (20%):
Dobutamine:
Mechanical ventilation:
Other: 
Phenylephrine:
Specify other:
Highest FiO2:
Signature:
Completed by:
Date completed:
Crystalloid:
Vasoactive agents:
Sedated:
Neuromuscular blocking agent:
CVP: mmHg
MAP:
SBP:
ScvO2: 
mmHg
mmHg
%
If yes
If yes
If yes
Yes Y
Yes NoY N
.
Yes NoY N
Supplemental O2: Yes Y
Yes NoY N
Yes NoY N
NR
NR
NR Haemoglobin: g dl-1
. NR
NR
D D M M 2 0 Y Y
Not recorded (NR) Not recorded (NR)
N
Specify other:
No
→Yes Y
→Yes Y .
Max. infusion rate
→Yes Y .
→Yes Y .
→Yes
→Yes Y .
→Yes Y .
→Yes Y NNo
→Yes Y
→Yes Y
→Yes Y
→Yes Y
→Yes Y .
Max. infusion rate
l min-1
.
Specify other:
ml
ml
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
ml
ml
ml
ml
ml
μg kg-1 min-1
Yes NoY N
Sedative(s):
NNo
H H : 0 0
Y
IV fluid(s):
If yes
Yes NoY N
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(24-hour clock)
→
→
Opioid:
Propofol:
Other:
B
D
P
O
Benzodiazepine:
Colloid:
(exclude blood products)
Dopamine:
Dopexamine:
Epinephrine:
Norepinephrine:
Other:
PRBC:
Other blood products: 
Platelets:
FFP:
Albumin (20%):
Dobutamine:
Mechanical ventilation:
Other: 
Phenylephrine:
Specify other:
Highest FiO2:
Signature:
Completed by:
Date completed:
Crystalloid:
Vasoactive agents:
Sedated:
Neuromuscular blocking agent:
CVP: mmHg
MAP:
SBP:
ScvO2: 
mmHg
mmHg
%
If yes
If yes
If yes
Yes Y
Yes NoY N
.
Yes NoY N
Supplemental O2: Yes Y
Yes NoY N
Yes NoY N
NR
NR
NR Haemoglobin: g dl-1
. NR
NR
D D M M 2 0 Y Y
Not recorded (NR) Not recorded (NR)
N
Specify other:
No
→Yes Y
→Yes Y .
Max. infusion rate
→Yes Y .
→Yes Y .
→Yes
→Yes Y .
→Yes Y .
→Yes Y NNo
→Yes Y
→Yes Y
→Yes Y
→Yes Y
→Yes Y .
Max. infusion rate
l min-1
.
Specify other:
ml
ml
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
ml
ml
ml
ml
ml
μg kg-1 min-1
Yes NoY N
Sedative(s):
NNo
H H : 0 0
Y
IV fluid(s):
If yes
Yes NoY N
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(24-hour clock)
→
→
Opioid:
Propofol:
Other:
B
D
P
O
Benzodiazepine:
Colloid:
(exclude blood products)
Dopamine:
Dopexamine:
Epinephrine:
Norepinephrine:
Other:
PRBC:
Other blood products: 
Platelets:
FFP:
Albumin (20%):
Dobutamine:
Mechanical ventilation:
Other: 
Phenylephrine:
Specify other:
Highest FiO2:
Signature:
Completed by:
Date completed:
Crystalloid:
Vasoactive agents:
Sedated:
Neuromuscular blocking agent:
CVP: mmHg
MAP:
SBP:
ScvO2: 
mmHg
mmHg
%
If yes
If yes
If yes
Yes Y
Yes NoY N
.
Yes NoY N
Supplemental O2: Yes Y
Yes NoY N
Yes NoY N
NR
NR
NR Haemoglobin: g dl-1
. NR
NR
D D M M 2 0 Y Y
Not recorded (NR) Not recorded (NR)
N
Specify other:
No
→Yes Y
→Yes Y .
Max. infusion rate
→Yes Y .
→Yes Y .
→Yes
→Yes Y .
→Yes Y .
→Yes Y NNo
→Yes Y
→Yes Y
→Yes Y
→Yes Y
→Yes Y .
Max. infusion rate
l min-1
.
Specify other:
ml
ml
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
ml
ml
ml
ml
ml
μg kg-1 min-1
Yes NoY N
Sedative(s):
NNo
H H : 0 0
Y
IV fluid(s):
If yes
Yes NoY N
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(24-hour clock)
→
→
Opioid:
Propofol:
Other:
B
D
P
O
Benzodiazepine:
Colloid:
(exclude blood products)
Dopamine:
Dopexamine:
Epinephrine:
Norepinephrine:
Other:
PRBC:
Other blood products: 
Platelets:
FFP:
Albumin (20%):
Dobutamine:
Mechanical ventilation:
Other: 
Phenylephrine:
Specify other:
Highest FiO2:
Signature:
Completed by:
Date completed:
Crystalloid:
Vasoactive agents:
Sedated:
Neuromuscular blocking agent:
CVP: mmHg
MAP:
SBP:
ScvO2: 
mmHg
mmHg
%
If yes
If yes
If yes
Yes Y
Yes NoY N
.
Yes NoY N
Supplemental O2: Yes Y
Yes NoY N
Yes NoY N
NR
NR
NR Haemoglobin: g dl-1
. NR
NR
D D M M 2 0 Y Y
Not recorded (NR) Not recorded (NR)
N
Specify other:
No
→Yes Y
→Yes Y .
Max. infusion rate
→Yes Y .
→Yes Y .
→Yes
→Yes Y .
→Yes Y .
→Yes Y NNo
→Yes Y
→Yes Y
→Yes Y
→Yes Y
→Yes Y .
Max. infusion rate
l min-1
.
Specify other:
ml
ml
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
ml
ml
ml
ml
ml
μg kg-1 min-1
Yes NoY N
Sedative(s):
NNo
H H : 0 0
Y
IV fluid(s):
If yes
Yes NoY N
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(24-hour clock)
→
→
Opioid:
Propofol:
Other:
B
D
P
O
Benzodiazepine:
Colloid:
(exclude blood products)
Dopamine:
Dopexamine:
Epinephrine:
Norepinephrine:
Other:
PRBC:
Other blood products: 
Platelets:
FFP:
Albumin (20%):
Dobutamine:
Mechanical ventilation:
Other: 
Phenylephrine:
Specify other:
Highest FiO2:
Signature:
Completed by:
Date completed:
Crystalloid:
Vasoactive agents:
Sedated:
Neuromuscular blocking agent:
CVP: mmHg
MAP:
SBP:
ScvO2: 
mmHg
mmHg
%
If yes
If yes
If yes
Yes Y
Yes NoY N
.
Yes NoY N
Supplemental O2: Yes Y
Yes NoY N
Yes NoY N
NR
NR
NR Haemoglobin: g dl-1
. NR
NR
D D M M 2 0 Y Y
Not recorded (NR) Not recorded (NR)
N
Specify other:
No
→Yes Y
→Yes Y .
Max. infusion rate
→Yes Y .
→Yes Y .
→Yes
→Yes Y .
→Yes Y .
→Yes Y NNo
→Yes Y
→Yes Y
→Yes Y
→Yes Y
→Yes Y .
Max. infusion rate
l min-1
.
Specify other:
ml
ml
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
ml
ml
ml
ml
ml
μg kg-1 min-1
Yes NoY N
Sedative(s):
NNo
H H : 0 0
Y
IV fluid(s):
If yes
Yes NoY N
Lactate: mmol l-1. NR
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End of early, goal-directed, protocolised resuscitation (if randomised to)
Date: Time: (24-hour clock)H H : M M
Speciality of most senior doctor:
Emergency Medicine
Intensive Care Medicine
E
I
Acute Medicine
Surgery
A
S
Other O
Most senior doctor to review patient (T0 T6):
Foundation Year 1/2
Specialty Registrar (year 1 – 7)
F
R
Consultant
Clinical Fellow
C
L
Staff or Associate Specialist
Other
S
O Specify:
Specify:
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
x109 l-1Lowest platelets:
Highest creatinine: μmol l-1
PaO2:
FiO2:
NR
NR
Not recorded (NR) Not recorded (NR)
kPa mmHgK M.
.
Obeys commands:
Pre-sedation:
Motor response
Spontaneous:
To speech: 3
To painful stimuli:
No response:
2
1
Localises to painful stimuli:
6
5
Withdrawal to painful stimuli:
Abnormal flexion:
4
3
Extends to painful stimuli:
No response:
2
1
Oriented: 5
Confused:
Inappropriate words:
4
3
Incomprehensible sounds:
No response:
2
1
Lowest total GCS:
Eye opening response
4
Not recorded: NR
Verbal response
Yes NoY N
D D M M 2 0 Y Y
Lowest P/F ratio:
P/F ratio on mechanical 
ventilation:
Yes NoY N
μmol l-1Highest bilirubin: . NR
NR
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Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
→
→
Opioid:
Propofol:
Other:
B
D
P
O
Benzodiazepine:
Colloid:
(exclude blood products)
Dopamine:
Dopexamine:
Epinephrine:
Norepinephrine:
Other:
PRBC:
Other blood products: 
Platelets:
FFP:
Albumin (20%):
Dobutamine:
Mechanical ventilation:
Other: 
Phenylephrine:
Specify other:
Highest FiO2:
Crystalloid:
Vasoactive agents:
Sedated:
Neuromuscular blocking agent:
If yes
If yes
If yes
Yes Y
Yes NoY N
.
Yes NoY N
Supplemental O2: Yes Y
Yes NoY N
Yes NoY N
N
Specify other:
No
→Yes Y
→Yes Y .
Max. infusion rate
→Yes Y .
→Yes Y .
→Yes
→Yes Y .
→Yes Y .
→Yes Y NNo
→Yes Y
→Yes Y
→Yes Y
→Yes Y
→Yes Y .
Max. infusion rate
l min-1
.
Specify other:
ml
ml
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
ml
ml
ml
ml
ml
μg kg-1 min-1
Yes NoY N
Sedative(s):
NNo
Y
IV fluid(s):
If yes
Yes NoY N
Date: Time: (24-hour clock)D D M M 2 0 Y Y H H : 0 0
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Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
Obeys commands:
Pre-sedation:
Motor response
Spontaneous:
To speech: 3
To painful stimuli:
No response:
2
1
Localises to painful stimuli:
6
5
Withdrawal to painful stimuli:
Abnormal flexion:
4
3
Extends to painful stimuli:
No response:
2
1
Oriented: 5
Confused:
Inappropriate words:
4
3
Incomprehensible sounds:
No response:
2
1
Eye opening response
4
Not recorded: NR
Verbal response
Yes NoY N
x109 l-1Lowest platelets:
Highest creatinine:
Lactate: Haemoglobin:
μmol l-1
mmol l-1
Lowest MAP:
Lowest 
SBP/DBP:
mmHg
mmHg
g dl-1. .
NR
NR
NR
NR
Not recorded (NR) Not recorded (NR)
NR
or
Lowest total GCS:
PaO2:
FiO2:
NRkPa mmHgK M.
.
P/F ratio on mechanical 
ventilation:
Yes NoY N
μmol l-1Highest bilirubin: . NR
Lowest P/F ratio:
Not recorded (NR) Not recorded (NR)
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Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
→
→
Opioid:
Propofol:
Other:
B
D
P
O
Benzodiazepine:
Colloid:
(exclude blood products)
Dopamine:
Dopexamine:
Epinephrine:
Norepinephrine:
Other:
PRBC:
Other blood products: 
Platelets:
FFP:
Albumin (20%):
Dobutamine:
Mechanical ventilation:
Other: 
Phenylephrine:
Specify other:
Highest FiO2:
Crystalloid:
Vasoactive agents:
Sedated:
Neuromuscular blocking agent:
If yes
If yes
If yes
Yes Y
Yes NoY N
.
Yes NoY N
Supplemental O2: Yes Y
Yes NoY N
Yes NoY N
N
Specify other:
No
→Yes Y
→Yes Y .
Max. infusion rate
→Yes Y .
→Yes Y .
→Yes
→Yes Y .
→Yes Y .
→Yes Y NNo
→Yes Y
→Yes Y
→Yes Y
→Yes Y
→Yes Y .
Max. infusion rate
l min-1
.
Specify other:
ml
ml
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
μg kg-1 min-1
ml
ml
ml
ml
ml
μg kg-1 min-1
Yes NoY N
Sedative(s):
NNo
Y
IV fluid(s):
If yes
Yes NoY N
Date: Time: (24-hour clock)D D M M 2 0 Y Y H H : 0 0
Lactate: Haemoglobin:mmol l-1 g dl-1. . NRNR
Not recorded (NR) Not recorded (NR)
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Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
Site: Lungs:
Abdomen:
L
A
Blood: B
Central nervous system: Specify:
SSoft tissue:
Urinary tract: U
OOther:
Organism: Gram positive coccus:
Gram positive rod:
C
R
Gram negative coccus: K
Gram negative rod: D
Specify:
FFungus/yeast:
Parasite: P
VVirus:
OOther:
Has the antimicrobial(s) changed since ED presentation? Yes NoY N
If yes
Specify new antimicrobial(s):
C
Obeys commands:
Pre-sedation:
Motor response
Spontaneous:
To speech: 3
To painful stimuli:
No response:
2
1
Localises to painful stimuli:
6
5
Withdrawal to painful stimuli:
Abnormal flexion:
4
3
Extends to painful stimuli:
No response:
2
1
Oriented: 5
Confused:
Inappropriate words:
4
3
Incomprehensible sounds:
No response:
2
1
Eye opening response
4
Not recorded: NR
Verbal response
Yes NoY N
Vasoactives administered:
If yes
Dobutamine:
Dopamine:
Epinephrine:
Norepinephrine:
Yes NoY N
Yes Y
≤5 μg kg-1 min-1
>5 μg kg-1 min-1
L
M
Yes Yes Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Yes Y
≤0.1 μg kg-1 min-1
>0.1 μg kg-1 min-1
L
U
Y
Max. rate
>15 μg kg-1 min-1 U
Lowest total GCS:
Lowest MAP:
Lowest 
SBP/DBP:
mmHg
mmHg
NR
Not recorded (NR) Not recorded (NR)
or
PaO2:
FiO2:
NRkPa mmHgK M.
.
P/F ratio on mechanical 
ventilation:
Yes NoY N
Lowest P/F ratio:
Max. rate
Max. rate
x109 l-1Lowest platelets:
Highest creatinine: μmol l-1 NR
NR
μmol l-1Highest bilirubin: . NR
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Start time: (24-hour clock)
*Location:      A=Acute Admissions Unit (or equivalent), W=Ward, I=ICU or ICU/HDU, 
       H=HDU, E=Emergency Department, T=Theatre
Location*: Start date:
Date of discharge: Date of death:
Acute hospital discharge status (from your hospital):
If alive If dead
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y H H : M M
Alive DeadA D
D D M M 2 0 Y Y
Discharge location: Home:
Nursing Home:
H
N
Transfer to other hospital: T
Other: O
Specify:
D D M M 2 0 Y Y
H H : M M
H H : M M
H H : M M
H H : M M
H H : M M
From ED 
Time of death: H H : M M
Ultimate discharge from acute hospital:
Date:
Status: Alive DeadA D
D D M M 2 0 Y Y
Note: Please obtain Retrospective Consent prior to discharge
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.
Basic respiratory:
Advanced respiratory:
Basic cardiovascular:
Advanced cardiovascular:
Renal:
Total calendar days:
Neurological:
Liver:
Gastrointestinal:
Dermatological:
Surgery:
Started: If yes (24-hour clock)
Yes NoY N
D D M M 2 0 Y Y H H : M M
APC:
Started: If yes (24-hour clock)
Yes NoY N
D D M M 2 0 Y Y H H : M M
Finished: (24-hour clock)D D M M 2 0 Y Y
Steroids:
Started: If yes (24-hour clock)
Yes NoY N
D D M M 2 0 Y Y
Finished: (24-hour clock)D D M M 2 0 Y Y
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
Level 2:
Level 3:
H H : M M
H H : M M
H H : M M
Total calendar days:
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Bleeding:
Haemo-pneumothorax:
Start date: Start time: (24-hour clock)Severity1:
Thrombosis:
Vascular catheter infection:
Pulmonary oedema:
Blood transfusion reaction:
Myocardial ischaemia:
Peripheral ischaemia:
Adverse event:
Pneumothorax:
Related2: 
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
D D M M 2 0 Y Y
Pulmonary emboli:
D D M M 2 0 Y Y
H H : M M
2Related (to trial treatment):     0=None, 1=Unlikely, 2=Possibly, 3=Probably, 4=Definitely
1Severity:     0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening, 5=Fatal
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
 Note: If Severity 3 or more, complete the Serious Adverse Event Reporting Form and fax to ICNARC CTU
Start date: Start time: (24-hour clock)Severity1: Related
2: 
D D M M 2 0 Y Y
H H : M M
H H : M M
H H : M M
H H : M M
H H : M M
H H : M M
H H : M M
H H : M M
H H : M M
H H : M M
D D M M 2 0 Y Y H H : M M
D D M M 2 0 Y Y H H : M M
D D M M 2 0 Y Y H H : M M
D D M M 2 0 Y Y H H : M M
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Regained mental capacity:
Retrospective consent:
Date:
Yes NoY N
D D M M 2 0 Y Y
Obtained
Part-obtained
O
P
Refused
Not sought
R
N
If part-obtained/ not sought
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
Details:
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Date of death: D D M M 2 0 Y Y
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
If completed, return to ICNARC CTU
By fax: 
By email: 
By post: 
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 Reason (if available):
Date of withdrawal: D D M M 2 0 Y Y
Signature:
Completed by:
Date completed: D D M M 2 0 Y Y
If completed, return to ICNARC CTU
By fax: 
By email: 
By post: 
  
  
Consent/agreement 
withdrawn by: Patient 1
Personal Consultee 2
Professional Consultee 3
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Appendix 4 Severity of illness scores
Acute Physiology And Chronic Health Evaluation version II
The APACHE II Acute Physiology Score consists of weightings for 12 physiological parameters to
give a total score ranging from 0 to 60, with higher scores indicating greater severity of illness.33
The 12 physiological parameters are as follows:
l temperature
l mean arterial pressure
l heart rate
l respiratory rate
l alveolar–arterial gradient (if F iO2 ≥ 0.5) or PaO2 (if F iO2 < 0.5)
l arterial pH (or serum bicarbonate if no arterial blood gas recorded)
l serum sodium
l serum potassium
l serum creatinine (with double weighting for acute renal failure)
l haematocrit (estimated from haemoglobin)
l white blood cell count
l GCS score (assumed to be normal for patients sedated or paralysed).
The APACHE II score comprises the Acute Physiology score plus additional weightings for age and severe
comorbidities in the past medical history to give a total score ranging from 0 to 71. Severe comorbidities
must have been present and documented in the past medical history within the 6 months prior to
presentation at hospital and are defined as follows:
l severe liver condition – presence of portal hypertension, biopsy proven cirrhosis or
hepatic encephalopathy
l severe cardiovascular condition – presence of fatigue, claudication, dyspnoea or angina at rest
(New York Heart Association Functional Class IV)
l severe respiratory condition – presence of permanent shortness of breath with light activity due to
pulmonary disease, or on home ventilation
l renal condition – receiving chronic renal replacement therapy (haemodialysis, haemofiltration and
peritoneal dialysis)
l immunological condition – receiving chemotherapy, radiotherapy or daily high-dose steroid treatment
(≥ 0.3mg/kg, prednisolone or equivalent) for 6 months, or diagnosis of human immunodeficiency virus
(HIV)/acquired immunodefiency syndrome (AIDS), lymphoma, acute or chronic myelogenous/
lymphocytic leukaemia, multiple myeloma and active metastatic disease.
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Sequential Organ Failure Assessment
The SOFA score consists of weightings for six organ systems to give a total score ranging from 0 to 24,
with higher scores indicating a greater degree of organ failure.30 Organ dysfunction is defined as follows:
l respiratory dysfunction, defined as PaO2/F iO2 < 400mmHg
l cardiovascular dysfunction, defined as mean arterial pressure < 70mmHg (irrespective of
vasopressor use)
l renal dysfunction, defined as creatinine of ≥ 1.2 mg/dl (110 µmol/l)
l neurological dysfunction, defined as GCS score of ≤ 14
l hepatic dysfunction, defined as bilirubin of ≥ 1.2mg/dl (20 µmol/l)
l coagulation dysfunction, defined as platelets < 150 × 109/l.
Mortality in Emergency Department Sepsis
The MEDS score is derived from nine variables to give a total score ranging from 0 to 33, with higher
scores indicating a greater risk of death.34 The nine variables are as follows:
l terminal illness, defined as presence of metastatic disease [distant (not regional lymph node) metastases
documented by surgery, imaging or biopsy]
l respiratory difficulties, defined as tachypnea (respiratory rate of > 20 breaths per minute) or hypoxia
(SpO2 < 90% or F iO2 of ≥ 0.4)
l septic shock, defined as severe sepsis plus hypotension (systolic blood pressure < 90mmHg) that
persists after initial fluid challenge of 20–30ml/kg body weight of intravenous crystalloid
l low platelet count, defined as < 150 × 109/l
l bandemia, defined as baseline immature neutrophils (band forms) < 5%
l age > 65 years
l suspected lower respiratory tract infection
l nursing home residence
l altered mental status, defined as a recent change in sensorium (confusion, disorientation, drowsiness,
obtundation, stupor or coma) by history or physical examination or GCS score of ≤ 14.
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Appendix 5 Critical Care Minimum Data Set
criteria
Definitions
Duration of organ support in the critical care unit was defined as the number of days alive and free from
support of each of the following organ systems, as defined by the UK Department of Health Critical Care
Minimum Data Set,31 during the first 28 days following randomisation. Patients that died within the
first 28 days were assigned 0 days alive and free from organ support. Organ support definitions were
as follows:
l advanced respiratory – indicated by one or more of invasive mechanical ventilatory support through a
translaryngeal tube or tracheostomy; bilevel positive airway pressure through a trans-laryngeal tube or
tracheostomy; continuous positive airway pressure through a trans-laryngeal tube; or extracorporeal
respiratory support
l advanced cardiovascular – indicated by one or more of receipt of multiple intravenous and/or rhythm
controlling drugs (of which at least one must be vasoactive) when used simultaneously to support or
control arterial pressure, cardiac output or organ/tissue perfusion; continuous observation of cardiac
output and derived indices; an intra-aortic balloon pump or other assist device; or a temporary
cardiac pacemaker
l renal – indicated by receipt of acute renal replacement therapy (e.g. haemodialysis, haemofiltration,
etc.) or receipt of renal replacement therapy for chronic renal failure where other acute organ support
is received.
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Appendix 6 Patient follow-up cover letter
 
 
<TITLE FIRSTNAME SURNAME> 
<ADDRESS 1> 
<ADDRESS 2> 
<ADDRESS 3> 
<CITY> 
<POSTCODE> 
 
          DATE 
 
Dear <TITLE> <SURNAME> 
 
Re: ProMISe: Protocolised Management in Sepsis 
 
When you were treated at <NAME OF HOSPITAL> in <MONTH, YEAR>, you may remember that 
you agreed to take part in a research study called ProMISe, which is comparing different 
treatments for patients admitted to hospital with a severe infection.  A Patient Newsletter is 
enclosed which contains further information about ProMISe. 
 
As part of the study, we are contacting patients <THREE MONTHS/ONE YEAR> after they were 
admitted to hospital to find out about their general health and well-being.  We would be very 
grateful if you would complete the enclosed questionnaire – this should only take about 10 minutes 
of your time. A stamped, self-addressed envelope is provided for ease of return.   
 
 
 
 
 
 
 
 
The ProMISe Study, coordinated by the Intensive Care National Audit & Research Centre 
(ICNARC), is being conducted in 48 NHS hospitals and general information about the trial is 
available at the following website: www.icnarc.org.  If you have any questions, or would like help 
completing the questionnaire, please contact the ProMISe Team at ICNARC (contact details 
above).   
 
Thank you very much for your time.  If you do not wish to fill in the questionnaire, please tick the 
relevant box on the questionnaire and return to us in the stamped self-addressed envelope 
provided. 
 
Yours sincerely  
 
Encs: 
  
Version 2.1, 21/10/2013  Patient Trial number:  
 
If you are the carer for the person to whom this letter is addressed and they are unable to 
read it, we would be very grateful if you could take the time to read this letter and the Patient 
Information Sheet on their behalf.  If you feel that they would like to participate, please complete 
the questionnaire either with them or on their behalf. By better understanding the recovery of the 
person you care for, we hope to improve the care of future patients admitted to hospital with a 
severe infection. 
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Appendix 7 Patient follow-up questionnaire
 
 
  
Trial Number: <Patient Trial ID No> 
 
 
 
Protocolised Management In Sepsis: a multi-centre, randomised controlled trial of the 
clinical and cost-effectiveness of early, goal-directed, protocolised resuscitation for 
emerging septic shock. 
 
 
 
We would be grateful if you would complete this questionnaire. The ProMISe trial aims to improve the 
care of patients with severe infection. 
 
A pen is provided and a stamped self-addressed envelope for return of the questionnaire. Please 
answer multiple choice questions by putting a    in ONE BOX for each question. 
 
Please complete today’s date below: 
 
 /  /  
Day  Month  Year 
 
Please also let us know whether you completed this questionnaire: 
 
 Alone 
 With help 
 Or it was completed by someone who cares for you 
 
 
NOW PLEASE TURN THE PAGE TO START THE QUESTIONNAIRE     
  
If you do not wish to complete this questionnaire, please tick the box and return the unanswered 
questionnaire in the stamped self-addressed envelope provided.  
 
I do not wish to complete this questionnaire             
 
Your current and future care will not be affected whether you decide to, or not to, fill in this 
questionnaire. 
 
 
Health Questionnaire, Version 2.0, 21/11/11 
HEALTH QUESTIONNAIRE 
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We would be grateful if you could complete the following questions. We would like to understand how 
your health is since you left the hospital. 
 
There are no right or wrong answers. We have found that the best way to answer the questions is to 
go with your first instinct, whatever you think is the correct response for you. Under each heading, 
please tick the ONE box that best describes your health TODAY  
 
MOBILITY 
I have no problems in walking about       
I have slight problems in walking about       
I have moderate problems in walking about      
I have severe problems in walking about      
I am unable to walk about         
 
SELF-CARE 
I have no problems washing or dressing myself     
I have slight problems washing or dressing myself     
I have moderate problems washing or dressing myself    
I have severe problems washing or dressing myself       
I am unable to wash or dress myself       
 
USUAL ACTIVITIES (e.g. work, study, housework, family or leisure activities) 
I have no problems doing my usual activities      
I have slight problems doing my usual activities     
I have moderate problems doing my usual activities     
I have severe problems doing my usual activities     
I am unable to do my usual activities       
 
PAIN / DISCOMFORT 
I have no pain or discomfort        
I have slight pain or discomfort        
I have moderate pain or discomfort       
I have severe pain or discomfort        
I have extreme pain or discomfort       
 
ANXIETY / DEPRESSION 
I am not anxious or depressed        
I am slightly anxious or depressed       
I am moderately anxious or depressed       
I am severely anxious or depressed       
I am extremely anxious or depressed       
YOUR HEALTH 
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
144
  
· We would like to know how good or bad your health is  
TODAY. 
· This scale is numbered from 0 to 100. 
· 100 means the best health you can imagine. 
0 means the worst health you can imagine. 
· Mark an X on the scale to indicate how your health is 
TODAY.  
· Now, please write the number you marked on the scale 
in the box below.  
                     
 
 
 
YOUR HEALTH TODAY  = 
 
 
 
 
 
 
 
 
 
 
 
10 
0 
20 
30 
40 
50 
60 
80 
70 
90 
100 
5 
15 
25 
35 
45 
55 
75 
65 
85 
95 
The best health     
 you can imagine 
The worst health   
 you can imagine 
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We would be grateful if you could complete the following questions. It will help us understand the 
care you needed after leaving the hospital. 
 
The questions refer to ALL health services that you have used since leaving the hospital on 
<Discharge date>, and before <Three months/one year>. 
 
 
 
 
A Since you left hospital on <Discharge date> have you stayed overnight in hospital for any 
reason? 
      No  - Go to Part 2 
      Yes - Please give details about the number of stays below 
 
B For EACH TIME you stayed in hospital please answer the following 
     
 
Number of 
nights 
 
1-3 
nights 
4-10 
nights 
11 or more 
nights 
Did you spend any part of 
your stay in critical care? 
1st Stay  or      
2nd Stay  or      
3rd Stay  or      
4th Stay*  or      
 
*If you have stayed in hospital overnight more than 4 times, please could you provide information on 
these further hospital stays in Part 6 of the questionnaire. 
 
 
 
 
 
Part 1. Hospital Stay 
HEALTH SERVICES 
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Outpatient visits are when a patient comes to the hospital to see a specialist (e.g. consultant) but 
does not stay overnight. 
 
A Since you left the hospital on <Discharge date> have you visited hospital outpatients about 
ANY ASPECT of your health? 
      No  - Go to Part 3 
      Yes - Please give details about the number of outpatients visit(s) below 
 
B 
 
Number of  
visits 
 1-3 
visits 
4-10 
visits 
11 or more 
visits 
 
 
or     
  
 
 
 
A Since you left the hospital on <Discharge date> have you visited any of the health care 
providers listed below? 
      No  - Go to Part 4 
      Yes - Please give details about your visits below 
 
B For EACH PROVIDER please answer the following 
     
Did you visit this provider? 
Number of 
visits 
 
1-3 
visits 
4-10 
visits 
11 or more  
visits 
GP   or     
Nurse at your 
GP clinic 
  or     
Nurse at hospital 
or elsewhere 
  or     
Health visitor   or     
 
 
Part 2.  Hospital outpatient visits 
Part 3. Visits to health care providers   
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A Since you left the hospital on <Discharge date> have you had home visits from any the 
following health care providers about ANY ASPECT of your health? 
      No  - Go to Part 5 
      Yes - Please give details about your visits below 
 
B For EACH HOME VIST please answer the following 
Were you visited at home  
by this provider? 
Number of 
visits 
 
1-3 
visits 
4-10 
visits 
11 or more  
visits 
GP   or     
Nurse from your 
GP clinic   or     
Occupational 
Therapist   or     
Health visitor or 
District nurse   or     
 
 
 
A Since you left the hospital on <Discharge date> please indicate whether you have had 
contact (either visits to the provider or home visits) with any of the following service 
providers about any aspect of your health? 
      No  - Go to Part 6 
      Yes - Please give details below 
 
B For EACH PROVIDER please answer the following 
 
Have you had contact with any of 
these providers? 
Number of 
visits 
 
1-3 
visits 
4-10 
visits 
11 or more  
visits 
Occupational therapist  
 
or     
Psychologist  
 
or     
Speech and Language 
therapist 
 
 
or     
Physiotherapist  
 
or     
Dietician  
 
or     
       
 
Part 4.  Visits to your home by health care providers 
Part 5. Visits to other service providers 
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A Since you left the hospital on <Discharge date> have you had further hospital stays or used  
ANY OTHER health care services for any aspect of your health that you haven’t included 
above? 
      No  - Go to Part 7 
      Yes - Please give details below 
 
B For EACH PROVIDER please answer the following 
 
Type of service provider Number of visits Reason 
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part 6. Other services not listed so far 
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Your views are important to us.  Please feel free to provide any other comments you have in the box 
below. 
 
 
 
Thank you for help 
 
If you would like to ask us any questions about completing the questionnaire please email or call: 
 
ProMISe Team        
                                                 
 
 
  
 
 
 
 
 
 
 
Part 7.  Comments 
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